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ABSTRACT 
TEST OF A MULTIDISCIPLINARY HEALTH BEHAVIOR MODEL OF 
MEDICARE ELDERS' ANTIHYPERTENSIVE ACQUISITIONS 
Ann Marie Kopitzke 
Old Dominion University, 2009 
Chair: Dr. Karen Karlowicz 
This study examined the relative utility of the enhanced Health Belief Model as 
compared to the proposed Pharmaceutical Acquisition Model for Medicare Elders 
(PAMME) in describing antihypertensive acquisition with usage intentions for Medicare 
elders (65 years or older) in Southeastern Virginia. Data collection included record reviews 
to identify hypertensive Medicare elders. Consenting Medicare elders were randomly 
selected for invitation, with consenting Medicare elders contacted by telephone or in-
person interviews. The survey instrument utilized open and closed ended questions. The 
target population for this study is Southeastern Virginia Medicare elders enrolled in a Part 
D plan and prescribed at least one antihypertensive. This study employed a quasi-
experimental, retrospective, mixed methods design. A combination of primary and 
secondary data was obtained through telephone, face-to-face interviews and administrative 
record review. This study retrospectively examined antihypertensive acquisition 
experiences of Southeastern Virginia's Medicare elders, to explore how the Medicare 
Modernization Act of 2003 affected out-of-pocket costs and antihypertensive acquisitions. 
Analyses employed aggregate-based information to test the research hypotheses. Statistical 
analysis was conducted with SPSS Version 16. The majority (94 percent) of Medicare 
elders were able to legally acquire their antihypertensives. When comparing the enhanced 
Health Belief Model (HBM) with the Pharmaceutical Acquisition Model for Medicare 
Elderly (PAMME) the HBM has 95.5 while 96.2 indicating slightly increased prediction 
with the added constructs of Medication Adherence and Consumer Choice Theory. This 
study confirms other research findings regarding Medicare elders' beliefs about generics 
with the majority (71.6 percent) who believe that the generic works just as well as the 
name brand. The complexity of antihypertensive acquisition decisions and beliefs about 
hypertension continue to provide a challenge for researchers. While this study has 
furthered our understanding of what factors influence legal antihypertensive acquisitions, 
much research remains to be conducted to fully comprehend the multidimensional 
constructs of hypertension and antihypertensives. 
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Chapter I 
INTRODUCTION 
This study sought to understand antihypertensive acquisition behaviors' of 
Medicare elders to determine which factors most influence acquisition decisions in the 
context of the enhanced Health Belief Model (HBM). The effective treatment of disease 
and illness depends upon patients actually adhering to prescribed treatment regimens (Ead, 
1998) and begins with acquiring antihypertensives to treat hypertension (American Heart 
Association, 2007). Special emphasis is placed on the acquisition of prescribed 
antihypertensives, as approximately two-thirds of Medicare elders over 65 years of age and 
approximately 76% of those 75 years of age and older are affected by hypertension 
(American Heart Association, 2007; Centers for Disease Control and Prevention, 2005; 
White, 2002). The ability to acquire antihypertensives is essential for reducing health 
disparities for aging populations increasingly afflicted with hypertension and other health 
complications (Centers for Disease Control and Prevention, 2007). 
This study specifically examined those factors, which might influence legal methods 
of acquisition for antihypertensives to include: (a) doctor prescribed and purchased, (b) 
obtained through physician-supplied samples, (c) prescription drug plan mail order 
(Centers for Medicare and Medicaid Services, 2005). 
When acquired and taken as prescribed, antihypertensives have the ability to reduce 
hypertension related morbidity and mortality (Benson & Britten, 2002). Often Medicare 
1
 Acquistion behaviors are defined as any method utilized to acquire antihypertensives 
through legally approved methods. 
2 
elders under-use (Voelker, 2004) and may not acquire all needed prescription drugs2, 
including those for hypertension (Robeznicks, 2004). While treatable, under-use of 
antihypertensives adversely affects morbidity and mortality rates (American Heart 
Association, 2007) and under-treated or untreated hypertension has the potential to 
adversely affect cognitive, cardiovascular, renal and other functions (Blustein, 2000; 
Rosendorff et al., 2007) and accounts for approximately 1.2 million hospitalizations 
annually (Middleton, Hing & Xu, 2007). 
Since Medicare Modernization Acts' (MMAs) full implementation on January 1, 
2006, approximately 22 million Medicare elders have enrolled in Part D plans (both stand-
alone prescription drug plans and Medicare Advantage plans with and without 
prescriptions) which provides a prescription drug benefit to Medicare elders previously 
lacking coverage (Henry J. Kaiser Family Foundation, 2008). The Medicare Modernization 
Act of 2003 (MMA) was implemented to increase access to affordable prescription drugs 
for Medicare beneficiaries by reducing out-of-pocket costs, but little has been done to 
examine the extent to which the policy has actually increased prescription drug acquisition, 
specifically for antihypertensives (Henry J. Kaiser Family Foundation, 2006; Neff, 2004; 
O'Brien, 2003). 
Proposed methods for understanding antihypertensive acquisition include the 
development of a model that builds upon the enhanced Health Belief Model (HBM). This 
study tested an enhanced version of the HBM (Bandura, 1986; Rosenstock, Strecher, & 
Becker, 1988;) to determine if it accurately identifies factors that influence acquisition 
-Drugs were use in place of medications or antihypertensives when interacting with 
Medicare elders regarding their prescription drug plans and drug behaviors. 
3 
behaviors for antihypertensives of Medicare elders better than the proposed 
Pharmaceutical Acquisition Model for Medicare Elders (PAMME). The enhanced HBM 
was augmented with select components of the Medication Adherence Model (MAM) 
(Johnson, 2002) to explore usage (adherence) decisions and with constructs from the 
Consumer Choice Theory (Friedman, 1990) to assess the influence of price on 
antihypertensive acquisition behavior. The proposed model that was tested is named the 
Pharmaceutical Acquisition Model for Medicare Elders (PAMME). 
Background 
Demographics of the Elderly Population 
Increasing Elderly Population 
The increase in the number of elderly contributes to markedly higher incidence of 
treatable chronic disease and illness (American Heart Association, 2007b). An examination 
of factors that enable Medicare elders to acquire prescriptions, especially 
antihypertensives, is important as the number of elderly in the United States is expanding 
rapidly, with approximately 37 million elders residing in the U.S. in 2005 (U.S. Census 
Bureau, 2005) and approximately 39 million in 2006 (Henry J. Kaiser Family Foundation, 
2006). The projections for 2010 estimate that more than approximately 40 million people 
in the United States population will be older than 65 years of age, with more than 
approximately 6 million older than age 85 (U.S. Census Bureau, 2005). The first cohort of 
Baby Boomers will reach 65 by 2011, which will expand the elderly population to 
approximately 20% of the U.S. population (U.S. Census Bureau, 2005). By 2040, these 
Figures are expected to nearly double (U.S. Department of Health and Human Services, 
2004). One of the fastest growing segments of U.S. society are those aged 85 years of age 
4 
and older; which accounts for approximately 9% of Medicare elders (U.S. Department of 
Health and Human Services, 2004). In Virginia, those Medicare elders 85 years of age and 
older are expected to increase five times faster than the state's total population (Virginia 
Department for the Aging, 2006). 
Gender 
Historically, elderly women were disproportionately represented in Medicare 
populations due to longevity (U.S. Census Bureau, 2005). While on average men's life 
expectancy has increased to approximately 75 years of age, women's average life 
expectancy is approximately 86 years of age (U.S. Census Bureau, 2006). According to 
the U.S. Census Bureau (2006), the majority (67%) of Medicare elders older than 65 years 
of age are women. However, men and women have comparable levels of hypertension 
(approximately 27%) of those adults living with chronic disease or illness (Centers for 
Disease Control and Prevention, 2007). Additionally, more women than men experience 
incidences of uncontrolled hypertension (Reinberg, 2008). However, the gap between 
elderly men and women is expected to narrow by 2025 with 18% more men reaching 
advanced ages (U.S. Census Bureau, 2006). 
Ethnicity and Health Disparities 
Ethnicity for the approximately 300 million people in the United States varies 
slightly from the state of Virginia's 8 million people (U.S, Census Bureau, 2008). 
According to the U.S. Census Bureau (2008), the U.S. is comprised of approximately 80% 
white, 13% black, 1% American Indian and Alaskan Native, 15% Hispanic, and 4% Asian 
whereas Virginia has approximately 73% white, 20% black, less than 1% American Indian 
and Alaskan Native, 6% Hispanic, and nearly 5% Asian. Ethnicity is an important 
5 
consideration as black, Hispanic and others are increasingly identified with hypertension as 
health care disparities continue to be addressed (U.S. Census Bureau, 2006). Research 
indicates that hypertension disproportionately affects blacks (57%) and other minorities 
(16%) who increasingly present with blood pressure levels well above acceptable levels 
(Reed, Hargraves, & Cassil, 2003). Additionally, treatment of hypertension in non-whites 
has been and continues to be inadequately addressed in the health-care setting (Clinical 
Drug Investigation, 2000; James, Thomas, Lillie-Blanton, & Garfield, 2007). 
Education and Health Literacy Status 
Education attained and literacy level influences the ability to comprehend complex 
health care directives (Wilson, Schoen, & Neuman, 2007). Health literacy may be a serious 
concern in this population. In a study by Prudential Center for Health Care Research, 
researchers recently found that 34% of English-speaking and 54% of Spanish-speaking 
respondents in their study of elders more than 65 years of age lacked health literacy 
(Gazmararian et al., 2008). 
Currently, 23% of elders have less than a high school education while one-quarter 
have completed a minimum of high school education and 47% have completed some 
college and advanced degrees (Centers for Disease Control and Prevention, 2007). 
Income and Poverty Status 
More than one-third of elders are considered low income (Centers for Medicare 
and Medicaid Services, 2006). Affordability issues for prescription drugs that improve lives 
or prevent disease have become critical due to 36% of those aged 65 years or more and 
58% of those aged 85 or greater are living in poverty (Moran & Simon, 2005; U.S. 
Department of Health and Human Services, 2004). Low-income Medicare elders often 
6 
lack the income or resources necessary to prevent or treat chronic disease and illness, 
including hypertension (Piette, Heisler, & Wagner, 2004). The prevalence of multiple 
chronic illnesses is greater for low-income Medicare elders than for those who are more 
affluent (Federman, Halm, Zhu, Hochman, & Siu, 2006). In addition, the ability to acquire 
supplemental health insurance is affected by income status (Stuart, Simoni-Wastila, & 
Chauncey, 2005) 
Poverty status also affects access to health care by making it less affordable (U.S. 
Department of Health and Human Services, 2004). The gap between access to prescription 
drugs for low-income elderly and those more affluent elders is a specific area of concern 
(World Health Organization, 2002). Additionally, women and minorities have 
disproportionately higher incidences of poverty (Agnew, Halprin, & Lipton, 2003; Moran 
& Simon, 2005). However, Medicare elders below 150% of the federal income poverty 
level are eligible for both Medicaid and Medicare and are considered Dual Eligible 
(Centers for Medicare and Medicaid Services, 2006; U.S. Government Accounting Office, 
2007). Medicaid provides an income supplement that includes food stamps, payment of 
Medicare Part B and automatic qualification for Extra Help. Extra Help pays Medicare 
Part D premiums, eliminates the deductible, and lowers co-pays at the drug store (Centers 
for Medicare and Medicaid Services, 2006; U.S. Government Accounting Office, 2007). 
Chronic Health Conditions 
The proper medical management of almost all chronic illnesses requires the 
ongoing use of prescription drugs (Brewer, Chapman, Brownlee, & Leventhal, 2002; Ead, 
1998; Loeb, Penrod, Falkenstern, Gueldner, & Poon, 2003; McCloskey, 2002; Sherer, 
2003; Stuart, 2004). Approximately 80% of all elderly have at least one chronic health 
7 
condition, with approximately 50% having two or more (U.S. Census Bureau, 2005) with 
approximately 36% of elderly Medicare elders having three or more chronic conditions to 
manage (Agency for Healthcare Research and Quality, 2002; Henry J. Kaiser Family 
Foundation, 2007b). With chronic illness comes the need for affordable prescriptions to 
treat or prevent adverse health events (Benson & Britten, 2002; Weschler, 2004; Wilson, 
Schoen, & Neuman, 2007). Through consistent, affordable prescription drug acquisition 
and usage, the possibility of a better quality of life may be attained through reductions in 
preventable morbidity and mortality (Soumerai et al., 2006; U.S. Department of Health 
and Human Services, 2004). 
Underuse Decisions: Intentional or Unintentional 
Prescription drug underuse may be either intentional or unintentional (Cooper, 
Love, & Raffoul, 1982; Corrigan, 2002; Lehan & McCarthy, 2006). The choice to 
underuse prescription drugs may stem from beliefs about effectiveness or safety (Vik, 
Maxwell, Hogan, Patten, Johnson, & Romonko-Slack, 2005) of the prescription drugs as 
well as unpleasant side effects (George et al., 2006). Intentional underuse may reflect 
acquisition decisions by marked decreases in the need to refill prescriptions (Vik et al., 
2005). Intentional acquisition or underuse of necessary prescription drugs may also be 
influenced by perceived needs for various prescription drugs (Benson & Britten, 2002; 
Cooper, Love, & Raffoul, 1982; George, Munro, McCaig, & Stewart, 2006). Conversely, 
research also indicates that multiple dosing and multipharmacology often contribute to 
unintentional adherence problems due to the number of pills, busy schedules and 
remembering (Haynes, McDonald, & Garg, 2002; Kirking, Lee, Ellis, Briesacher, & 
8 
McKercher, 2006; Lehan & McCarthy, 2004). However underuse occurs it, is necessary to 
understand the potential influence that may be exerted on acquisition decisions and health-
seeking behaviors (Yagoda, 2004). 
Cost Considerations 
Rising prescription drug prices affect both overall healthcare expenditures and 
perceived affordability of prescription drugs, especially for low-income Medicare elderly 
(Families USA, 2003,2006). Rising prescription drug prices adversely affect Medicare 
elders due to higher co-pays and higher out-of-pocket expenditures, especially when 
coverage gaps occur (Centers for Medicare and Medicaid Services, 2006; Crystal, 
Johnson, Harman, et al., 2000; Families USA, 2004; Klein, Turvey, & Wallace, 2004; 
Stuart, Simon-Wastila, & Chauncey, 2005). As of 2004, prescription drug costs accounted 
for more than 10% of Medicare elders' incomes and constituted 56% of Medicare elders' 
health-care costs, with average out-of-pocket costs approximately $2,500 per year 
(Gregory, 2004; Sloane, 2004; U.S. Department of Health and Human Services, 2005). 
While approximately 9% of elderly had no prescription drug costs, 91% of Medicare elders 
filled an average of 30 prescriptions annually (U.S. Department of Health and Human 
Services, 2004). Medicare elders with incomes of $10,001-$20,000 had the lowest average 
with coverage (73%) due to Medicaid eligibility (U.S. Department of Health and Human 
Services, 2004). 
Cost is a significant barrier to acquiring necessary drugs for the elderly (Ganguli, 
2003; James et al., 2007; LeBuono, 2004; Vik, Hogan, Patten, Johnson, Romonko-Slack, 
& Maxwell, 2006). For those with chronic health conditions, 18% of U.S. adults indicated 
that cost-related drug underuse occurs at least once per year (Piette, Heisler, & Wagner, 
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2004). Additionally, those elderly with high out-of-pocket expenses of $ 100 or more and 
annual incomes of less than $20,000 were more likely to have cost-related underuse 
(Piette, Heisler, & Wagner, 2004; Stuart & Briesacher, 2002). Ethnicity also affects cost-
related usage with approximately 17% of black Medicare elders reporting prescription 
drug underuse due to affordabiliry concerns as compared to 9% of whites (Gaskin, 
Briesacher, Limeangeo, & Brigantti, 2006; Reed, Hargraves, & Cassil, 2003). 
Preventable Cost and Health Consequences of 
Prescription Drug Non-use and Underuse 
In order for prescription drugs to provide beneficial outcomes (reducing morbidity 
and mortality), prescribed guidelines must be followed (Williams, 2002). When 
prescription drugs are not taken as prescribed the therapeutic benefits or prevention efforts 
are less than optimal (American Medical Association, 2002; Gottlieb, 2000; Mojatabai & 
Olfson, 2003). The implications for underuse or improper usage of prescription drugs have 
been linked to increases in emergency department visits (Lu et al., 2006; Piette, 2005; 
Prendergast, Marquez, Jr., Schilichting, & Figuroa-Pal, 2007) and doctor visits (Piette, 
Heisler, & Wagner, 2004). The costs of preventable readmissions attributable to underuse 
of prescription drugs range from approximately $1.4 billion to more than $374 billion, with 
increases of approximately 19% each year (Friedman & Basu, 2004). Research studies that 
track patient readmissions indicate that inappropriate prescription drug usage accounts for 
approximately 14 to 20% of emergency department visits and accounts for approximately 
35% of doctor visits annually (Budnitz, Shehab, Kegler, & Richards, 2007; Wofford, 
Schwartz, Timerding, Folmar, Ellis, & Messick, 1996). However, overall, adherence to 
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prescription drugs ranges from 17 to 70% depending upon type of medication and disease 
state (National Institutes of Health, 2003). 
Hypertension 
Hypertension (see Table 1) is defined as having persistent blood pressure levels 
above 140/90 (American Heart Association, 2007b). Current recommendations are to 
begin treatment in the pre-hypertension stage to prevent adverse consequences of damage 
that occurs at higher blood pressure levels (National Health Lung and Blood Institute, 
2006). Therefore, the need for antihypertensives that treats as well as prevents adverse 
Table 1 
Hypertension Levels 
Category 
Adult Blood Pressure Levels 
Systolic (mmHg) Diastolic (mmHg) 
(Top Number) (Bottom Number) Result 
Normal 
Pre-hypertension 
Hypertension 
Stage 1 
Stage 2 
Less than 120 
120-139 
140-159 
160 or higher 
Less than 80 
80-89 
90-99 
100 or higher 
Good 
May lead to 
Hypertension 
Need Rx to Control 
May need 
additional Rx 
Note. From data acquired from the National Heart Lung and Blood Institute, 2006 and the 
U.S. Department of Health and Human Services, 2003. 
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complications of hypertension is expected to continue to be a concern for the aging U.S. 
population (American Heart Association, 2007b; Chobanian, 2007; Ma, Lee, & Stafford, 
2006). 
Complications 
In 2004, cardiovascular disease accounted for approximately 22% of deaths 
(Minino, Heron, & Smith, 2006). Antihypertensives, when taken as prescribed, have the 
potential to prevent stroke and other cardiovascular complications (Andrawes, Bussy, & 
Belmin, 2006). However, left untreated, hypertension poses increased risk for heart disease 
and stroke (Centers for Disease Control and Prevention, 2005; Pinto, 2007). 
Antihypertensive underuse significantly influences preventable complications for 
hypertension and contributes to premature morbidity (American Heart Association, 2007b; 
Ryan, 1991). 
Antihypertensives 
Hypertension Treatment 
This study focused upon the acquisition of antihypertensives that have been shown 
to reduce hypertension and prevent further disease related complications (Centers for 
Disease Control and Prevention, February 2007a). The ability to treat and prevent adverse 
health outcomes depends upon continuous prescription drug acquisition and usage of 
antihypertensives to reduce preventable hypertension related morbidity and mortality 
(Field, Gilman, Subramanian, Fuller, Bates, & Gurwitz, 2005; Soumerai et al., 2006; U.S. 
Department of Healm and Human Services, 2004). In addition to use of one or more 
antihypertensives, hypertensive treatment also may include diet (Appel, Brands, Daniels, 
Karanja, Elmer, & Sacks, 2006), and lifestyle modifications (Schwartz & Sheps, 2006). 
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The classification of prescription drugs designated as antihypertensives and designed to 
prevent or treat hypertension, includes five main categories: ACE inhibitors, ACE II 
inhibitors, diuretics, beta-blockers, and calcium blockers (American Heart Association, 
2007b). The purpose of each targets a specific area that influences management of 
hypertension (high blood pressure) by regulating blood flow to increase heart efficiency 
(American Heart Association, 2007b). 
Current Use/Underuse of Antihypertensives 
Antihypertensives are prescribed for more than half of Medicare elders; with low-
level diuretics often used as the first line of treatment (Al Khaja, Sequeira, & Mather, 
2000; Nickolaus & Becker, 2000). After initial diagnosis, additional antihypertensives may 
be added to treat hypertension and prevent further complications related to the protection 
of the heart, liver, brain, eyes, and blood vessels (National Heart Lung and Blood Institute, 
2006). Initially, adherence for antihypertensives is high (approximately 87%) for the first 
few months after diagnosis, with sharp declines in usage within 6 months of diagnosis 
(American Heart Association, 2007b; Raehl, Bond, Woods, Petry, & Sleeper, 2006). 
Antihypertensive Costs 
The cost of antihypertensives have been rising approximately 19% annually while 
Medicare elders' incomes have remained relatively fixed (Blustein, 2000). Prescription 
drug costs are often indicated as reasons for underuse (Piette, Wagner, Potter, & 
Schillinger, 2004). Patients often indicate that prescription drug costs play an important 
role in underuse, which contributes to preventable readmissions (Fischer & Avorn, 2003; 
Lynch, 2006). Hypertensive Medicare elders, without prior prescription drug coverage, 
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faced immense difficulty in acquiring their antihypertensives due to cost considerations and 
were at greater risk for increased morbidity and mortality (RAND, 1999). 
Antihypertensive Prescription Drug Prices 
Table 2 provides examples of commonly prescribed antihypertensives (name brand 
and generic equivalent) using 2005 average costs (U.S Government Accounting Office, 
2005). 
Table 2 
Antihypertensive Prescription Drugs 
Antihypertensives 
ACE inhibitors 
Diuretics 
Beta-blockers 
Calcium Channel 
Blockers 
Name Brand 
Lotesin 
Vasotec 
Accupril 
Lasix 
Lopressor 
Corgard 
Inderal 
Toprol XL 
Norvasc 
Cardizem CD 
Procardia XL 
Calan SR 
Generic 
Benazepril 
Enalapril 
Quinapril 
Furosemide 
Metoprolol Tartrate 
Nadolol 
Propranolol 
Metoprolol Succinate 
Amlodipine 
Diltiazem 
Nifedipine 
Verapamil 
Average Monthly Cost 
$43 
$39 
$51 
$38 
$35 
$59 
$44 
$32 
$55 
$58 
$94 
$66 
Note. Adapted from Consumer Reports, 2005. 
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Pre-Medicare Modernization Act (MMA) 
Prior to the passage of the Medicare Modernization Act of 2003 (MMA), 
Medicare elders without prescription drug coverage had affordability issues due to the lack 
of coverage (Agnew, Halpin, & Lipton, 2003). The main consideration was cost due to the 
rapid increases in prescription drug prices (Centers for Medicare and Medicaid Services, 
2005c). In 2000, prescription drug costs on average amounted to approximately $1,340 
per elderly person with 17% having costs of $2,000 or more (U.S.. Department of Health 
and Human Services, 2004). In 2001, prescription drugs were 11% of health care costs 
and approximately 5% of elderly reported delays in health care needs due to cost 
considerations (U.S. Department of Health and Human Services, 2004). 
Overall out-of-pocket expenditures for prescription drugs accounted for 
approximately 56% of health care service spending for elderly Americans for 2000-2001 
(U.S. Department of Health and Human Services, 2004). Medicare elders without prior 
prescription drug coverage often had to choose between prescriptions or other basic 
support needs such as food or utilities (Conway-Welch, 2000; Crystal, Johnson, Harman et 
al., 2000; Poisal & Chulis, 2000; Sarver, Sudano, & Baker, 2000). In 2002, nearly one-half 
(48%) of those aged 65 and older took three or more prescriptions monthly, spending 
approximately $3 billion annually on prescription drugs (Williams, 2002). The high out-of-
pocket costs were especially difficult for one-third of Medicare elders, who, without prior 
prescription drug coverage, paid 45% of the cost of prescriptions (Meyer, 2002). In 2004, 
out-of-pocket expenses were approximately 42% with 35% covered by private insurance 
and public programs covering 23% of prescription drug costs (U.S. Department of Health 
and Human Services, 2004). 
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The goal to provide community-based health education and outreach for basic 
health services to underserved populations is highlighted by Healthy People 2010 (U.S. 
Department of Health and Human Services, 2000). The Medicare Modernization Act 
(MMA) prescription drug benefit was designed to address this goal by increasing access to 
affordable prescription drugs for the more than 44 million U.S. Medicare elders through 
education and outreach efforts (Agnew, Halpin, & Lipton, 2003; World Health 
Organization, 2002) to include approximately 947,000 Virginians (Virginia Department for 
the Aging, 2005). Current research indicates that despite MMA's best efforts to increase 
access to affordable prescription drugs for Medicare elders, cost related problems remain 
(Bowman, 2007; Hsu, Fung, Price, Huang, Brand et al., 2008). Additionally, since the 
MMA of 2003 was implemented to increase access to affordable prescription drugs by 
reducing out-of-pocket costs (Henry J. Kaiser Family Foundation, 2006; Neff, 2004; 
O'Brien, 2003) little has been done to examine the extent to which the policy has actually 
increased prescription acquisitions, specifically for antihypertensives. 
Highlights of Medicare Modernization Policy 
Medicare Modernization Act Implementation 
The Medicare Modernization Act of 2003 (MMA) was implemented in several 
stages and open enrollments periods differ depending upon Part D product (Centers for 
Medicare and Medicaid Services, 2007). The full-scale implementation of the MMA began 
January 1, 2006, following an initial, voluntary two-year (FY2004 and FY 2005) Medicare 
Approved Drug Discount card with an annual credit (up to $600) qualifying, low-income 
Medicare enrollees (Centers for Medicare and Medicaid Services, 2005c). 
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Timeline 
Older Americans Act (OOA) of 1965 - Excluded Prescription Drug Coverage 
Legislation to amend OAA to include prescription drugs passes December 8,2003 
Transitional Program (Medicare Approved Drug Discount Card [MDC]) FY 2004 -
FY 2005 
Part D Implementation - Fully implemented January 1,2006 
Open Enrollment completed December 31,2006, for Prescription Drug Plans (PDPs) 
Open Enrollment completed March 15,2007, for Medicare Advantage Plans (MA & 
MA-PDs) 
Open Enrollment completed December 31,2007, for Prescription Drug Plans (PDPs) 
Open Enrollment completed March 31,2008, for Medicare Advantage Plans (MA & 
MA-PDs) 
The MMA of 2003 was enacted to reduce disparities due to prescription drug affordability 
(Matthews, 2004). The MMA expanded Medicare to provide a prescription drug benefit 
previously lacking in the original Older Americans Act of 1965 and subsequent revisions 
(Centers for Medicare and Medicaid Services, 2005c; Klein, 2003; Swartz, 2003; Weeks, 
2004). 
Medicare Modernization Act: Voluntary Options (FY 2004 - FY 2005) 
Medicare Approved Drug Discount Card Program 
The two-year voluntary Medicare Approved Drug Discount Card program (MDC) 
in FY 2004 - FY 2005 was a transitional program, which provided 40% discounts and 
monetary credits (up to $1,200) for qualifying low-income Medicare elders (Centers for 
Medicare and Medicaid Services, 2005a; U.S. Department of Health and Human Services, 
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2004). Monetary credit approval was determined by annual gross income and excluded 
assets (Centers for Medicare and Medicaid Services, 2005c). The MDC program's 
intentions were to reduce prescription drug costs, especially for those previously without 
prescription drug coverage (Centers for Medicare and Medicaid Services, 2005a). For FY 
2004, Medicare elders had 28 nationwide and 19 regional Medicare Approved prescription 
discount card (MDC) choices (Barlas, 2004). For FY 2005, Medicare elders in the state of 
Virginia had 39 plans to choose from in making their enrollment decisions (Centers for 
Medicare and Medicaid Services, 2005a). Medicare elders who enrolled in 2004 were able 
to change cards in 2005, if the card selected did not meet their drug discount needs; 
however, premiums varied by program enrollment, wraparound coverage and drug plan's 
formularies that could be frequently changed or not used (Barlas, 2004). Approximately 
187,000 Medicare elders in southeastern Virginia were screened for this benefit (Virginia 
Department for the Aging, 2005). 
Medicare Modernization Act: Part D Implementation (FY 2006- FY 2008) 
Medicare Part D 
The MDC program was phased out as of January 1,2006, when the Medicare 
Modernization Act (MMA) became fully implemented (Centers for Medicare and Medicaid 
Services, 2006). Since MMA's full implementation, 19 million Medicare elders have 
enrolled in Part D plans (both stand-alone prescription drug plans and Medicare Advantage 
plans with prescription coverage) thereby providing a prescription drug benefit to 
Medicare elders previously lacking coverage (Centers for Medicare and Medicaid Services, 
2005e). Additionally, as of 2006, only 8% of Medicare elders were without coverage, as 
opposed to 33% in 2005 (Kaisernetwork.org, 2007). For FY 2006, the number of 
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Medicare approved plans from which Virginia Medicare elders had to choose was 41. That 
number increased to more than 51 for FY" 2007 and more than 53 for FY 2008 (Centers for 
Medicare and Medicaid Services, 2008). Since MMA's full implementation in FY 2006, 
open enrollment has been completed for FY 2007 and FY 2008 (Centers for Medicare and 
Medicaid Services, 2008). 
Medicare Advantage Plans 
Medicare elders who decide to bundle Part A, B, and D benefits may choose a 
Medicare Advantage plan (Centers for Medicare and Medicaid Services, 2005d). Medicare 
Advantage plans were formerly called Part C or Medicare + Choice (Centers for Medicare 
and Medicaid Services, 2005d). Medicare elders may choose to enroll in a Medicare 
Advantage plan if they perceive them as providing the best benefit (maximum utility) since 
these plans are expected to result in increased savings (Centers for Medicare and Medicaid 
Services, 2006). Another possible reason for selecting a Medicare Advantage plan is that 
the premium is paid by Medicare while the Medicare elders' health care provision is 
managed by approved coverage providers (Centers for Medicare and Medicaid Services, 
2005c). Medicare elders must continue to pay their Part B premium, with the exception 
being those Medicare elders who also have Medicaid, which will pay their Part B premium 
(Henry J. Kaiser Family Foundation, 2006). However, Medicare elders without Extra Help 
who select Advantage plans may experience unexpected higher co-pays at both the 
doctors' office and at the pharmacy (Hoadley, Thompson, Hargrave, Merrell, Cubanski, & 
Neuman, 2007). For Dual Eligibles (with both Medicare and Medicaid) who automatically 
qualify for the Extra Help benefit, Advantage plans have fixed co-pays for prescription 
drugs and have no deductible or coverage gap (Elam, 2006). 
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Complexity of the Part D Decision-making Processes 
Creditable Coverage Status 
Medicare elders' decision to participate in the Medicare Modernization Act 
(MMA) implementation often depends upon creditable coverage3 status. Medicare elders 
with creditable coverage are not required to participate in MMA. However, Medicare 
elders without creditable coverage must enroll in a Medicare prescription drug discount 
plan or pay a late enrollment penalty when they later decide to participate (Centers for 
Medicare and Medicaid Services, 2005a). 
Medicare elders with creditable coverage may choose to explore their MMA 
options to determine if they may be able to reduce their current prescription drug costs by 
selecting a cost-effective alternative (utility maximizing) to employer-based plans (Folland, 
Goodman, & Stano, 2004). In addition, those with employer-based plans who are able to 
isolate the prescription drug portion may elect to utilize MMA to reduce their out-of-
pocket expenditures (Centers for Medicare and Medicaid Services, 2006). Lastly, 
employees with creditable coverage who retire or turn 65 are increasingly losing coverage 
when become eligible for Medicare (Henry J. Kaiser Family Foundation, 2007b). 
Extra Help Decision-making Processes 
Extra Help (i.e., Low-Income Subsidy [LIS]) approval status may influence Part D 
enrollment decisions since Extra Help eliminates plan deductibles and premiums, and 
subsidizes co-pays for qualifying Medicare beneficiaries (U.S. Government Accounting 
Office, 2007). Medicare elders are screened for Extra Help eligibility, which has income 
(150% of poverty level), and assets (less than $11,700) requirements (Elam, 2006). 
^Creditable coverage is defined as previous insurance that is considered "as good or better" 
than Medicare (Centers for Medicare and Medicaid Services, 2004). 
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The three methods by which Medicare elders may apply for the Extra Help benefit 
are as follows: (a) at Social Security Administration, (b) by mail, or (c) via an online 
submission process (Centers for Medicare and Medicaid Services, 2005a). Medicare elders 
who are denied Extra Help may appeal the decision with an independent qualifying agency 
(Centers for Medicare and Medicaid Services, 2005a; U.S. Government Accounting 
Office, 2007). Medicare elders who are ineligible or denied Extra Help may choose to 
participate in an MMA benefit plan to avoid the late or non-enrollment penalty (Centers for 
Medicare and Medicaid Services, 2005a). Since the full implementation of the MMA on 
January 1,2006, there remain Medicare elders who are still unaware of Part D or Extra 
Help (Henry J. Kaiser Family Foundation, 2007b). For this study, only Medicare elders 
who are aware of Extra Help, have been screened for it, and who are currently enrolled in 
an MMA plan will be included. 
Part D Decision-making Processes 
Part D Enrollment 
Medicare elders without previous prescription drug coverage may utilize the 
Medicare prescription drug discount plan finder through the Medicare website to narrow 
the choices by deductible, co-payments, and annual expected out-of-pocket costs (Centers 
for Medicare and Medicaid Services, 2005d). Medicare elders who perceive enrollment as 
potentially beneficial in reducing their out-of-pocket costs for prescription drugs and know 
that a non-enrollment penalty may be imposed will usually join a Part D plan (Henry J. 
Kaiser Family Foundation, 2005). 
Figure 1 illustrates the different choices involved in application and enrollment 
decisions. Dual Eligible (both Medicare and Medicaid) automatically qualify for the Extra 
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Help benefit and usually are automatically enrolled in a prescription drug discount plan. 
For those eligible who apply, they may either be approved or denied. For those who are 
denied, an appeals process is available. Based upon Extra Help status, they may choose to 
either enroll or not enroll. Some Medicare elders are eligible but prefer not to apply for 
Extra Help or to enroll in a Part D plan, despite their knowledge of a penalty. 
The Part D enrollment decision-making process (see Figure 2) allows making 
informed decisions regarding the selection of a best plan for a given coverage year 
Extra Help (Low Income Subsidy "LIS") Status Part D Status 
Eligible 
Appeals Process 
Apply 
Appeal vA 
Approved 
Denied 
Auto 
Enrolled 
Enroll 
Ineligible Do Not Apply 
Not Enroll 
Figure 1. Influence of Extra Help (Low-Income Disability or LIS) and Part D Enrollment 
Decisions. 
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(Centers for Medicare and Medicaid Services, 2005b). Medicare participation in MMA is 
expected to result in savings of up to 40% for those Medicare elders who elect to enroll in 
a prescription drug discount plan (Centers for Medicare and Medicaid Services, 2005a). 
The plan finders utilize the generic costs where requested to estimate the annual 
prescription drug costs. Medicare elders with Extra Help are able to save money by not 
having a deductible, low co-pays, and Medicare paying Part D premiums. Medicare elders 
with Dual Eligibility automatically qualify for Extra Help with Medicare paying Part D 
premiums and Medicaid paying Part B premiums. Medicare elders without Extra Help are 
Individual 
Perceptions 
Adhere to 
treatment 
Decrease Disease 
Related 
Complications 
Perceived 
Barriers 
Late Enrollment 
Penalty 
Number of Plan 
Choices 
Premiums 
Co-pays 
Coverage gaps 
Rxnoton 
Formulary 
Extra Help 
Approval 
Perceived 
Benefits 
Health 
Improved 
Reduce Annual 
Out-of-Pocket 
costs for Rx 
Enrollment 
Status 
Enroll in 
PartD 
Do Not 
Enroll in 
PartD 
Figure 2. Part D Enrollment Decision-Making Process. 
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subject to periods when they are responsible for 100% of their prescription drug costs 
versus Extra Help elders who never reach the gap. 
The acquisition decision-making process may lead Medicare elders to participate in 
the MMA prescription drug benefit depending upon their perceptions of the benefits and 
the barriers that may ultimately influence their ability to acquire antihypertensives. MMA 
decisions apply only to the current year and Medicare elders may rollover their Part D plan 
(Centers for Medicare and Medicaid Services, 2006); however, Medicare encourages 
Medicare beneficiaries to reevaluate plan choices each year as plan choices are updated 
and health status may have changed (Centers for Medicare and Medicaid Services, 2005a). 
Various Methods Utilized to Solve the MMA Benefit Dilemma 
For those who do not qualify for the Extra Help benefit, the decision is the 
verification that the prescription drug plan's formulary includes the drugs that are taken 
with no or a low deductible and the monthly premium costs are affordable. For Medicare 
elders who take no prescription drugs, they are advised to enroll in the plan with the least 
expensive premiums to avoid a late enrollment penalty. 
To illustrate the complexity of the MMA decision-making process the following 
three representative scenarios highlight individualized approaches to addressing the 
MMA's health care decisions. The first scenario explores Medicare Part D without Extra 
Help. The second scenario describes Medicare Part D using a prescription drug discount 
plan with Extra Help. Lastly, the third scenario discusses the decision to choose a 
Medicare Advantage plan (previously called Medicare Part C) to solve the health care and 
prescription drug dilemma. Each case has its own unique benefits and drawbacks. 
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MMA Decision-making Process Scenario I: Medicare Part D without Extra Help 
The MMA's prescription drug discount plan benefit process often starts with Mr. 
Green (not his real name) receiving correspondence from the Centers for Medicare and 
Medicaid Services (CMS) when he becomes eligible for Medicare (up to three montiis 
before his 65th birthday). Initially, Mr. Green has seven months to select a MMA plan (three 
months before, the month of, and three months after his 65* birthday) if he is not covered 
by an equitable (creditable coverage) plan. Mr. Green's Welcome Package from the CMS 
indicates that Medicare beneficiaries without creditable coverage (employer- or military-
based insurance plan) must enroll in the Medicare prescription drug benefit or be subject to 
a late enrollment penalty (Centers for Medicare and Medicaid Services, 2005). Those who 
must participate are directed to their local SSA or the website (www.ssa.gov) to apply for 
their Medicare card and be screened for Extra Help (Medicare also provides their website 
and toll-free number for further assistance. Often callers are referred to their local State 
Health Insurance Programs [SHIPs] or Agency on Aging). Mr. Green learned that 
Medicare elders who met the assets and income requirements for Extra Help might apply 
to be screened through their local SSA office or SHIP office (Centers for Medicare and 
Medicaid Services, 2006). 
In addition, while Mr. Green had creditable coverage with his employer, his 
benefits department informed him that he would lose this coverage when he turns 65 years 
of age and encouraged him to choose a Medicare prescription drug discount plan. Mr. 
Green is angry and disappointed to learn that he will have to find his own health plan that 
includes a prescription drug plan. He is overwhelmed by the amount of correspondence 
that he has been receiving from the CMS, the SSA and numerous Medicare approved and 
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non-approved health insurance companies providing health coverage both with and 
without prescription drugs. The information that Mr. Green received from CMS indicates 
that there are 53 stand-alone prescription drug discount plans (PDPs), 21 Advantage (MA-
PD & MA only) as well as 2 Special Needs plans in southeastern Virginia (Centers for 
Medicare and Medicaid Services, 2007). 
Mr. Green started by calling CMS's 800 number and navigating through the 
numerous prompts. The expected wait time for the next available representative was 
approximately 25 minutes. A recording indicated that he cold hold, call back, or use the 
Medicare website to receive assistance. After about 20 minutes, Mr. Green became tired of 
waiting and called his brother, Mr. Lane (not his real name), who went through this 
process last year. Mr. Green learned that Senior Services of Southeastern Virginia, the 
local VICAP (Virginia Insurance Counseling Assistance Program) office, could assist by 
simplifying the enrollment process and answering questions about his options. Mr. Green 
brought the mailings that he received, his prescription drug bottles, and a copy of the 
insurance information from his employer's group plan to his appointment. He hoped to get 
similar coverage under the MMA that he had with his employer's group-based plan. Mr. 
Green was screened for Extra Help, but did not qualify because his assets were more than 
the limit (more than $11,750) and greater than the income (less than $12,675 for a single 
person) to qualify for the benefit. Additionally, Mr. Green believed that he would get 
approximately $30,000 annually (after taxes) and wanted a Medicare plan that minimized 
his annual out-of-pocket expenses for health insurance and prescription drug costs. 
Mr. Green had been taking three prescriptions each day that cost him 
approximately $230 per month in co-pays. For 2007, Mr. Green selected a Medigap 
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supplement and a stand-alone prescription drug discount plan (PDP) with approximately 
$7,700 estimated annually to cover his health insurance expenses. Annually, Mr. Green has 
estimated out-of-pocket expenses for prescription drugs were approximately $2,695 
including premiums and co-pays. Mr. Green selected a PDP that did not have gap 
coverage, so during five months his out-of-pocket expenses were expected to be 
approximately $275. However, when he reached the coverage gap (donut hole) he found 
he was paying $678 per month for the same three prescriptions. After Mr. Green 
discovered how much more he would pay in the coverage gap, he stopped taking one of 
his prescriptions and asked his doctor about free samples for another one. During open 
enrollment (November 15 - December 31) for the next year Mr. Green considered 
switching his PDP but did not want to go through the aggravation of selecting another 
plan especially when gap coverage was not widely available for any of the plans. 
Medicare Part D Decision-making Process Scenario 2: Medicare Part D and Extra Help 
Ms. Smith (not her real name) wanted to retire and researched the possibility of 
affording health insurance when she stopped working. She had worked for 25 years as a 
night auditor for a well-known chain store. Her benefits were good, but her wages were 
modest. She was unable to accumulate much retirement savings ($9,000) and would not 
receive more than $1,025 monthly from her retirement and Social Security. Ms. Smith was 
recently hospitalized. She takes seven prescription drugs that cost $90 in co-pays with her 
employer-based health plan. Her health plan covered all her hospital expenses except 
$2,000, for which she has arranged to make payments. 
Ms. Smith contacted her local VICAP to discuss her retirement options. She 
received information about discounted senior housing that can help her to reduce her living 
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expenses. Ms. Smith also discovered that applying for Medicaid would pay her Part B 
premium (upon approval) and that when she stopped working she would become eligible 
for Medicaid. As a Dual Eligible (having both Medicare and Medicaid) Ms. Smith would 
automatically qualify for Extra Help (i.e., Low-Income Subsidy) and automatically be 
enrolled in a Medicare Part D plan. 
Ms. Smith retired, was approved for Medicaid, and got her Medicare Part D plan. 
However, Ms. Smith found that the plan that was randomly chosen for her did not cover 
three of her prescription drugs. Ms. Smith contacted her local VICAP office and assisted 
with selecting another plan whose formulary included the prescription drugs she was 
currently taking. Since she qualified for Extra Help, Ms. Smith has no deductible, no 
premium, and low co-pays (approximately $2.40 for generics and $5.00 for name brands) 
for her prescription drugs. Ms. Smith is satisfied with her new plan and will keep it for the 
upcoming year. Ms. Smith will re-evaluate her plan as her health care provider prescribes 
new prescription drugs. 
Medicare Decision-making Process Scenario 3: Medicare Advantage Plan 
Mr. and Mrs. Brown (not their real names) live in a senior citizens' housing 
complex where an insurance presentation was offered for the Medicare Modernization Act 
(MMA) benefit. Pizza and drinks were served during the presentation and the Browns 
were asked to sign-in to prove that they had attended the event. Mr. and Mrs. Brown got a 
welcome package, approximately a week later, and learned that they had been enrolled in a 
Medicare Advantage plan. They did not understand why they were placed into this plan, 
but as there was no premium, they decided that they would keep the plan and see how it 
worked. When Mrs. Brown went to the doctor two months later, she was informed that 
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her doctor did not accept her Medicare Advantage plan and she would have to pay out-of-
pocket for the visit. 
As Mr. and Mrs. Brown are over the limit for Extra Help, they are not able to 
change their plan except during their annual enrollment period. Mr. and Mrs. Brown's 
previous health insurance had been employer-based with affordable monthly premiums and 
co-pays. However, upon being enrolled in the Medicare Advantage plan, Mr. and Mrs. 
Brown lost this coverage. While the Brown's appreciated not having to pay a premium, the 
Advantage plan did not offer comparable coverage and they were forced to seek a doctor 
who would accept their plan. 
The couple contacted their local VICAP office to see what could be done to assist 
them with getting their former coverage back. The Medication Education Counselor tried 
to contact the agent who had given the presentation and a fraudulent enrollment complaint 
was submitted to Medicare Complaints. Within a day, the assigned caseworker contacted 
the Browns for a follow-up. Mr. and Mrs. Brown explained that they did not agree to have 
their plan switched and they were never told that their doctor does not have to accept their 
Medicare Advantage plan. The caseworker was willing to switch the them back to their 
previous plan; however, the employer-based plan was not willing to do so. The caseworker 
dis-enrolled them from the Advantage plan and placed them back into original Medicare. 
The couple then discussed their options with the VICAP counselor who assisted 
them with obtaining a stand-alone PDP and a Medigap supplement, which works with 
original Medicare (Advantage plans do not). The Browns each selected a PDP based upon 
their different prescription drugs, but were able to select the same Medigap supplement. 
The Browns were happy that they could continue to see their same doctor and their overall 
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out-of-pocket health care expenses were less than before, even with having higher monthly 
premiums. The Browns were satisfied with their choices. They were advised to re-evaluate 
their plan choices annually to insure that they had the most affordable coverage given the 
revised plans each year. 
Out-of-Pocket Expenses 
Out-of-pocket expenses influence acquisition abilities and include those items that 
Medicare elders pay out-of-pocket to meet their healthcare needs (Centers for Medicare 
and Medicaid Services, 2005a). Part D enrollment and Extra Help (Limited Income 
Subsidy [LIS]) approval status may reduce out-of-pocket expenses possibly influencing 
antihypertensive acquisition decisions. These out-of-pocket expenses include the 
premiums, deductibles, and prescription drug co-pays as well as gap {donut hole) expenses 
and may influence Medicare elders' decisions to enroll in a Part D plan that may ultimately 
influence antihypertensive acquisitions. 
Premiums 
Part D premiums (see Table 3) vary by covered prescription drug and the amount 
of gap coverage offered by each plan (Blum, Bowman, & White, 2005; Centers for 
Medicare and Medicaid Services, 2006). The average monthly premium for PDPs rose by 
approximately 17% as contrasted widi the Medicare Part B premium that experienced only 
a 3.1% increase from 2006 to 2007 (Hoadley, Thompson, Hargrave, Merrell, Cubanski, & 
Neuman, 2007). For 2008, the average monthly Part D premium is approximately $25 with 
annual increases expected (Henry J. Kaiser Family Foundation, 2008). Part D premiums 
may influence Medicare elders' decisions to enroll in a Part D plan and may affect their 
ability to acquire antihypertensives. 
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Table 3 
Part D Premiums, Deductibles, Co-pays, Gap ("Donut Hole "), and 
Catastrophic Coverage Limits 
Out of Pocket Expenditures 2006 2007 2008 
Monthly Premiums (Range) $8.81 - $56.50 $13.51-$92.30 $15.10-$64.80 
Annual Deductibles $250 $265 $275 
Co-pays (per Rx) Vary by plan Vary by plan Vary by plan 
Annual Donut Hole ("Gap") $2,400 $2,510 $2,525 
Annual Catastrophic 
Coverage Limits $5,451 $5,726 $5,754 
Note. Adapted from Medicare Prescription Drug Discount Plans, 2006,2007,2008. 
Deductibles 
The decision to acquire a plan with a deductible lowered the monthly premium 
(Centers for Medicare and Medicaid Services, 2006). For those Medicare elders with LIS, 
deductibles were not applicable (Centers for Medicare and Medicaid Services, 2007). The 
deductibles (see Table 4) for Part D are subject to annual increases and vary by plan. 
Currently, Part D plan deductibles range from $0 to $275 for 2008. In 2007, the deductible 
ranged from $0 to $265 for those plans with a deductible and was slightly lower at $250 
for 2006 (Henry J. Kaiser Family Foundation, 2006,2007a). 
Gap or Donut Hole Coverage 
Coverage in the gap or donut hole is offered on a plan-by-plan basis; coverage is 
extremely limited (Centers for Medicare and Medicaid Services, 2006,2008; Wilensky, 
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2004). In FY 2006, coverage gaps occurred when Medicare elders reached out-of-pocket 
costs of approximately $2,400 until catastrophic coverage began at $3,051 (with total out-
of-pocket expenditures of $5,451). In 2006, several plans offered gap coverage for both 
name brand and generics. However, for FY 2007 only one plan provided full gap coverage 
and discontinued that benefit for FY 2008. Often, plan providers have limited gap 
coverage (generics only) with six companies offering that benefit. For 2008, once 
Medicare members have paid more than $5,754 out-of-pocket costs, their co-pays will be 
5% and Medicare will assume the other 95%. In die donut hole or coverage gap, Part D 
premiums are collected even though prescription drug discounts are minimal (Centers for 
Medicare and Medicaid Services, 2008). 
Since the implementation of the Medicare Modernization Act (MMA), Medicare 
elders unwilling to pay higher premiums for minimal gap coverage {donut hole) may 
experience periods where they are responsible for 100% of prescription drug costs despite 
having a prescription drug discount plan (Centers for Medicare and Medicaid Services, 
2006; Families USA, 2006). While in the coverage gap, Medicare elders may eliminate 
costly prescription drugs or reduce those perceived as nonessential without telling their 
physicians (Wilson, Schoen, & Neuman, 2007). The implications for these benefit limits are 
that Medicare elders are using fewer prescriptions with higher hospitalizations and 
decreased clinical outcomes (Hsu et al., 2008). 
Bridging the Coverage Gap or Donut Hole 
The ability to obtain coverage in the donut hole or coverage gap is extremely 
limited and currently applies to select generics (Centers for Medicare and Medicaid 
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Services, 2008). Methods utilized to save money may include pharmaceutical assistance 
programs covered by state funding (SPAPs), pharmaceutical assistance programs (PAPs) 
offered by individual prescription drug manufacturers, and charitable programs (national 
and community) that may provide discounted or free drugs. Additionally, switching to 
over-the-counter (OTC) or lower-cost generics or store brands may reduce out-of-pocket 
costs (Centers for Medicare and Medicaid Services, 2008). However, using the Medicare 
prescription drug plan throughout the year allows the appropriate accumulation of 
prescription drug spending to apply toward the catastrophic coverage amounts (Centers 
for Medicare and Medicaid Services, 2008). 
Recent research (Madden, Graves, Zhang, Adams, Briesacher, Ross-Degnan et al., 
2008) indicates that proposed donut hole or coverage gap solutions are minimally effective 
as not all Medicare elders know about the options and often only generics are available 
while the more expensive, name-brand drugs are excluded. Approximately 20% of 
Medicare elders continue to struggle when acquiring their prescription drugs. 
Prescription Drug Co-pays 
Prescription drug co-pays are based upon the negotiated prices offered under 
specific plans and are not the same at all drug stores (Centers for Medicare and Medicaid 
Services, 2006). Co-pays affect the total out-of-pocket costs and may influence Medicare 
elders' ability to acquire their prescription drugs with Medicare elders opting out of having 
prescription drugs refilled if they perceive that plan premiums and prescription drug co-
pays (approximately $2.35 for generics and approximately $5.35 for name brands) are too 
high (Williams, 2002). Medicare elders with Extra Help (LIS) premiums are paid by 
Medicare and their co-pays are much lower (Centers for Medicare and Medicaid Services, 
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2008). While seemingly affordable, often Medicare elders with approved Extra Help are 
still unable to acquire their prescription drugs despite the financial assistance (Centers for 
Medicare and Medicaid Services, 2008; Kanavos & Gemmill, 2004; Williams, 2002). 
Name Brands versus Generics 
Research (Federman et al., 2006; Spence, Hui, & Chan, 2006) indicates that 
Medicare elders could greatly reduce their out-of-pocket expenses by switching to 
generics. Medicare's plan finder (www.medicare.gov) uses generic prices, where available, 
to calculate expected annual plan costs for the prescription drug benefit (Gavin, 2007). 
Additionally, Medicare elders are instructed to ask their doctors to switch their brand name 
prescriptions to generics in effort to lower out-of-pocket expenses, as well as to help 
bridge coverage gaps (Centers for Medicare and Medicaid Services, 2008). Cost savings 
of approximately 73% are expected for Medicare beneficiaries who switch from brand 
name prescribed drugs to generic versions (Centers for Medicare and Medicaid Services, 
2005c). However, research to determine if income influenced generic prescription drug use 
indicated that slightly more low-income Medicare elders were more likely to use generics 
as opposed to those who were more affluent (Federman et al., 2006). 
Mail Order and Reimportation Options 
Two cost-saving methods being used by Medicare elders to save money on 
prescription drugs include mail order and reimportation (Reed, 2005). Mail order offered 
by PDPs may legally save Medicare elders on prescription drug costs (Centers for 
Medicare and Medicaid Services, 2005a). However, Medicare elders must consider the 
availability of mail order under plans and its costs to acquire prescription drugs; of special 
concern to Medicare elders when using mail order are the perceived costs (90-day supply) 
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and shipping costs (Centers for Medicare and Medicaid Services, 2006). Additionally, in 
their efforts to save money Medicare elders may choose to acquire prescription drugs 
through reimportation from Canada, Mexico, or European countries {American Journal of 
Nursing, 2004; Weschler, 2004a). Although Medicare elders believe savings are being 
realized, reimportation is a grey area with some plans recognizing prescription drugs 
acquired from abroad, while other plans provide no cost incentive to pursue reimportation 
(American Journal of Nursing, 2004; Weschler, 2004a). 
Understanding Health Behavior 
To address health behaviors and propose solutions for overcoming health-related 
barriers, researchers developed models to examine these phenomena (Johnson, 2002; 
Rosenstock, Strecher, & Becker, 1988). These models have been used to develop 
intervention methods for improving health outcomes. They attempt to explain health-
related behaviors with the intent of developing interventions to improve health outcomes 
(Johnson, 2002; Rosenstock, Strecher, & Becker, 1988). The Health Belief Model (HBM) 
and the Medication Adherence Model (MAM) are two models designed to examine health 
beliefs and behaviors that influence whether individuals will overcome barriers necessary to 
practice healthier behaviors or adhere to prescribed treatment regimens (Bandura, 1986; 
Janz & Becker, 1984; Johnson, 2002). However, antihypertensive acquisition decisions, 
due to their complex nature, require integrated multidisciplinary approaches to understand 
decision-making strategies and processes used by Medicare elders. 
Theory and Models 
The intent of this study was to develop and test an integrated multidisciplinary 
theoretical model that accurately depicted antihypertensive acquisition behaviors. This 
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study tested the enhanced Health Belief Model (HBM), which includes self-efficacy 
(Bandura, 1997; Janz & Becker, 1984), against the proposed Pharmaceutical Acquisition 
Model for Medicare Elders (PAMME) to determine whether the proposed model is better 
at explaining Medicare elders' antihypertensive acquisition behaviors. The proposed 
PAMME was tested to determine if it could explain which factors influence 
antihypertensive acquisition by Medicare elders, accounting for cost and usage intentions. 
In particular, it explored the attitudes and beliefs of Medicare elders as they specifically 
relate to health insurance, hypertension, antihypertensives, and adherence decisions to 
determine what influences they have on antihypertensive acquisition. This study examined 
those attitudes and behaviors that influence antihypertensive acquisition to determine 
predictability from the various influencers that may contribute to antihypertensive 
acquisition. By understanding the health beliefs and behaviors that lead to acquisition 
behavior, utilizing consumer choices, and adherence decisions for Medicare elders, it may 
be possible to improve prediction for antihypertensive acquisition and adherence behaviors. 
Assumptions 
In an examination of Medicare elders' acquisition of antihypertensives several 
assumptions were made, namely: 
1. Medicare elders are capable of rational decision making with respect to 
antihypertensive acquisitions. 
2. Medicare elders who enroll in a Part D plan do so with the belief that they will 
reduce their out-of-pocket acquisition costs for antihypertensives. 
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3. Medicare elders who apply and are approved for Extra Help believe that they 
will reduce their out-of-pocket acquisition costs for antihypertensives. 
4. Medicare elders were honest about their antihypertensive acquisitions. 
Limitations 
Several limitations to this study were indicated. They are as follows: 
1. Administered survey responses are self-reported and may not accurately reflect 
antihypertensive acquisition experiences. 
2. The telephone may not be the best method of communication for Medicare 
elders due to hearing or comprehension concerns. 
3. The study is limited to English-speaking, hypertensive, consenting Medicare 
elders. Their experiences may differ from those not consenting to participate. 
4. Medicare elders who are not competent to make their own health-care decisions 
were excluded from the study. 
5. Medicare enrollment data to be utilized excludes disabled and those not subject 
to Medicare Part D enrollment (military or government retirees or other individuals with 
creditable coverage). 
Research Questions 
1. To what extent do Medicare elders actually acquire antihypertensives as 
prescribed? 
2. To what extent does the enhanced Health Belief Model (HBM) overall explain 
antihypertensive acquisition behavior for hypertensive Medicare elders? 
2a. Do individual perceptions about disease severity influence Medicare elders' 
decision to acquire antihypertensives? 
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2b. Do perceived benefits of antihypertensives influence Medicare elders' decision 
to acquire antihypertensives? 
2c. Do perceived barriers to acquiring antihypertensives influence Medicare elders' 
decision to acquire antihypertensives? 
2d. Does perceived seriousness of hypertension influence Medicare elders' decision 
to acquire antihypertensives? 
2e. Do cues to action influence Medicare elders' decision to acquire 
antihypertensives? 
3. To what extent do constructs from other models (Medication Adherence Model 
and Consumer Choice Theory Model) help to explain antihypertensive acquisition behavior 
for Medicare elders? 
3a. Are Medicare elders confident that they can overcome antihypertensive out-of-
pocket cost barriers in order to acquire antihypertensives? 
3b. Do Medicare elders perceive other barriers to acquiring antihypertensives? 
4. Does the integrated Pharmaceutical Acquisition Model for Medicare Elderly 
(enhanced Health Belief Model with constructs from Consumer Choice Theory and 
Medication Adherence) explain antihypertensive acquisition behavior for Medicare elders 
better than the enhanced Health Belief Model? 
Significance of the Study 
This study examined underuse as it related to antihypertensive acquisitions. 
Prescription drug underuse has been a concern for healthcare providers who want to 
improve patients' health (Ead, 1998; Gottlieb, 2000; Kirking et al., 2006). Through 
treatment regimens that include regular access to and refill acquisitions by Medicare elders, 
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healthcare providers may assist in controlling or preventing adverse health events (Ead, 
1998; Mojatabai & Olfson, 2003; Vik et al., 2006). However, despite the implementation 
of the Medicare Modernization Act (MMA) of 2003 to reduce prescription drug costs, 
acquisition decisions and related underuse continue to affect Medicare elders (Bowman, 
2007; Henry J. Kaiser Family Foundation, 2007; Hsu et al., 2008). Acquisition of 
affordable prescriptions, including antihypertensives, is necessary so mat Medicare elders 
can take antihypertensives as prescribed (Bardel, Wallander, & Svardsudd, 2007). 
Understanding low-income, Medicare elders' antihypertensive acquisition behaviors 
has important implications for future prescription drug treatment and health 
implementation efforts. The acquisition of antihypertensives has the potential to reduce 
hypertension-related complications by reducing preventable doctor and emergency 
department visits, thereby reducing hypertension-related mortalities and health-care costs 
(Cutler et al., 2007; Malhotra, Karan, Pahdhi, & Jain, 2001; Mojatabai & Olfson, 2003; 
Nilsson, 2005). For this study, antihypertensive acquisition specifically was examined as an 
outcome to analyze Medicare elders' beliefs about hypertension. Medicare elders' Part D 
enrollment decisions and behaviors were examined to determine which factors influenced 
legal antihypertensive acquisitions. Understanding what decision-making and consumer 
processes Medicare elders follow to decide whether to be screened for Extra Help, 
participate in a Part D plan, and ultimately acquire their antihypertensives may help in 
forming or refining policy. These findings also may have multiple applications for other 
services and products designed to benefit the health of Medicare elders. 
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Chapter 2 
LITERATURE REVIEW 
Theoretical Framework: Models Used to Explain Health Behaviors 
Health Belief Model (HBM) 
The original Health Belief Model (HBM) was designed to explain general health-
related behavior (Janz & Becker, 1984; Rosenstock, Strecher, & Becker, 1988). The 
Health Belief Model (HBM) (Janz & Becker, 1984) (see Figure 3) may be useful in 
determining which antihypertensive perceptions and beliefs have an influence on 
antihypertensive acquisition behaviors for Medicare elders. 
Perceived 
Susceptibility 
of the 
Disease or 
Disability 
Health-Seeking 
Behavior 
Perceived Benefit 
of Health 
Improving 
Behavior 
Figure 3. Health Belief Model (HBM). 
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Constructs of the Health Belief Model 
The five constructs of the original Health Belief Model are as follows: perceived 
susceptibility, perceived severity, perceived benefit, perceived barrier, and health-seeking 
behaviors) (Janz & Becker, 1984; Rosenstock, Strecher, & Becker; 1988). Perceived 
susceptibility of a disease or illness relates to Medicare elders' perceptions about the 
disease; i.e., what they know about their chances of being diagnosed with the disease 
(University of Maryland, 2003). Perceived severity for the disease often depends upon the 
severity of symptoms or severity of an illness (Balkrishnan, 1998). Perceived benefits may 
include feeling better by controlling hypertension and preventing adverse health 
complications (Home & Weinman, 1999). Perceived barriers to antihypertensive 
acquisitions may include the cost, pharmacy location, and insurance status (Bowman, 
2007; George et al., 2006; Home & Weinman, 1999). Additional perceived barriers may 
include transportation (Klein, Turvey, & Wallace, 2004), the ability to open bottles, health 
literacy level, and remembering to refill prescriptions (Grymonpre, Didur, Montgomery, & 
Sitar, 1998; Spiers & Kutzik, 1995). Health-seeking behaviors may include acquiring 
prescribed prescription drugs and taking them as directed in support of health-seeking 
behaviors for chronic disease control (Antonacci, 2002). 
Enhanced Health Belief Model 
The enhanced Health Belief Model (see Figure 4) adds Bandura's self-efficacy 
theory (Bandura, 1986) to the original Health Belief Model (HBM) (Janz & Becker, 
1984), which examines an individual's perceived abilities with regard to performing health-
seeking behaviors and actions (Bandura, 1986). The enhanced HBM is useful for exploring 
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behavior changes and using motivation as a function of action to achieve a specified 
outcome (Bandura, 1986; Janz & Becker, 1984; Rosenstock, Strecher, & Becker, 1988). 
Individual 
Perceptions 
Self-efficacy 
Perceived 
Susceptibility/ 
Seriousness of 
Disease 
Modifying 
Factors 
Age, Gender, Ethnicity 
Personality 
Socioeconomics 
Knowledge 
Perceived threat of 
disease 
Cues to Action 
•Education 
•Symptoms 
• Media Information 
Figure 4. Enhanced Health Belief Model. 
Likelihood of Action 
Perceived Benefits 
Versus Barriers to 
Behavioral Change 
Likelihood of 
Behavioral Change 
Constructs of the Enhanced Health Belief Model 
The enhanced Health Belief Model (HBM) has three constructs (individual 
perceptions, modifying factors, and likelihood of action) that influence levels of health 
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Individual Perception 
Individual Perceptions includes self-efficacy, perceived susceptibility, and 
seriousness. Individual perceptions were explored to determine if self-efficacy has an 
influence on perceived susceptibility and perceived seriousness of hypertension has an 
influence on Medicare elders' ability to make decisions for antihypertensive acquisitions. 
Self-efficacy is an individual's perception of being able to complete the desired task 
or health behavior (Bandura, 1997). Including self-efficacy in the enhanced Health Belief 
Model strengthens the willingness to change or perform an action by an individual 
believing that he or she has the ability to perform the desired health behavior (Bandura, 
1997). Without the ability to perform the behavior, while the desire may be there, the 
action will remain incomplete (Bandura, 1997). However, attitudes and beliefs alone may 
not be sufficient to motivate an individual to perform the health action if he or she 
perceives the barriers as too great to accomplish the task (Rosenstock, Strecher, & Becker, 
1988) 
Perceived susceptibility refers to the likelihood that an individual may be diagnosed 
with the disease. Medicare elders may or may not perceive that they are susceptible for 
hypertension. 
Perceived seriousness of disease may influence individual perceptions about the 
threat of disease. Individual perceptions may lead to behavioral changes if the perceived 
seriousness and perceived threat of the disease lead to health-seeking behaviors. As 
hypertension often is a "silent killer," asymptomatic Medicare elders may not perceive 
hypertension as a real threat. Medicare elders not experiencing adverse hypertensive 
symptoms may not perceive the need for treatment (American Heart Association, 2007b). 
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Modifying Factors 
Modifying factors include demographics (age, gender, ethnicity, and marital status) 
and socioeconomic variables (e.g., income level, social support systems) (Balkrishnan, 
1998). 
Age continues to be a factor as Medicare elders are increasingly diagnosed with 
hypertension (American Heart Association, 2007a). Gender may also be a factor since both 
men and women are equally affected by the hypertension. Ethnicity is important, as African 
Americans are more prone to hypertension while Hispanics and Asians are increasingly 
being afflicted, as their dietary conditions resemble Western society (University of 
Maryland, 2003). Marital Status has an influence, as married Medicare elders are more 
likely to have their hypertension under control (U.S. Department of Health and Human 
Services, 2003). 
Income level has an influence as lower-income Medicare elders are increasingly 
diagnosed with hypertension in comparison with their more affluent peers (Federman et al., 
2006; Sarver, Sudano, & Baker, 2000). Social support systems may provide some benefit 
in both friends and relatives helping to reduce hypertension and in monitoring 
antihypertensive usage (University of Maryland, 2003). Perceived threat of disease may 
depend upon Medicare elders' knowledge and perception about the seriousness of their 
illness, and their perceptions about taking prescription drugs (Home & Weinman, 1999). 
Cues to action may include media coverage of antihypertensive issues via television or 
radio announcements, talk shows, newspaper articles, and health fairs (Mattson, 1999). 
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Likelihood of Action 
Perceived benefits to behavioral change include a greater likelihood that an 
individual will obtain and use a antihypertensive as prescribed if it is perceived that it is 
effective for treating hypertension (Piette, Heisler, & Wagner, 2004a). Acquisition and 
adherence decisions may be influenced by the number of prescriptions, dosage frequency, 
and beliefs about the benefits of specific prescription drugs (Graupner, Frost, Weinman, 
Wright, & Hankins, 2004; Osterberg & Blaschke, 2005; Ostrosky, 2003; Piette, 2005). 
Perceived barriers to behavioral change for antihypertensive acquisition may 
include the cost, pharmacy location, insurance status (George et al, 2006; Home & 
Weinman, 1999; Klein, Turvey, & Wallace, 2004), or their effectiveness and safety, which 
may influence adherence motivations (Cooper, Love, & Raffoul, 1982). 
The likelihood of behavioral change, in the likelihood of action component of the 
enhanced HBM would be following treatment guidelines through the acquisition of 
antihypertensives as prescribed. The likelihood of behavioral change also may depend upon 
the perceived threat of hypertension and perceptions of elders' ability to obtain prescribed 
antihypertensives (Jackson, Doescher, Saver, & Fishman, 2004). 
Empirical Support for the Health Belief Model 
The Health Belief Model (HBM) utilizes behavioral change theories in an attempt 
to explain and predict health behaviors by examining individual attitudes and beliefs that 
prompt the individual to take a specific health action (Foley, Vasey, Berra, Alexander, & 
Markson, 2005; Glanz, Lewis, & Rimer, 1990). The HBM has been used to explain health 
promotion and prevention behaviors utilizing individual perceptions and beliefs for disease 
states and treatment approaches. The enhanced HBM, with the inclusion of self-efficacy, 
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has applications to research that explore individual perceptions about access and the 
perceived ability to overcome barriers necessary to achieve a desired health outcome 
(Bandura, 1986; Rosenstock, Strecher, & Becker, 1988). Previous research studies have 
effectively used the HBM to understand change within patient populations (Al-Ali & 
Haddad, 2004; Aquino, Fyfe, MacDougall, & Remple, 2004; Atta, 1994; Carroll, 2003; 
Mattson, 1999; Nex^e, Kragstrup, & SjEgaard, 1999; Vernon, 1999). The HBM also has 
been used to develop the Osteoporosis Health Belief Scale (Kim, Horan, Gendler, & Patel, 
1991) to examine breast and other cancer-screening programs (Barnes & Thomas, 1990; 
Brown & Williams, 1994; Lasbley, 1987) as well as explore bodily changes of illness in 
older adults (Haug, Musil, Warner, & Morris, 1998). 
The Health Belief Model (HBM) has been used to study patient compliance for 
congestive heart failure (Lacey, 1988) and hypertension (Leeser, 1989). The perceived 
seriousness of the illness and perceptions individuals have about a specific disease or illness 
may reflect their need to adhere to prescription drug regimens (Balon, 2002; Bardel, 
Wallander, & Svardsudd, 2007; Jackson et al., 2004). However, the impetus to change a 
situation must be present to achieve a desired outcome (Janz & Becker, 1984). Often, 
multiple and complex decision-making processes exist for specific prescription drug 
acquisitions decisions including those for antihypertensives (Morrow, Leirer, & Sheikh, 
1988), and individuals may choose to discontinue specific prescription drugs (for 
cholesterol and high blood pressure) that they believe to be no longer necessary, especially 
when they are feeling better (Vik et al., 2005). 
47 
Review of Studies that Use Health Beliefs to Predict 
Prescription and Other Health Behaviors 
Health Belief-related Research 
Studies that examine perceptions about disease state are necessary to 
understanding hypertension-related perceptions and health-seeking behaviors. Several 
studies have specifically addressed prescription drugs (Xu, Smith, & Borders, 2003). 
Research to study health-seeking behaviors for myocardial infarction, based upon elders' 
perceptions of symptoms, found that four factors (symptom, attribution, severity and 
duration, attribution to comorbid and chronic conditions) as well as previous experience 
may influence treatment-seeking behaviors (Ryan & Zerwic, 2003). Medicare elders with a 
family history of hypertension or with friends or family members with disease-related 
complications may perceive the hypertension as more threatening than Medicare elders 
who have not experienced adverse symptoms or previous disease-related experience(s) 
(Schlomann & Schmitke, 2007). Family members, caregivers, or social support systems 
also may contribute to Medicare elders' decision to acquire antihypertensives with usage 
intentions (Jackson et al., 2004). 
Research has shown that individuals who perceive barriers to affordability or do 
not perceive that their illness is that severe may use rationing methods to extend 
prescriptions through pill splitting, skipping dosages, and delays in refilling prescriptions or 
sharing prescriptions with friends or family members (Hughes, 2004). Other barriers 
explored in research include individual perceptions about the effectiveness and safety of 
antihypertensives, which have influenced adherence motivations (Cooper, Love, & Raffoul, 
1982; Gohar, Greenfield, Beevers, Lip, & Jolly, 2008). Low self-efficacy for acquisition 
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and adherence to prescription drug regimens has been shown to influence adversely 
acquisition and usage (Resnick, Wehren, & Orwig, 2003). 
Attitude and Behavior-based Research for Prescription Drugs 
Research gathered prior to the Medicare Modernization Act (MMA) with Medical 
Expenditure Panel Survey data for Medicare elders used an access-based approach to 
examine prescription drugs (i.e., determinants of realized, perceived, and potential access) 
and found that perceptions about overcoming illness without assistance was linked to 
lower odds of taking prescription drugs (Xu, Smith, & Borders, 2003). Other research 
studies have indicated that higher acquisition and adherence rates may be linked to beliefs 
about health-care providers (MacLaughlin, Raehl, Treadway, Sterling, Zoller, & Bond, 
2005). The level of relationship that patients have with their doctors, specifically 
supportive relationships, reflects improvement in adherence levels (Piette, 2005; 
Rosenblatt, Wright, Baoldwin, Chan, Clitherow, Chen, et al., 2000). Other hypertensive 
research has focused upon nutrition education programs (Klinedinst, 2005) to reinforce 
health-promoting behavior and beliefs such as losing weight, controlling salt intake, and 
working out at a fitness club also may reflect health-seeking behaviors (Antonacci, 2002). 
The conscious decision to acquire or adhere to specific prescription drugs often 
reflects patients' attitudes about their effectiveness and safety (Home & Weinman, 1999) 
and varies by ethnicity (Reed, Hargraves, & Cassil, 2003), disease states (Jackson et al., 
2004) and income levels (Bowman, 2007). Medicare elders with knowledge about 
hypertension's possible symptoms, signs, and complications may perceive that 
hypertension is more threatening than those who are not as knowledgeable (Schlomann & 
Schmitke, 2007) and may be more likely to perceive antihypertensive acquisition as 
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necessary to their health (American Heart Association, 2007a). Perceived benefits also may 
be the perception of an improved quality of life through chronic disease control that may 
include the reduction in emergency room visits, increased disease control or the prevention 
of disease-related complications derived from following treatment regimens by acquiring 
antihypertensives as prescribed (Andrawes, Bussy, & Belmin, 2006; Benson & Britten, 
2002; Meyer, 2002). Additionally, acquiring antihypertensives according to prescribed 
guidelines may have the potential to improve health outcomes through increased adherence 
(Schwartz & Sheps, 2006). If Medicare elders perceive that hypertension is a serious 
disease with preventable complications, or if they perceive there is a chance of 
experiencing adverse disease-related complications, then they may be more likely to seek 
and adhere to treatment (University of Maryland, 2003). 
However, Medicare elders may not always refill prescription drugs regularly due to 
cost considerations (Bowman, 2007). Individuals who perceive barriers to affordability or 
do not perceive that their illness is that severe may use rationing methods to extend 
prescriptions through pill splitting, skipping dosages, and delays in refilling prescriptions or 
sharing prescriptions with friends or family members (Hughes, 2004). However, barriers to 
antihypertensive drug usage may include affordability issues, the ability to open bottles, 
literacy levels, as well as remembering (Grymonpre et al., 1998; Piette et al., 2004; Spiers 
& Kutzik, 1995). 
Components Added to the Enhanced Health Belief Model 
While the Health Belief Model (HBM) has proved useful for explaining the 
behavioral and cognitive factors related to health beliefs and behaviors, the components for 
understanding consumer acquisition decisions and specific antihypertensive usage as 
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influenced by cost considerations is still lacking. The specific model components to be 
added to the enhanced HBM include consumer decision-making factors (Consumer Choice 
Theory) and medication adherence-related (Medication Adherence Model) health 
behaviors and attitudes Medicare elders exhibit with respect to acquisition of 
antihypertensives. The focus of this examination was upon antihypertensive drug 
acquisition; specifically, how price (Part D plan premiums and prescription drug co-pays) 
influence Medicare elders' consumer acquisition decisions and health-seeking behaviors. 
The Consumer Choice Theory 
The Consumer Choice Theory (see Figure 5), as adapted from Friedman (1990), 
was used to examine to what extent premium price influences plan enrollment and whether 
Extra Help status influences antihypertensive acquisition decisions in the construct of the 
enhanced HBM. The Consumer Choice Theory attempts to explain the behavior of rational 
consumers in maximizing acquisition opportunities given their budget constraints (Folland, 
Goodman, & Stano, 2004). Medicare elders often subsist on fixed or limited incomes such 
that budget constraints and price are often factors considered in antihypertensive 
acquisition decisions and behaviors (Gaskin et al., 2006). 
Constructs for Consumer Choice Theory 
To examine consumer acquisition decisions, constructs from the Consumer Choice 
Theory (Friedman, 1990) are employed to understand what factors influence an 
individual's decision to acquire antihypertensives with usage intentions. Consumer Choice 
Theory extends the behaviors of individuals to acquiring decisions that are designed to 
maximize their utility while reducing costs (Friedman, 1990). Consumer Choice Theory is 
based upon economic theory that looks at the relationship between the price and the value 
Purchase Decisions 
• Budget Constraints 
• Price Considerations 
• Perceived Benefit 
• Availability of Substitutes 
Economic Considerations 
• Best Value 
• Perceived Need 
• Perceived Benefit 
Satisficing - Partial Knowledge 
versus Complete Knowledge 
Figure 5. Consumer Choice Theory. 
that consumers place on select goods (Friedman, 1990). The cost-benefit tradeoff decision-
making behaviors for antihypertensive acquisitions were examined to determine whether 
price is a good indicator of acquisition decision (Winter et al., 2006). Satisficing requires 
trade-offs with Medicare elders making informed choices by researching plan information, 
prescription drug costs, and estimating their expected annual out-of-pocket expenditures 
(Folland, Goodman, & Stano, 2004). Consumer choices are satisficing; if complete 
information had been available, then the decision might have been different (Folland, 
Goodman, & Stano, 2004). The Consumer Choice Theory is incorporated into the 
enhanced HBM by adding select components under Cues to Action. The assumptions that 
the Consumer Choice Theory makes is that consumers are rational and make acquisition 
decisions to maximize utility (Friedman, 1990). As resources are limited, cost-benefit 
trade-offs that maximize consumer utility makes rational sense (Friedman, 1990). The 
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Consumer Choice Theory (see Figure 6) as it relates to the Medicare Modernization Act of 
2003 (MMA) includes various options to be included in the complex decision-making 
process. 
Empirical Support for the Consumer Choice Theory 
Recently, researchers have attempted to develop an understanding of consumers' 
choices, predictions, judgments, and outcomes (Fonseca & Zeidan, 2004; Lynch & 
Zauberman, 2007). A correlated research study looks at construing consumer decision 
making to understand "how consumers represent outcomes and weigh different decision 
criteria" (Lynch & Zauberman, 2007, p. 107). The decision to acquire often involves 
complex decision making for which consumers may not have enough information to make 
an informed decision (Thull, 2007). However, understanding the decision-making 
processes, as well as the cost benefit trade-offs that are used when selecting a Part D 
prescription drug plan or applying for Extra Help, may lead to a better understanding of 
Medicare elders' perceptions of the barriers to and benefits of acquiring antihypertensives. 
Previous research in 1996 was conducted to understand long-term care choices and 
personal decision-making styles that outlined four decision-making style categories 
(scramblers, reluctant consenters, wake-up call, and advance planners) that highlighted 
trade-offs given long-term care decision-making scenarios (Maloney, Finn, Bloom, & 
Andresen, 1996). A more recent study examined media interaction between the ageism 
message and elderly perceptions of health care needs (Hodgetts, Chamberlain, & Bassett, 
2003). Additionally, research conducted to understand consumer health plan switching has 
been studied for quality effect with results showing low satisfaction for those with chronic 
illness (Abraham, Feldman, Carlin, & Christianson, 2006). 
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Figure 6. Consumer Choices -Acquiring Antihypertensives. 
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Willingness to Pay 
The ability to pay is often based upon income and wealth, while the willingness to 
pay is the value that an individual places upon a good or service and the price he or she 
is willing to pay to get it (Donaldson, Thomas, & Torgerson, 1997). The ability to test for 
willingness to pay is difficult if the question is phrased too broadly; whereas, if a choice 
between two items is offered (i.e., "Would you rather pay $10 to go the circus or would 
you rather go to a movie?") specific preferences may be identified (Donaldson, Thomas, & 
Torgerson, 1997). In the case of healthcare, willingness to pay may be determined by the 
perceived need for the procedure or treatments (e.g., spend $5,000 for liposuction versus 
putting a down payment on a new car or spend $300 to have a mole removed and biopsied 
versus having dental work). 
Economics-based Medicare Prescription Drug Research 
A 1978 study of perception of risk for generically prescribed drugs showed concern 
among consumers for generic drugs that indicates a shift in perceptions in more recent 
research that shows increased acceptance of generics for certain socioeconomic status and 
based upon reflected cost savings (Bearden & Mason, 1978). Another study, which used 
the RAND Elderly Health Supplement to the 1990 Panel Study of Income Dynamics 
(PSID) demand model of drugs, examined insurance status and the effects on 
expenditures. Results revealed significant findings for out-of-pocket expenditures for 
hypertension as well as proposing the addition of the prescription drug benefit to Medicare 
to reduce significantly out-of-pocket costs (Lillard, Rogowski, & Kington, 1999). 
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The Medication Adherence Model 
The Medication Adherence Model (MAM) (see Figure 7) was developed to 
understand medication-taking behaviors and to explain prescription drug adherence 
decision-making processes for treating hypertension (Johnson, 2002). Understanding how 
Medicare elders perceive the effectiveness, safety, and benefits of antihypertensives will 
require components of the MAM (Johnson, 2002), which may influence antihypertensive 
acquisitions. The MAM also may be useful in examining acquisition behaviors for 
antihypertensives. 
Purposeful Action 
• Perceived Need 
• Perceived Effectiveness 
• Perceived Safety 
Patterned Behavior 
• Remembering 
• Access 
• Routines 
Feedback 
Appraisal Process 
• Information 
• Prompts 
• Events 
Figure 7. Medication Adherence Model. 
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Constructs of the Medication Adherence Model (MAM) 
The Medication Adherence Model (MAM) has three constructs that include 
purposeful action, patterned behavior, and feedback (Johnson, 2002). Purposeful action 
encompasses individual decisions to use prescription drugs based upon perceived 
effectiveness and safety. Patterned behavior includes access, routines, and remembering. 
Feedback includes an individual's use of events, information, or prompts, which influence 
levels of purposeful action and patterned behavior. 
Select components of the Medication Adherence Model (MAM) were added to the 
enhanced Health Belief Model (HBM) to test these constructs as well. These factors were 
included in the enhanced HBM with a special emphasis on interaction between behaviors 
and beliefs, cost considerations, and actual reported usage resulting from decisions to 
acquire antihypertensives. The beliefs and perceptions that Medicare elders have about 
antihypertensives, as well as Medicare elders' perceptions about the effectiveness and 
safety of antihypertensives, may influence decisions to acquire antihypertensives with 
usage motivations (Lehan & McCarthy, 2006). Acquisition with intention to use decisions 
are important when exploring the decisions and behaviors related to antihypertensive 
acquisitions, as acquisition of antihypertensives would not be perceived as necessary if 
Medicare elders had no intention of taking them once acquired. 
Constructs adapted from the MAM (see Figure 8) were used; specifically the 
perceptions about need, effectiveness, and safety of antihypertensives, based upon health 
beliefs and behavior components (Johnson, 2002) that were included in the proposed 
Pharmaceutical Acquisition Model for Medicare Elders (PAMME). 
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Figure 8. Medication Adherence Model for Antihypertensives. 
Empirical Support for the Medication Adherence Model 
Research that examines adherence for Type 2 Diabetes Mellitus has been studied to 
develop interventions that will improve health treatment behaviors (Vermeire, Wens, 
Roy en, Biot, Hearnshaw, & Lindenmeyer, 2008). Several other studies have been 
conducted to develop interventions for adherence to oral hygiene instructions (Renz, Ide, 
Newton, Robinson, & Smith, 2008), lipid-lowering medication (Schedlbaurer, Schroeder, 
Peters, & Fishey, 2008) as well as high blood pressure treatment (Schroeder, Fishey, & 
Ebrahim, 2008). The studies reviewed for high blood pressure found that simplified dosing 
and complex reminder systems were effective in improving adherence; however, the 
studies did not report education to be effective (Schroeder, Fishey, & Ebrahim, 2008). 
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Limitations of Current Theories 
Understanding the complexity of adherence to treatment regimens has been heavily 
researched, but the interaction of acquisition, price, and intention to use is lacking. While 
the current health behavior theories have proven quite useful in understanding health-
related behaviors for prenatal care (Atta, 1994), oral hygiene (Carroll, 2003), exercise 
participation (Ali-Ali & Haddadd, 2004), and chronic health behaviors (Home & Weinman, 
1999), they lack a utility component related to acquisition. Often health behavior and 
health belief theories are individualized. They exclude external monetary aspects of the 
cost of acquiring health care. The influence of price and the effect that price has on health 
beliefs and behaviors are missing from the current theories. In an attempt to incorporate 
economic and nursing theory into the existing enhanced Health Belief Model 
multidisciplinary approach an integrated model to understand the complexity of Medicare 
elders' decision-making process for the acquisition of antihypertensives was necessary. 
Pharmaceutical Acquisition Model for Medicare Elders (PAMME) 
As no model currently exists that incorporates beliefs, decision-making strategies, 
consumer behaviors (with respect to cost and underuse factors) specific components of the 
enhanced Health Belief Model (HBM), which includes self-efficacy (Bandura, 1997) and 
constructs from the Consumer Choice Theory (Friedman, 1990) were used to develop the 
Pharmaceutical Acquisition Model for Medicare Elders (PAMME) (see Figure 9). For the 
purpose of this examination the five factors of the enhanced HBM (Janz & Becker, 1984), 
with constructs from the Consumer Choice Theory (Friedman, 1990) and the Medication 
Adherence Model (Johnson, 2002) were used to develop a new multidisciplinary 
theoretical model to predict the processes that Medicare elders undergo when making 
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Figure 9. Proposed Model of the Pharmaceutical Acquisition Model for Medicare Elders 
(PAMME) 
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antihypertensive acquisition decisions. Perceptions that Medicare elders have regarding 
their health status may influence their willingness to acquire prescription drugs designed to 
prevent or treat health conditions, specifically hypertension. Understanding what influences 
Medicare elders' MMA participation, Extra Help application, and antihypertensive 
acquisition decisions requires a complex decision-making process that involves trade-offs 
among the competing barriers and benefits. 
The proposed Pharmaceutical Acquisition Model for Medicare Elders (PAMME) 
incorporates components from the enhanced Health Belief Model (HBM) with select 
components from Consumer Choice Theory and the Medication Adherence Model. The 
performance of this proposed model against the enhanced HBM was tested to determine if 
Medicare elders' antihypertensive acquisition behaviors can be predicted using the 
developed new model. The influence of multiple factors were examined to determine 
which, if any, of the variables may be used to predict acquisition behaviors for Medicare 
elders under various model conditions. 
This study examined the linkage between individual perceptions and beliefs about 
hypertension, including self-efficacy of acquiring antihypertensives, to try to understand 
what decision-making processes Medicare elders engage in when deciding to acquire 
antihypertensives. Ultimately, this study attempted to determine whether the enhanced 
HBM or the proposed PAMME were useful frameworks for examining elderly Medicare 
elders' antihypertensive acquisition decisions and behaviors. 
PAMME Constructs 
The proposed PAMME examines various components of consumer decision 
making (Friedman, 1990) that have been found to effect antihypertensive acquisitions for 
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Medicare elderly (perceived health status, price of individual prescription drug, Part D plan 
premiums, Extra Help status, perceived antihypertensive side effects, perceived 
effectiveness of antihypertensives, beliefs about antihypertensive safety, and benefits of 
acquiring antihypertensives among others). 
Demographic Factors 
Demographic factors include age, gender, marital status, income, and ethnicity. 
Treatment, adherence, and disease control may vary by ethnicity, age, and marital status 
(Bardel, Wallander, & Svardsudd, 2007). 
Age may influence antihypertensive acquisitions as hypertension becomes more 
prevalent as the population ages (American Heart Association, 2007b). Gender may 
influence antihypertensive acquisitions as approximately one-fourth of Medicare-aged men 
and women have been diagnosed with hypertension (Centers for Disease Control and 
Prevention, 2007b). Marital status might influence whether Medicare elders acquire their 
antihypertensives. Married couples may be concerned for each other's health and remind 
each other to acquire and take their antihypertensives as prescribed (Davis & Srivastava, 
2003). Income level may have an influence on treatment affordability and antihypertensive 
acquisitions as lower-income Medicare elders may have more difficulty acquiring their 
prescribed antihypertensives and other prescription drugs (Blustein, 2000; Bowman, 2007; 
Federman et al., 2006). Ethnicity influences acquisition of health care and prescription 
drugs for African-American Medicare elders who are not equally able to acquire their 
prescription drugs (Center for Studying Health System Change, 2003). 
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Individual Perceptions 
Individual perceptions include self-efficacy, perceived threat of disease, perceived 
susceptibility/seriousness of illness, perceived barriers versus benefits of acquiring 
antihypertensives, perceived benefit versus cost of prescription plan and antihypertensives 
cost as well as perceived need, effectiveness and safety of antihypertensives. 
Self-efficacy is the perception or belief that an individual has about his or her ability 
to complete a desired task (Antonacci, 2002). Sell-efficacy with respect to acquiring 
antihypertensives includes an individual's belief in his or her ability and the desire to 
overcome the barriers to acquiring antihypertensives as prescribed by a physician. 
Willingness to pay is the value perception that an individual places upon items 
(includes health) and the price he or she is willing to pay. Often, with the Medicare Part D 
premiums and co-pays, willingness to pay may be influenced by the range of premiums, the 
number of prescription drugs taken, and the individual's perceptions about the cost benefit 
trade-offs of coverage for one plan when compared to another (e.g., Advantage plan with 
zero premium versus a stand-alone drug plan with a $ 14.40 monthly premium). 
Perceived health status is an individual's perception of his or her health, which may 
differ from his or her health care provider's perception related to the clinical diagnosis. 
Perceived threat of disease includes how real a threat a Medicare elder perceives 
hypertension to be for him or her. If Medicare elders have been diagnosed with pre-
hypertension or hypertension, then they may perceive the threat as greater than that 
perceived by elders not diagnosed (Pinto, 2007). 
Perceived susceptibility/seriousness of illness may be affected by a lack of 
symptoms or signals from the body that something is wrong, which may, in turn, 
63 
incorrectly influence an individual's perceptions about his or her chances of having 
hypertension or his or her perceptions about the severity of disease state and the need for 
treatment (Balkrishnan, 1998; Leeser, 1989). Asymptomatic hypertensive Medicare elders 
may delay obtaining medical care or treatment if they perceive that they are not susceptible 
to hypertension or that hypertension is a mild disease that has little adverse health effects 
(Leeser, 1989). 
Perceived barriers versus benefits of acquiring antihypertensives may be influenced 
by distance to the pharmacy, availability of transportation, or the adverse consequence of 
not obtaining the prescribed antihypertensives (Balkrishnan, 1998; Cooper, Love, & 
Raffoul, 1982). The desire to acquire antihypertensives must be strong enough to 
overcome the barriers of cost, beliefs about health status, hypertension beliefs, and 
attitudes about prescription drugs as well as other perceived barriers. 
Perceived need, effectiveness, and safety of antihypertensives may have an 
influence on antihypertensive acquisitions. Examining Medicare elders' beliefs about a 
prescription drug's effectiveness (McDonald-Miszczak, Maris, Fitzgibbon, & Ritchie, 
2004) and beliefs about the severity of their illness or effectiveness of prescription drugs 
designed to prevent illness or treat chronic diseases are important in determining to what 
extent these perceptions influence their acquisition behaviors (Home & Weinman, 1999; 
Okonofua, Cutler, Lackland, & Egan, 2005). Adherence also may be influenced by 
perceived need, effectiveness, and safety, which could affect whether an individual 
perceives antihypertensives as essential for the treatment of hypertension or chronic illness 
(Balkrishnan, 1998; Cooper, Love, & Raffoul, 1982; Lehan & McCarthy, 2006). 
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Modifying Factors 
Modifying Factors include knowledge of their condition, cognitive ability, social 
support, and cues to action (symptoms, side effects, information, and media events). 
Knowledge about hypertension and methods to improve disease control may have an 
influence on Medicare elders' antihypertensive acquisition by understanding what is 
required to prevent adverse health outcomes (Esposito, 1992; Hsu et al., 2008). 
Cognitive ability is influenced by both the aging process and hypertensive 
treatment (Terrera, Matthews, & Brayne, 2008; Wang, Alexander, & Stafford, 2007). 
Antihypertensive acquisition may possibly be influenced by cognitive impairment for 
hypertensive Medicare elders for whom additional screening and treatment may be 
required (van Uffelen, Chin, Hopman-Rock, & van Mechelen, 2007). Cognitive ability may 
be affected by stroke or the development of dementia (McGuinness, Todd, Passmore, & 
Bullock, 2006; Yaan, Fischer, Gamat, Bagwell, & Thai, 2006). 
Social Support could influence antihypertensive acquisitions if friends, family, and 
health care providers are actively involved monitoring the health-seeking behaviors of 
parents, neighbors, or patients (Centers for Medicare and Medicaid Services, 2006). 
Additionally, physicians and pharmacists taking an active interest in their patients' 
treatment and acquisition abilities may have an influence on treatment adherence 
(Mojatabai,2005). 
Cues to Action may include symptoms, side effects, information, and media events. 
Symptoms may not be recognized by Medicare elders as related to an illness, but may be 
erroneously attributed to non-threatening conditions such as the aging process (Ryan & 
Zerwic, 2003). Side effects of antihypertensives may influence Medicare elders' willingness 
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to acquire them as prescribed (Benson & Britten, 2002). If side effects are more 
unpleasant then the benefits derived from specific antihypertensives, Medicare elders may 
choose not to acquire their prescriptions (Benson & Britten, 2002). Information about 
hypertension may allow Medicare elders to choose dietary methods for hypertension 
prevention and treatment (Appel et al., 2006). Learning about preventing adverse 
cardiovascular events (Andrawes, Bussy, & Belmin, 2006) may influence antihypertensive 
acquisitions and provide information for making informed choices (Benson & Britten, 
2002). Media events may have an influence on antihypertensive acquisitions as direct 
marketing to Medicare elders may induce them to visit their physician to discuss treatment 
options (Datti & Carter, 2006). 
Access Behavioral Methods 
Access Behavioral Methods includes acquisition of antihypertensives by legal 
methods, by other than purchase, and not acquired. Acquisition of antihypertensives by 
legal methods may be influenced or dependent upon perceptions of affordability. Dual 
Eligible (Medicare elders with both Medicare and Medicaid) with PDPs may perceive that 
they are able to acquire affordable antihypertensives (Elam, 2006). Medicare elders who 
are able to afford prescribed drugs may be able to take dosage amounts as prescribed 
(Gottlieb, 2000). Increases in adherence through improved access may improve an 
individual's quality of life through better disease control (Meyer, 2002). 
Acquisition of antihypertensives other than purchase may include free samples 
from the doctor's office (Montemayer, 2002). Additionally, the availability of non-
prescription drug alternatives may influence antihypertensive acquisitions (Balkrishnan, 
1998). Not acquired by any method is an option for Medicare elders who either do not 
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believe that antihypertensives are necessary to treat their hypertension (Home & Weinman, 
1999) or are unable to afford their antihypertensives despite having a prescription drug 
plan (Blustein, 2002; Bowman, 2007). 
Outcome 
Outcome includes (a) acquired prescribed supply of antihypertensives by legal 
methods, (b) did not acquire prescribed supply of antihypertensives, and (c) did not 
acquire any antihypertensives. Acquired prescribed supply of antihypertensives by legal 
methods includes purchase through pharmacy or by mail order utilizing the Medicare Part 
D plans or obtaining samples in prescribed amounts from doctors' offices or clinics. Did 
not acquire prescribed supply of antihypertensives includes any non-legal method, which 
may include sharing, skipping, or utilizing reimportation from non-U.S. countries. Did not 
acquire any antihypertensives includes use of herbal treatment remedies or not acquiring 
any of the prescribed treatments by a health care professional. 
Empirical Support for the Proposed Pharmaceutical Acquisition 
Model for Medicare Elders (PAMME) 
This study tested the proposed Pharmaceutical Acquisition Model for Medicare 
Elders (PAMME) against the enhanced Health Belief Model (HBM), thereby providing an 
initial assessment of the proposed PAMME's usefulness predicting antihypertensive 
acquisition behaviors. Testing the proposed model against the time-tested enhanced HBM 
was expected to provide information previously lacking for Medicare elders' 
antihypertensive acquisition behaviors. 
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Chapter 3 
METHOD 
Overview 
The purpose of this study was to test the usefulness of the proposed 
Pharmaceutical Acquisition Model for Medicare Elders (PAMME). This model expanded 
upon the constructs from the enhanced Health Belief Model (HBM) (Janz & Becker, 
1984), Consumer Choice Theory (Friedman, 1990), and the Medication Adherence Model 
(Johnson, 2002) with respect to decision making for antihypertensive acquisitions. The 
various components of the PAMME were tested to determine which factors, if any, exert 
influence upon decision making for antihypertensive acquisitions. The performance of the 
proposed PAMME was compared to that of the enhanced HBM to determine if it a better 
predictor of antihypertensive acquisition behavior by Medicare elders. 
This study employed a quasi-experimental, retrospective, mixed-methods design. A 
combination of primary and secondary data was used to examine the various factors that 
may influence antihypertensive acquisitions. The population of interest in this study was 
low-income, Medicare elders in southeastern Virginia (see Appendix I). Low-income was 
assessed at 150% of the poverty level (Centers for Medicare and Medicaid Services, 
2005a). A Medicare elder is a beneficiary who has attained at least 65 years of age 
(Centers for Medicare and Medicaid Services, 2006). Antihypertensive Acquisition (Yes/ 
No) was assessed based upon whether Medicare elders legally obtained the prescribed 
amounts of antihypertensives with the intention of taking them as directed by their 
physician. 
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Human Subjects Review 
This study complied with all Human Subjects Review guidelines and was approved 
by the Institutional Review Board (IRB) prior to the beginning of data collection. Copies 
of the sample consent letters are included in Appendix V. 
Target Population 
The target population of this study was Medicare elders who were prescribed at 
least one antihypertensive and who were assisted by Senior Services of Southeastern 
Virginia (SSSEVA) to enroll in the Medicare prescription drug discount or Advantage 
plans. Medicare elders were screened for Extra Help (i.e., Low Income Subsidy or LIS). 
SSSEVA is the local Agency on Aging (AoA), the Virginia Insurance Counseling 
Assistance Program (VICAP), and the local State Health Insurance Program (SHIP) for 
southeastern Virginia. 
Sample Size Selection 
Sample size calculations were made using the formula (see Appendix II) for 
statistical power and optimal sample size to obtain a power of alpha = .05. It was 
necessary to select an appropriate sample size sufficient to identify a meaningful difference 
between elderly Medicare elders who acquire prescription drugs as prescribed and those 
who do not. The formula was used to calculate the correct sample size for the power 
selected: too much power (or too large a sample) might decrease the ability to identify 
appropriate statistical significance (Creative Research Systems, 2003; Israel, 2003; Sigma 
Six, 2007). Conversely, too small a sample had the potential to identify incorrectly a 
difference that might exist (Creative Research Systems, 2003; Israel, 2003; Sigma Six, 
2007). 
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Approximately 1,179 Medicare elders (65+ years of age) could be contacted using 
complete contact data. Of the Medicare PDP enrollees, 96 had applied for the Extra Help 
program (i.e., Low Income Subsidy or LIS). Closer examination of the database records 
revealed that not all 1,179 were eligible to be contacted. A portion of this sample was 
taking prescription drugs for the treatment of mental health (e.g., dementia, Alzheimer's, 
among others) or was lost to follow-up (e.g., moved, in a nursing home, living with 
relatives). These Medicare elders were excluded from the research study for obvious 
reasons. A total of 868 Medicare elders were eligible to participate. They were sent 
invitations with study materials and consent forms. All research materials were mailed to 
Medicare elders with self-addressed and postage-paid return envelopes to facilitate return 
mailing. 
Not all of the invited Medicare elders consented to participate. Additional 
invitation letters were sent to those who had not been contacted during the first mailing. 
Initially, 670 Medicare elders were contacted for interviews. A second, then a third mailing, 
was sent to those Medicare elders who had not previously been invited. The revised 
calculations for statistical power indicated that a sample size of 67 completed surveys was 
necessary for an alpha of .05 significance. The number of Medicare elders consenting was 
81; however, not all were able to complete the survey for reasons explained in Chapter 5. 
Medication Education Database Information 
The information collected in the Medication Education Database (see Table 4 in 
Chapter 1) contains information about the clients who were assisted by SSSEVA with 
insurance and health care needs. The Medication Education Access database contains 44 
fields of information collected for health insurance contacts. This database has been 
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continuously maintained and updated for the past five years (October 2004 to the present) 
and originated with the Medicare Modernization Act of 2003 implementation efforts. The 
portions of the database that are relevant to Medicare Part D and this study are Last 
Contact Date, Type of Contact, Age, Ethnicity, Marital Status, Home City, Emergency 
Contact Type, Extra Help-related, Hypertensive Status, Health Status, Insurance Status, 
Part D-related and New to Medicare. The other information, while not directly related, 
might be useful if the referral was from either a doctor (or other health professional) or an 
elder's pharmacist. 
Hypertensive Status was indicated separately from Health Status to identify elders 
who were prescribed at least one antihypertensive. Health Status differs from Hypertensive 
Status as it identifies Disability Status as well as hospitalizations and any other chronic 
illness(es). Insurance Status is used to identify whether a contact has Creditable Coverage 
or is Enrolled in Part D or a Medigap supplement with prescription drugs. 
Participant Selection Criteria 
Inclusion Criteria 
Participants were selected from consenting Medicare elders assisted by Senior 
Services of Southeastern Virginia (2006, 2007, 2008) for MMA enrollment and LIS 
screening for whom complete contact information (name, age, address, and telephone) was 
available. Age as of last birthday was used in place of birth date. Identification of age was 
necessary, as only those at least 65 years of age were included in this study. An elder's 
eligibility for Medicare was based upon being 65 years of age versus elders who were 
medically diagnosed with a disability and meeting the 24-month waiting period (Centers 
for Medicare and Medicaid Services, 2005a). All income levels were included in this study; 
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however, the focus was upon low-income elders since they were identified previously as 
having acquisition problems for prescription drugs (Elam, 2006; Klein, Turvey, & Wallace, 
2004). Low income was defined as 150% of poverty level income. Those elders not 
classified as having a low income were above the poverty level and were screened not 
eligible for Extra Help (Centers for Medicare and Medicaid Services, 2005b). 
Additionally, Medicare Modernization Act enrollees' records were screened for the 
prescription drug discount plan status enrollment (PDP or Advantage) and Extra Help 
status (application and approval). The inclusion of those enrolled during the full 
implementation of the MMA's prescription drug discount card program provided historical 
data for those continuously enrolled. 
Exclusion Criteria 
Medicare elders with creditable coverage (employer- or military-based insurance 
that is equivalent or better than Medicare) who are not required to participate in MMA 
were excluded. Database records of Medicare elders with incomplete or missing 
demographic or contact data were excluded from this study. In addition, Medicare elders 
were excluded from this study if they were unable to speak or understand English because 
the survey instrument was not available in other languages. Medicare elders who were not 
able to use a telephone or who were not mentally capable and/or unable to make their own 
decisions related to their health or health options were excluded (i.e., those elders whose 
files included a Power of Attorney to a caregiver). The administered survey instrument 
included questions from the Short Portable Mental Status Questionnaire (SPMSQ). 
Medicare elders who were unable to respond successfully to the initial four questions (i.e., 
if they failed the mental portion of the questionnaire) also were excluded from this study. 
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Data Collection 
Data collection included information from primary (administered surveys) and 
secondary data sources (Senior Services of Southeastern Virginia [SSSEVA] enrollment 
databases). Data collection forms and surveys were randomly assigned numbers to 
facilitate data entry into SPSS (Version 16.0 for Windows). Approval by the Chief 
Executive Officer and the Board of Directors of SSSEVA was granted to access the 
necessary Medicare enrollee databases and to contact those clients required to conduct this 
study (see Appendix VI). 
Screening and Data Collection Instruments 
A combination of quantitative and qualitative information was collected using three 
types of data-screening and collection instruments. The first was the master screening 
document that was used to compile the master record of hypertensive Medicare elders, 
including demographic data such as name, age, address, and telephone number. The 
second was the screening of plan enrollment and Extra Help, which recorded hypertension 
status and Extra Help status of Medicare elders. Lastly, the administered survey log was 
used to contact selected Medicare elders for the study. 
Screening and Random Sample Data Collection Instruments 
A records review was conducted to identify current enrollment information such as 
Medicare Part D enrollment status, Extra Help status, demographic information, 
antihypertensive usage, and any notable acquisition experiences. The framework for the 
collection of data from the master dataset included an assessment tool that allowed data 
matching with individual enrollment and application records collected from 2006 to 
present. 
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Identification of Medicare elders with hypertension who were prescribed at least 
one antihypertensive (see Table 5 and Table 6) was necessary so that invitations were sent 
only to those individuals meeting the inclusion criteria for the target population. 
Table 5 
Master Screening to Collect Demographic Information 
Random 
Database Number Name Phone Age Gender Ethnicity HBP 
Number Assigned (65+) 
Last, (757) M/F White YES/NO 
First XXX- Black 
XXXX Asian 
Hispanic 
Other 
Data screening of Medicare elders' hypertension status and their prescription drug 
plan and Extra Help status was conducted. This screening instrument (see Table 6) 
includes age (65+) and hypertension (HBP) with at least one blood pressure medicine 
prescribed. Additionally, the Medicare elders selected were those who had been assisted 
with Part D enrollment and Extra Help application. The data-screening instrument for 
hypertension and insurance status was used to select those Medicare elders from a 
secondary dataset who had been prescribed at least one antihypertensive and were assisted 
with enrollment into a Medicare Part D or Advantage plan for FY 2006, FY 2007, and/or 
FY 2008. All screening documents were securely maintained (i.e., password and key 
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protected) in a locked room within a locked filing cabinet. Additionally, Table 7 was used 
to match Extra Help and Part D for FY2006, FY2007, and FY2008. 
Table 6 
Data Screening for Hypertension and Insurance Status 
Number Name Phone Age HBP HBP MMA EH 
(65+) RX Status Status 
Random Last, (757) YES/NO YES/NO YES/NO YES/NO 
First XXX-
xxxx 
Table 7 
Survey Data Collection: Part D and Extra Help Status 
Number Name 2006 2007 2008 
Random Last, Extra PDP Extra PDP Extra PDP 
Number First Help or Help or Help or 
Assigned Approved ADV ADV ADV 
The Data Collection List for Consent Results (see Table 8) includes the random 
numbers assigned to the Medicare elders selected randomly from the Preliminary Data 
Screening Master List. The random numbers and contact information were used to send 
the invitation to participate in the research study. The Survey Data Collection List for 
Consenting Responses recorded the responses from Medicare elders who consented to 
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participate in administered interviews. Medicare elders had two methods for consent: 
signing and returning the invitation letter or verbal consent via the telephone. 
Table 8 
Survey Data Collection: Consent Response 
Number Name Phone Address Age Mailed Consent 
Date 
Random Last, (xxx) City, >65 Date Time Yes No 
Number First xxx- ST Zip 
Assigned xxxx 
Table 9 includes the random numbers of consenting Medicare elders. The 
administered survey instruments utilized to contact Medicare elders contained only the 
random number assigned, name, and administered number. Three attempts were made to 
contact Medicare elders from those randomly selected from among the Medicare elders 
agreeing to participate. 
Table 9 
Survey Data Collection: Medicare Elders'Administered Interview Results 
Number Name Phone Attempt Attempt Attempt Complete 
1 2 3 
Random Last, (xxx) Date Tune Date Time Date Time Yes No 
Number First xxx-
xxxx 
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Data Collection: Medicare Elders 'Administered Interview Results 
The survey instrument was a modified version of the Henry J. Kaiser Family 
Foundation's Medicare Elders Experiences with Part D, a nationally administered survey 
that obtained good results for Medicare beneficiaries. Approval was granted via e-mail and 
administered from the Henry J. Kaiser Family Foundation to use select portions of the 
Seniors' Early Experiences with Their New Drug Plan - June 2006 survey with the 
provision that a copy of the results would be forwarded to the Foundation upon 
completion of this study. The survey instrument comprised the Medicare section of the 
survey (Henry J. Kaiser Family Foundation, 2006b). Initial questions from the administered 
survey were taken from the Short Portable Mental Status Questionnaire (SPMSQ) to 
screen for mental deficiencies that would prevent Medicare elders from effectively 
completing the survey. Additionally, the survey contained Questions to Identify Patients 
Experiencing Medication Cost Problems (California Healthcare Foundation, 2005); 
Medication Adherence - Morisky Scale (Vik et al., 2005) as well as the SSSEVA's Access 
& Acquisition of Prescription Drugs Survey (Senior Services of Southeastern Virginia, 
2005). The modifications include additional questions relating to adherence (Morisky 
Scale) and acquisition decisions relating to affordability and adherence (Questions to 
Identify Patients Experiencing Medication Cost Problems). Overall, the survey questions 
were designed to elicit responses that might improve our understanding of prescription 
drug discount plan enrollment and usage experiences, as well as identify affordability or 
health beliefs related to antihypertensive acquisition with usage intentions. 
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Seniors' Early Experiences with Their New Drug Plan-June 2006 
The Henry J. Kaiser Family Foundation (2006b) was instrumental in conducting 
research to determine if the new MMA's implementation was beneficial for Medicare 
elders. The survey was administered nationwide to Medicare beneficiaries. The survey 
instrument has a demonstrated reliability of .927 for gathering Medicare beneficiaries' 
prescription drug plan experiences. 
The Short Portable Mental Status Questionnaire 
The Short Portable Mental Status Questionnaire has been used successfully (.738) 
with aging populations to measure cognitive impairment and to detect early stages of 
dementia (Eissa, Andrew, & Baker, 2003). 
Morisky Scale 
The Morisky Scale was developed to assess prescription drug adherence and has 
been used successfully for chronic disease medication-taking behaviors (Vik et al., 2005). 
The Morisky Scale has been used previously with hypertensive elders (Val, Amoros, 
Martinez, Fernandez, & Leon, 1992) and has a demonstrated reliability of .640 when used 
with elders who are similar to the target population of this study (Val et al., 1992; Vik et 
al., 2005). 
California Medication Affordability Survey 
The California Medication Affordability Survey has been used to determine how 
affordability influences medication acquisition. This survey instrument has been utilized 
successfully (.744) with populations with chronic illness and disease, including Medicare 
elders (California Healthcare Foundation, 2006). 
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SSSEVA: Access & Acquisition of Prescription Drugs Survey 
The SSSEVA: Access & Acquisition of Prescription Drugs Survey has been useful 
(.854) in determining how the MMA affected prescription drug access and acquisition 
(SSSEVA, 2006). Table 10 summarized the reliability coefficients for each of the surveys 
and scales used in this research. 
Table 10 
Summary of Reliability Coefficients 
Survey Instruments Reliability 
Coefficients 
Senior's Early Experiences with Their New Drug Plan - June 2006 .927 
Short Portable Mental Status Questionnaire (SPMSQ) .738 
Morisky Scale .640 
California Medication Affordability Survey .1AA 
The Senior Services of Southeastern Virginia (SSSEVA) 
Access and Acquisition of Prescription Drugs Survey .854 
Survey Administration 
The survey was administered by trained interviewers (approximately 25 to 30 
minutes in-person and approximately 45 minutes by telephone). The instrument included 
research variables (see Table 11) and questions about experiences with prescription drug 
plan enrollment, Extra Help approval status, demographics, health status, prescription drug 
insurance status, and antihypertensive acquisitions (including affordability and usage 
Table 11 
Research Variables Linked to Model Constructs 
Variables 
Outcome 
Variable 
Independent 
Variables 
Demographic/ 
Socioeconomic 
Age 
Label 
Acquire 
Antihypertensive 
(Yes/No) 
Age on Last 
Birthday 
Measurement 
Nominal 
Ratio 
Data 
Source 
Individual 
Survey 
Access 
Database/ 
Instrument 
Administered 
Survey 
Data 
Collection 
Model 
Components 
Likelihood of 
Action: 
Likelihood of 
Behavioral 
Change 
Demographics 
Age 
Gender Male 
Female 
Nominal 
Individual 
Survey 
Access 
Database 
Form/ 
Administered 
Survey 
Data 
Collection 
Form 
Demographics 
Gender 
Marital Status 
Ethnicity 
Married 
Separated 
Divorced 
Widowed 
Single 
Caucasian 
African-
American 
Asian 
Hispanic 
Other 
Nominal 
Nominal 
Access 
Database/ 
Individual 
Survey 
Access 
Database/ 
Individual 
Survey 
Data 
Collection 
Form/ 
Administered 
Survey 
Data 
Collection 
Form 
Demographics 
Marital Status 
Demographics 
Ethnicity 
Gross Monthly 
Income 
Self-Reported 
Amount 
Ratio Access 
Database/ 
Individual 
Survey 
Data 
Collection 
Form/ 
Administered 
Survey 
Demographics 
Income 
Annual 
Income 
Gross Monthly 
Income x 12 
Ratio 
mos. 
Access 
Database/ 
Individual 
Survey 
Data 
Collection 
Form/ 
Administered 
Survey 
Demographics 
Income 
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Variables Label Measurement Data Instrument Model 
Source Components 
Education 
Level 
Self-Efficacy 
Highest Level Ordinal 
Completed 
Very 
Confident-Not 
Confident 
Decision of # # 
Antihypertensive Antihypertensive 
Not Taken Not Taken 
Decision to Name 
acquire Antihypertensive 
Antihypertensive Acquired 
(which per 
month) 
Decision to 
obtain 
Antihypertensive 
other than 
acquisition 
Perceived 
Health Status 
Antihypertensives 
Obtained By 
Other than 
Acquisition 
Diseases 
taking Rx to 
treat or 
Prevent 
Perceived Hypertension: 
Need for Serious/Not 
Antihypertensive Serious 
Perceived Easily 
Barriers for Acquire/Not 
Antihypertensive Easily Acquire 
Antihypertensives 
Ordinal 
Self-Reported 
Self-Reported 
Medication 
Taking 
# # Ratio 
Antihypertensive Antihypertensive 
Prescribed Prescribed by 
Doctor 
Decision of # # Ratio 
Antihypertensives Antihypertensive 
to Take Taken 
Ratio 
Nominal 
Self-Reported 
Self-Reported 
Self-Reported 
Self-Reported 
Ratio Self-Reported 
Nominal 
Scale 
Scale 
Administered 
Survey 
Administered 
Survey 
Administered 
Survey 
Administered 
Survey 
Administered 
Survey 
Administered 
Survey 
Administered 
Survey 
Demographics 
Education 
Individual 
Perceptions: 
Self-Efficacy 
Individual 
Perceptions: 
Perceived 
Severity 
Likelihood of 
Taking Action 
Individual 
Perceptions: 
Barriers 
Likelihood of 
Taking Action 
Likelihood of 
Taking Action 
Self-Reported 
Self-Reported 
Self-Reported 
Administered 
Survey 
Administered 
Survey 
Administered 
Survey 
Individual 
Perceptions; 
Perceived 
Health 
Individual 
Perceptions: 
Cost vs. 
Benefit 
Individual 
Perceptions: 
Barriers 
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Variables Label Measurement Data Instrument Model 
Source Components 
Perceived 
Effectiveness 
of 
Antihypertensive 
Prescription 
Drug 
Acquisition 
Behaviors 
What other 
methods used 
Plan 
Experiences 
Part D Status 
Believe 
Antihypertensive 
helps prevent/ 
control disease 
(Yes/No) 
Sharing 
Skipping 
Free Samples 
NonRx 
Alternatives 
Other 
Enrolled 
(Yes/No) 
Nominal Self-Reported 
Part D Usage 
Extra Help 
Applied Status 
Extra Help 
Approved 
Status 
Prescription 
Drug 
Enrollment 
Confusion 
Used to 
Acquire Rx 
(Yes/No) 
Applied 
(Yes/No) 
Approved 
(Yes/No) 
Confusion 
Enrolling in 
Part D: Not 
Confusing/ 
Very 
Confusing 
Nominal Self-Reported 
Nominal 
Nominal 
Nominal 
Nominal 
Scale 
Administered 
Survey 
Administered 
Survey 
Individual 
Perceptions: 
Perceived 
Effectiveness 
Likelihood of 
Action: 
Acquisition 
other than 
Purchase 
Database & 
Self-Reported 
Self-Reported 
Database & 
Self-Reported 
Database & 
Self-Reported 
Self-Reported 
Data 
Collection 
Form/ 
Administered 
Survey 
Administered 
Survey/Plan 
Quarterly 
Report 
Data 
Collection 
Form/Phone 
Survey 
Data 
Collection 
Form/Phone 
Survey 
Administered 
Survey 
Likelihood of 
Action: Part D 
Enrolled 
Likelihood of 
Action: Rx 
Acquisition 
Likelihood of 
Action: Extra 
Help Applied 
Likelihood of 
Action: Extra 
Help Approved 
Individual 
Perceptions: 
Barriers 
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Variables 
PartD 
Monthly 
Premiums 
PartD 
Co-Pays 
Prescription 
Drug 
Acquisition 
Problems 
Label 
Monthly 
Premiums 
Affordable/Not 
Affordable 
Co-Pays 
Affordable/Not 
Affordable 
Difficulty 
Using Part D 
to Acquire Rx: 
No Difficulty/ 
Very Much 
Difficulty 
Measurement 
Scale 
Scale 
Scale 
Data 
Source 
Self-Reported 
Self-Reported 
Self-Reported 
Instrument 
Administered 
Survey 
Administered 
Survey 
Administered 
Survey 
Model 
Components 
Individual 
Perceptions: 
Cost vs. 
Benefit 
Individual 
Perceptions: 
Cost vs. 
Benefit 
Individual 
Perceptions: 
Barriers 
intentions). The survey used existing valid and reliable survey instruments to address the 
hypotheses and research questions posed by this study. 
Seven-day pillboxes were given to those consenting Medicare elders who 
participated and completed the survey. Medicare elders who consented but were unable to 
participate also received the seven-day pillboxes. 
The administered survey items are linked with the variables for the enhanced 
Health Belief Model (see Table 12) and the proposed Pharmaceutical Acquisition Model 
for Medicare Elders (see Table 13). 
Table 14 maps the administered survey (including question source) to the PAMME. 
The questions reflect the addition of the Consumer Choice Theory and the Medication 
Adherence Model to the enhanced HBM. The inclusion of these additional questions 
enabled the researcher to compare the two models to determine if increased predictability 
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Table 12 
Administered Survey Items Matched to the Model Variables for the Enhanced Health 
Belief Model (HBM) 
Type of Variable Survey 
Item# 
Measurement 
Level 
Dependent Variable(s) 
Outcome 
Acquired prescribed supply of antihypertensive(s) 
Did not acquire prescribed supply of antihypertensive(s) 
Did not acquire any antihypertensive(s) 
Access Behavioral Method 
Acquire antihypertensive(s) from pharmacy 
Acquire hypertensive(s) other than purchase 
Not acquired by any method 
33 
34 
9B,35 
32A, 32D 
32E 
9B, 38B, 38C 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
Independent Variable(s) 
Demographic and Socioeconomic 
Age 
Gender 
Ethnicity 
Marital status 
Monthly gross income 
Annual income 
Educational level 
SPMSQ3 
Dl 
D2 
D3 
D4 
D5 
D6 
Ratio 
Nominal 
Nominal 
Nominal 
Ratio 
Ordinal 
Ordinal 
Antihypertensives Self-Efficacy 
Feel confident to acquire blood pressure Rx as prescribed 5 Nominal 
Perceived Barriers: Antihypertensive Acquisition 
Medicare plan and acquiring Rx 9A-9H 
17 
18 
Nominal 
Ordinal 
Ratio 
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Type of Variable Survey 
Item# 
38A-38G 
44 
52 
22 
Measurement 
Level 
Nominal 
Nominal 
Nominal 
Ratio 
Difficulties with Plan 
Problems? 
Perception of policy? 
Taking Antihypertensives? 
Perceived Benefits: Antihypertensive Acquisition 
Antihypertensive regular usage status 
# Antihypertensives prescribed? 
# Antihypertensives taken? 
Antihypertensives taken: Name 
Antihypertensive-taking behavior 
Perceived health status 
Perceived need for antihypertensives 
Perceived effectiveness of antihypertensives 
Perceived safety of antihypertensives 
33,34 
22 
31A 
31B 
30 
16 
13,14 
12 
15 
Nominal 
Ratio 
Ratio 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
Modifying Factors 
Knowledge 
Social support 
Doctor 
Cues to Action - Symptoms 
Cues to Action - Side Effects 
Cues to Action - Information 
Cues to Action - Media Events 
23 
24A-24J 
25 
26C, 26D 
27A-27J 
28A-28E 
29A-29E 
Nominal 
Nominal 
Nominal 
Ordinal 
Ordinal 
Nominal 
Nominal 
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Table 13 
Model Variables Matched to the Pharmaceutical Acquisition Model 
for Medicare Elders (PAMME) 
Type of Variable Survey Measurement 
Item# Level 
Dependent Variable(s) 
Prescription Drug Acquisition 
Acquired Antihypertensive with plan? 
Decision to Acquire Antihypertensives - Doctor 
Decision to Acquire Antihypertensives - Pharmacist 
How Many Antihypertensives Acquire Regularly? 
Decision to obtain - other than purchase 
33 
32A-32B 
241, 25 
24J 
33 
32E 
Nominal 
Nominal 
Nominal 
Nominal 
Ratio 
Ordinal 
Independent Variable(s) 
Demographic & Socioeconomic 
Age 
Gender 
Marital Status 
Ethnicity 
Monthly Gross Income 
Annual Income 
Education Level 
Cognitive Ability 
What are the date, month, and year? 
What is the day of the week? 
How old are you? 
When were you born? 
Plan Experiences 
Impression of Benefit 
Knowledge of Late Enrollment Penalty? 
SPSMQ 3 
Dl 
D2 
D3 
D4 
D5 
D6 
SPMSQ 1 
SPMSQ 2 
SPMSQ 3 
SPMSQ 4 
39 
46 
Ratio 
Nominal 
Nominal 
Nominal 
Ratio 
Ratio 
Ordinal 
Nominal 
Nominal 
Ratio 
Nominal 
Nominal 
Nominal 
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Type of Variable Survey Measurement 
Item* Level 
Extra Help Benefit? 
Difficulty of Enrollment 
Choosing a Plan - Importance 
Decisions About Choosing Plan 
Plan Experience - Better/Worse 
Type of Medicare Plan 
Plan Choice Satisfaction 
Plan Acquisition w/ Plan? 
Difficulties getting card? 
Rx not covered by plan 
Billing Mistake by plan 
Switching plan 
Coverage gap? (write in comments) 
Message to policy makers 
37 
42 
44,45 
46,47 
48A-48D 
36 
39 
34,35 
38A 
38D 
38F 
47 
— 
52 
Nominal 
Ordinal 
Nominal 
Nominal 
Nominal 
Nominal 
Ordinal 
Ordinal 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
Self-Efficacy 
Confidence in ability to acquire Nominal 
Affordability 
Saving Money w/ Plan? 
Saving a lot/a little? 
Paying a lot /a little" 
Help paying for Rx 
Find assistance to pay for Rx 
Ask whether could afford Rx 
Where to get less expensive 
49 
50 
51 
20A 
20E 
20C 
20D 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
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Type of Variable Survey Measurement 
Item# Level 
Willingness to Pay 
Pay for better health? 
Pay for Rx drug plan? 
Pay for Antihypertensive Rx 
17 
18 
19 
Ordinal 
Ratio 
Ratio 
Health Status 
Perceived Health Status 16 Nominal 
Hypertensive Status 
When Diagnosed with HBP? 31 Nominal 
Health-Care Decisions 
Social Support 
Doctor Assistance 
24A-24J 
25 
Nominal 
Nominal 
Antihypertensives 
Number of Antihypertensives prescribed 
Decision of Number Antihypertensives Taken 
Antihypertensives Actually Take by Name 
Switched Rx Effective 
Perceived Need for Antihypertensives 
Perceived Safety of Antihypertensives 
Antihypertensive Usage Status 
Perceived Barriers to Antihypertensive Acquisitions 
Rx not covered by plan 
Couldn't afford 
Transportation problems 
Problems Acquiring 
Not filled Rx or Skipped 
35 
37 
38 
47 
33 
32 
34 
22,41,46 
20D 
20C, 20E 
46 
20B 
26C 
Ratio 
Ratio 
Nominal 
Ordinal 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
Nominal 
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Table 14 
Pharmaceutical Acquisition Model for Medicare Elders (PAMME) Mapped to 
Administered Survey and Survey Question Sources 
Survey Survey 
Question Question(s) 
Number(s) Source 
Relating to the Model 
Demographic Factors 
Gender 
Marital Status 
Ethnicity 
Income 
Education 
Cognitive Ability 
Date, Month, Year 
Day of Week 
How old 
When born 
Individual Perceptions 
Self-Efficacy 
Health Status 
Willingness to Pay 
Perceived threat of hypertension 
Perceived susceptibility/ 
seriousness of hypertension 
Perceived barriers vs. 
perceived benefits of 
acquiring antihypertensives 
Dl 
D2 
D3 
D4 
D5 
D6 
1 
2 
3 
4 
5 
16 
17 
18 
19 
7 
6 
8 
36 
26A 
11 
7 
8 
9 
9A 
2006 SE Dl 
2006 SE D3 
2006 SE D4 
2006 SE D5 
2006 SE D6 
2006 SE D7 
SPMSQ 1 
SPMSQ 2 
SPMSQ 5 
SPMSQ 6 
Catz, Kelly, Bogart, 
Benotsch, & McAuliffe 
(2000) 
2006 SE 39 
Donaldson, Thomas, & 
Torgerson (1997) 
Gohar, Greenfield, Beevers 
Lip, & Jolly (2008) 
Gohar, Greenfield, Beevers 
Lip, & Jolly (2008) 
Morisky 
2006 SE 8 
2006 SE 10 
2006 SE 11 
2006 SE 12 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
:, Independent Variable 
i, Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
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Perceived need, 
effectiveness, and safety 
of antihypertensives 
Modifying Factors 
Knowledge 
Social Support 
Doctor Assistance 
Cues to Action: Symptoms 
Cues to Action: Side Effects 
Cues to Action: Information 
Cues to Action: Media Events 
Survey 
Question 
Number(s) 
9B 
9C 
9D 
12 
13 
14 
33 
34 
37 
38 
23 
24A - 24J 
25 
26C-26D 
27A-27J 
28A-28J 
29A-29F 
Survey 
Question(s) 
Source 
2006 SE 12 
2006 SE 12 
2006 SE 12 
2006 SE 9 
SSSEVA 
Relating to the Model 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variables 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Independent Variable 
Access Behavioral Method 
Acquire antihypertensive(s) 
from pharmacy 32A, 32D 
Acquire anti-hypertensive(s) 
other than purchase 32E 
Not acquire by any method 38B, 38C 
Dependent Variable 
Outcome 
Acquired prescribed supply 
of antihypertensive(s) 33 
Did not acquire prescribed 
supply of antihypertensive(s) 34 
Did not acquire 
any antihypertensive(s) 35 
Dependent Variable 
Dependent Variable 
Dependent Variable 
Dependent Variable 
Dependent Variable 
Dependent Variable 
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was possible given the added constructs. The inclusion of the cognitive ability questions 
allowed for exclusion of any consenting Medicare elders who were not mentally competent 
to answer the survey questions. The only demographic variable that was included in the 
cognitive ability portion was age. Age was not asked any other place in the survey 
instrument and was readily verifiable with database records. 
Research Hypotheses 
Ho 1: Medicare elders do not legally acquire 100% of prescribed antihypertensive. 
Hal: Medicare elders legally acquire at least 70% of their prescribed antihypertensives. 
Ho2: The enhanced Health Belief Model overall does not explain Medicare elders' 
antihypertensive behaviors. 
Ha2: The enhanced Health Belief Model overall explains less than 60% of 
antihypertensive behaviors for antihypertensive Medicare elders. 
Ho2a: Individual perceptions for disease severity have no influence on Medicare 
elders' decision to acquire antihypertensives. 
Ha2a: Medicare elders who perceive their hypertension as serious may be more 
likely to acquire their antihypertensives. 
Ho2b: Perceived benefits of antihypertensives have no influence on Medicare 
elders' decision to acquire antihypertensives. 
Ha2b: Medicare elders who perceive the benefits of taking antihypertensives will 
be more likely to acquire legally their antihypertensives. 
Ho2c: Perceived barriers have no influence on Medicare elders' acquisition of 
antihypertensives. 
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Ha2c: Medicare elders' perceptions about out-of-pocket expenditures will have a 
statistically significant influence on their decision to acquire 
antihypertensives. 
Ho2d: Perceived seriousness of hypertension will have no influence on Medicare 
elders' decision to acquire antihypertensives. 
Ha2d: Medicare elders who perceive hypertension as serious will be more likely to 
acquire antihypertensives than those who do not perceive hypertension as 
serious. 
Ho2e: Cues to action has no influence on Medicare elders' decision to acquire 
antihypertensives. 
Ha2e: Medicare elder's decision to acquire their antihypertensives is influenced by 
education and hypertension symptoms. 
Ho3: Constructs from the both the Medication Adherence Model and Consumer Choice 
do not significantly explain Medicare elders' antihypertensive acquisition behaviors. 
Ha3: Constructs from both the Medication Adherence Model and Consumer Choice 
significantly explain Medicare elders' antihypertensive acquisition behaviors. 
Ho3a: Constructs from the Medication Adherence Model added to the enhanced 
Health Belief Model does not help to explain antihypertensive acquisition 
behavior for Medicare elders significantly greater than the enhanced Health 
Belief Model. 
Ha3a: Constructs from the Medication Adherence Model helps to explain 
Medicare elders' antihypertensive acquisitions significantly greater than the 
enhanced Health Belief Model. 
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Ho3b: Constructs from Consumer Choice added to the enhanced Health Belief 
Model do not help to explain Medicare elders' antihypertensive acquisition 
behaviors significantly greater than the enhanced Health Belief Model. 
Ha3b: Constructs from Consumer Choice added to the enhanced Health Belief 
Model does help to explain Medicare elders' antihypertensive acquisition 
behavior significantly greater than the enhanced Health Belief Model. 
Ho4: The proposed Pharmaceutical Acquisition Model for Medicare Elder (enhanced 
Health Belief Model with constructs from Consumer Choice Theory and 
Medication Adherence) does not explain antihypertensive acquisition behavior for 
Medicare elders significantly better than the enhanced Health Belief Model. 
Ha 4: The proposed Pharmaceutical Acquisition Model for Medicare Elderly (enhanced 
Health Belief Model with constructs from Consumer Choice Theory and 
Medication Adherence) explains antihypertensive acquisition behavior for Medicare 
elders significantly better than the enhanced Health Belief Model. 
Data Analyses 
Once data collection was completed, data were entered into SPSS (Version 16.0 for 
Windows) for analyses. Statistically appropriate methods using bivariate and multivariate 
methods were conducted (see Tables 10 and Table 11). Odds ratios were calculated for the 
dichotomized variables (acquire/not acquire). Chi-square calculations were employed on 
nominal, categorical data. Logistic regression was used to determine those factors that 
exerted influence upon the likelihood of antihypertensive acquisitions, including enrollment 
and application decisions. Confirmatory factor analysis was conducted on the survey 
response data to determine if the questions captured the intended constructs (Meyers, 
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Gamst, & Guarino, 2006). Model-fitting techniques were used to examine specific 
hypothesized relationships as well as model comparison (Meyers, Gamst, & Guarino, 
2006) between the enhanced HBM and the proposed PAMME. Table 15 summarizes the 
types of analyses by research hypothesis. 
Table 15 
Hypotheses and Type of Analyses 
Hypotheses Number Type of Analyses 
HI 
H2 
H2a 
H2b 
H2c 
H2d 
H2e 
H3 
H3a 
H3b 
H4 
Logistic Regression 
Multiple Regression 
Multiple Regression 
Multiple Regression 
Chi-Square 
Chi-Square 
Chi-Square 
Model Comparison 
Model Comparison 
Model Comparison 
Model Comparison 
Data Management 
To prevent unauthorized access, Medicare elders' enrollment records and database 
files were properly safeguarded via password protection. All materials were kept in a 
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locked file cabinet in a locked office. The computer was accessible by password only, and 
only the primary researcher had access. Records will be destroyed within five years of the 
completion of the study, and the information filed on the research computer will be 
reformatted to make retrieval impossible after aggregate analyses and reporting has been 
completed. 
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Chapter 4 
FINDINGS 
Overview 
The purpose of this study was to test the usefulness of the proposed 
Pharmaceutical Acquisition Model for Medicare Elders (PAMME) which was expanded 
using constructs from the enhanced Health Belief Model (HBM) (Janz & Becker, 1984), 
Consumer Choice Theory (Friedman, 1990) and the Medication Adherence Model (MAM) 
(Johnson, 2002) with respect to decision making for antihypertensive acquisitions. The 
various components of the PAMME were tested to determine which factors, if any, exerted 
influence upon antihypertensive acquisition decisions. The performance of the PAMME 
compared to that of the enhanced HBM was slightly better at predicting antihypertensive 
acquisition behavior by Medicare elders using this target population. 
Data Collection 
Target Population 
The target population was selected from the Senior Services of Southeastern 
Virginia's (SSSEVA) Medicare Medication Management database. Initially, data and file 
review identified 1,079 individuals identified with hypertension. Further evaluation 
eliminated 181 individuals. Although Medicare eligible, they did not meet the qualifications 
set by the research protocol (65 years of age and older). 
Informed Consent 
Initially invitation letters (N= 858) were sent to potential participants to provide 
them with study details and to request their written consent for follow-up contact for the 
purposes of completing the administered survey. The individuals who consented were 
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contacted by the researcher and trained volunteers. Several attempts were made to contact 
the consenting Medicare elders. Follow-ups included site visits to three congregate meal 
sites to administer the survey at the consenting Medicare elders' request. 
Survey Administration 
Those who were contacted were able to complete the administered survey usually 
within one hour (approximately 45 minutes by telephone and approximately 25 minutes in 
person). The time of 45 minutes was under ideal conditions without Medicare elders 
relating additional healthcare experiences. The consenting Medicare elders were allowed to 
describe briefly their health care-related experiences. Their remarks were recorded by the 
trained interviewers. Rural Medicare elders were unable to be contacted by telephone as 
easily as urban dwellers due to attendance at congregate meal sites. Three site visits were 
scheduled to Isle of Wight, Suffolk, and Franklin to reach those consenting Medicare 
elders. The site directors and staff arranged appointment times for Medicare elders to meet 
with a trained interviewer. The Medicare elders explained that they preferred to see the 
interviewer face-to-face so that they could decide whether to complete the survey. Several 
participants explained that they screened their calls and do not answer surveys by 
telephone because they do not know if they can trust the person calling them. 
Description of Results of Consumer Choice Theory 
and the Medication Adherence Constructs 
Willingness to Pay 
Table 16 shows the responses for willingness to pay as they relate to better health, 
Medicare Part D, and Medicare elders primary blood pressure drug. 
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Better health. When asked, How much would you be willing to pay (per year) to 
have better health? the majority (53.7%) of respondents either "refused" (35.8%) or did 
not know (17.9%) how much they would be willing to pay. For those Medicare elders who 
responded to this question, less than one-quarter (23.9%) were "willing to pay between 
$101 and $500" with slightly more than 10% (10.4%) "willing to pay between $501 and 
$1,000." Less than 5% were either "willing to pay up to $100" (3%) or "over $1,001 or 
more" (4.5%). Additional comments by respondents indicated that they would be "willing 
to pay whatever was necessary if they could afford it" to have better health. 
Medicare Part D Plan. When asked, How much would you be willing to pay (per 
month) for a Medicare Part D plan? less than one-third (29.9%) of Medicare elders were 
willing to pay nothing ($0) for their Medicare plan or willing to pay from $1 to $35 per 
month (31.3%). Less than one-fifth (16.4%) were willing to pay from $36 to $50 per 
month to obtain a Medicare Part D plan with more than one-fifth (22.4%) willing to pay 
from $51 to $295 for their Medicare Part D plans. As some Advantage plans offered 
during the 2008 enrollment year had no premiums due from the member or Medicare 
elders who received Extra Help (monthly premium paid by Medicare), it really was 
possible to pay nothing ($0) for a plan. 
Primary blood pressure drug. Approximately 12% of Medicare elders were not 
willing to pay ($0) out-of-pocket expenses for their primary blood pressure drug. 
Approximately 49.2% were willing to pay from $1 to $20 per month and more than one-
third (31.3%) were willing to pay between $36 and $50. Only 7% were willing to pay 
from $51 to $250 out-of-pocket per month for their primary blood pressure drug. 
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Table 16 
Willingness to Pay for Better Health, Medicare Part D, and Primary Blood Pressure 
Drug 
Willingness to Pay n % 
Better Health 
Nothing 
Up to $100 
Between $101 and $500 
Between $501 and $1000 
Over $1001 or More 
Don't Know 
Refused 
Medicare Part D Plan 
Nothing ($0) 
Between $1 and $35 
Between $36 and $50 
Between $51 and $295 
Primary Blood Pressure Drug 
Nothing ($0) 
Between $1 and $20 
Between $21 and $50 
Between $51 and $250 
67 
3 
2 
16 
7 
3 
12 
24 
67 
20 
21 
44 
15 
67 
8 
33 
21 
5 
4.5 
3.0 
23.9 
10.4 
4.5 
17.9 
35.8 
29.9 
31.3 
16.4 
22.4 
11.9 
49.2 
31.3 
7.6 
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Affordability 
Table 17 outlines Medicare elders' responses to the survey question that asked, In 
the past 12 months, did someone ever? . . . (a) arrange assistance to pay for blood 
pressure drugs, (b) talk about which blood pressure drugs definitely not to skip, (c) discuss 
the affordability of prescribed blood pressure drugs, (d) provide information about less 
expensive blood pressure drugs, and (e) provide information about programs to pay for the 
blood pressure drugs. 
Arrange assistance to pay for blood pressure drugs. A majority (82.1%) of 
Medicare elders responding to questions about assistance from a social worker or other 
professional indicated that they had received no assistance. Approximately 18% had 
received some assistance. 
Blood pressure drugs definitely not to skip. More than two-thirds (73.2%) of those 
answering the question about whether anyone in the past 12 months had talk(ed)... 
about which blood pressure drugs you definitely should not skip responded "No." More 
than one-quarter (26.9%) of Medicare elders responded in the affirmative. 
Afford blood pressure drugs when prescribed. The majority (85.1%) of the 
Medicare elders responded that they had not been asked whether they could afford blood 
pressure prescriptions. Approximately 14.9% indicated that they had been asked. 
Information about less expensive blood pressure drugs. Medicare elders also were 
asked whether anyone had given them information about where to purchase less expensive 
blood pressure drugs. About two-thirds (65.7%) of the respondents indicated that they had 
not received information about where to purchase less expensive blood pressure drugs. 
Slightly more than one-third (34.3%) answered affirmatively (Yes). 
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Information about programs to pay for blood pressure drugs. Medicare elders also 
were asked if anyone had given them information about programs that assist individuals 
with paying for blood pressure drugs. Less than two-thirds (64.2%) had not received 
information; more than one-third (35.8%) had received such information (Yes). 
Table 17 
Affordability of Blood Pressure Drugs 
N=61 No Yes 
n (%) n (%) 
Arrange Assistance to Pay for Blood Pressure Drugs 55 (82.1) 12 (17.9) 
Blood Pressure Drugs Definitely Not to Skip 49 (73.2) 18 (26.9) 
Afford Blood Pressure Drugs when Prescribed 57 (85.1) 10(14.9) 
Information About Less Expensive 
Blood Pressure Drugs 44(65.7) 23(34.3) 
Information about Programs to Pay for 
Blood Pressure Drugs 43(64.2) 24(35.8) 
Medication Adherence Model (MAM) 
Adherence 
To address adherence behaviors, Medicare elders were asked to think about the 
blood pressure drugs PRESCRIBED to them by their respective doctors and to respond to 
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these questions: Do you ever forget to take your blood pressure drugs? and Are you 
careless at times about taking your blood pressure drugs'? Their responses are summarized 
in Table 18. 
Forget to take. Less than one-half (41.8%) indicated that they never forget to take 
their blood pressure drugs. More than one-third (35.8%) responded that they rarely 
forgot. Less than 10% (9%) sometimes forgot, and less than 2% (1.5%) forgot either often 
or always to take your blood pressure drugs. 
Careless about taking blood pressure drugs. Less than two-thirds (61.2%) 
indicated that they were never careless at times about taking blood pressure drugs. More 
than one-quarter (26.9%) responded that they rarely were careless. Less than 10% (9.0%) 
sometimes were careless. Less than 2% (1.5%) were careless at times either often or 
always about taking blood pressure drugs. 
Stop taking blood pressure drugs: Feel better or feel worse. Medicare elders also 
were asked how they felt while taking blood pressure drugs. Some respondents indicated 
(see Table 18) that they stopped taking their blood pressure medication when they felt 
better. Others indicated that they stopped medicating when they felt worse. More than 
three-quarters (85.1%) of respondents do not stop taking blood pressure drugs when they 
feel better while more than 10% (10.4%) rarely stop taking the medication when they feel 
better. However, approximately 5% (4.5%) admitted to not taking blood pressure 
medication sometimes when they feel better. More than three-quarters (85.1%) indicated 
that they do not stop taking their blood pressure drugs when they feel worse. However, 
more than 10% (11.9%) rarely stopped while 3% sometimes stopped taking them when 
they felt worse. 
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Table 18 
Adherence to a Blood Pressure Drug Regimen 
Never Rarely Sometimes Often Always 
AT =67 n(%) n(%) n (%) n (%) n(%) 
Forget to Take 28(41.8) 24(35.8) 14(20.9) 1(1.5) — 
Careless about Taking 41(61.2) 18(26.9) 6(26.9) 1(1.5) 1(1.5) 
Feel Better 57(85.1) 7(10.4) 3(4.5) — — 
FeelWorse 57(85.1) 8(11.9) 2(3.0) — — 
Access Behavioral Method 
Table 19 summarizes the responses of Medicare elders when asked where they 
usually acquire their primary blood pressure drugs. The majority (83.6%) always acquire 
medication from a local pharmacy. Less than 10% either always receive free samples (6 %) 
or acquire their prescription through mail order (9%). 
Free Samples 
Approximately one-third of Medicare elders who responded received no free 
samples (zero) from their doctor or health care provider. Having received no assistance 
was not one of the response categories; the answer was a written comment in the margin 
of the survey form to indicate that response (see Table 20). Approximately 3% do not 
know if they received any free samples. However, more than one-third of Medicare elders 
have received either a little help (35.8%) or some help (31.3%) with free samples from 
their doctor or health care provider. However, many indicated that free samples were 
offered less frequently than in years past. 
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Table 19 
Method of Acquisition of Primary Antihypertensive (HBP Rx) 
Acquisition of 
Primary HBP Rx: 
Local Pharmacy 
Receive free samples 
Share with someone 
From Mail Order 
Other 
Never 
n(%) 
4 (6.0) 
46 (68.7) 
66 (98.5) 
57 (85.1) 
65 (97.0) 
Rarely 
n(%) 
3 (4.5) 
7 (10.4) 
— 
1 (1-5) 
1 (1.5) 
Sometimes 
n(%) 
— 
8(11.9) 
1 (1-5) 
2 (3.0) 
1 (1.5) 
Often 
n(%) 
4 (6.0) 
2 (3.0) 
— 
1 (1-5) 
— 
Always 
n(%) 
56 (83.6) 
4 (6.0) 
— 
6 (9.0) 
— 
Table 20 
Free Samples of Prescription Drugs from Physician 
Receive Free Samples: % 
No Help (write in response) 
A Little Help 
Some Help 
Don't Know 
20 
24 
21 
2 
29.9 
35.8 
31.3 
3.0 
Antihypertensives Prescribed 
Table 21 summarizes the prescribed antihypertensives that respondents indicated as 
those prescribed for them. Of the 138 drugs prescribed, approximately one-third (29.9%) 
of respondents indicated that they were prescribed Lisinopril. The majority (72.5%) of 
respondents were prescribed generics rather than name brand antihypertensives. 
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Table 21 
Prescribed Antihypertensives 
Antihypertensive % 
Lisinopril 
Furosemide 
Atenolol 
HCTZ 
Diovan 
Metoprolol 
Cozaar 
Norvasc 
Clonidine 
Coreg 
Other 
Generic 
Name Brand 
21 
18 
10 
8 
7 
7 
5 
5 
4 
4 
40 
00 
38 
29.9 
13.0 
7.2 
5.8 
5.1 
5.1 
3.6 
3.6 
2.9 
2.9 
29.0 
72.5 
27.5 
Medicare Part D and Extra Help Status 
The majority (50.7%) of Medicare elders have a stand-alone prescription drug 
plan while less than one-quarter (23.9%) have been approved for Extra Help. Less than 
one-half (43.3%) have a favorable view of Medicare Part D, while nearly one-third 
(28.9%) indicated an unfavorable view. Approximately 26.9% indicated neutral or do not 
know. These responses are listed in Table 22. 
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Table 22 
Medicare Part D and Extra Help Status 
Medicare Part D n % 
Prescription Drug Plan (stand-alone) 
Medicare Advantage Plan w/ Rx 
Other (Medigap w/ PDP) 
34 
20 
13 
50.7 
29.9 
19.4 
Extra Help 
No 51 76.1 
Yes 16 23.9 
View of Part D 
Favorable 
Unfavorable 
Neutral 
Don't Know 
29 
20 
13 
5 
43.3 
28.9 
19.4 
7.5 
Medicare Part D Plan Experiences 
Medicare elders' were asked about their experiences obtaining an enrollment card 
and using their Medicare Part D plan (see Table 23). The majority (65.7%) have had to 
switch from a name brand to a generic drug. The majority have not had difficulty getting 
their enrollment card or had to switch to another drug because it was not covered by their 
plan. More than one-fourth (28.4%) have had to pay costs they had not expected for a 
drug or a premium. The majority (71.6%) of Medicare elders indicated that they believe 
that the generic works just as well as the name brand drug (see Table 24). 
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Table 23 
Medicare Part D Plan Experiences 
Medicare Part D Plan Experiences (N = 67) % Have % Have Not 
Had difficulty getting enrollment card 
Left Pharmacy w/o Rx - not covered by plan 
Left Pharmacy w/o Rx - not able to afford 
Switched Rx - not covered by plan 
Switched from name brand to generic 
Billing mistake for a Rx or a Premium 
Costs hadn't expected for Rx or a Premium 
3.0 
20.9 
13.4 
28.6 
65.7 
7.5 
28.4 
97.0 
79.1 
86.6 
71.6 
34.4 
92.7 
71.6 
Table 24 
Impressions of Generics versus Name Brand Antihypertensives 
Generics vs. Name Brand (N = 67) n % 
Works better 
Just as well 
Not as well as name brand 
Don't know 
2 
48 
7 
10 
3.0 
71.6 
10.4 
14.9 
Enhanced Health Belief Model (HBM) 
The demographic characteristics of the respondents are as follows: the majority of 
respondents were women (74.6%) who were at least 75 years of age or older (86.6%). 
Respondents were either currently married (32.8%) or widowed (44.8%) with a high 
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school education (25.4%) or greater (41.8%). The ethnicity of respondents was 
approximately one-half Caucasian/white (50.7%) or African-American/black (49.3%). 
Those consenting to participate did not indicate any other ethnicity. 
Only 57 of the 67 respondents answered the income-related questions. The other 
respondents declined to answer those financially sensitive questions. Of those who chose 
to respond, 68% had monthly gross incomes of $2,850 or less and 57.9% had annual 
family incomes of $20,000 or less. Assets were not surveyed as all participants had been 
screened for Extra Help and assets information was available in the Medication Education 
database. More than one-third of respondents had assets below $11,750. Table 25 
summarizes the demographic information for the survey respondents. 
Individual Perceptions 
Tables 26 through 29 present information about Medicare elders' perceptions 
regarding issues such as the benefits and barriers to acquiring prescribed antihypertensive 
drugs. Table 28 indicates that approximately 18% of the respondents are paying more than 
$50 in monthly out-of-pocket costs for their antihypertensives. While transportation is not 
perceived as a barrier by the majority (95.5%) of respondents, for those unable to obtain 
their antihypertensives as prescribed due to transportation barriers it is necessary to assist 
in minimizing this barrier. Possibly the use of pharmacies that deliver or Medicare elders' 
enrollment in the mail-order option of their prescription drug plans may provide a more 
reliable method of acquisition. Some respondents who indicated "No" had additional 
comments that their children or a neighbor took them to the pharmacy (often not exactly 
when their refills became available, but that they "eventually" were able to obtain their 
prescriptions). 
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Table 25 
Demographics 
Age (Mean = 76.5 years, SD = 6.9 years) 
65-74 years old 
75-84 years old 
85-93 years old 
Gender 
Male 
Female 
Ethnicity 
Caucasian/white 
African-American/black 
Marital Status 
Married 
Divorced 
Separated 
Widowed 
Never Been Married 
Education 
None, or grade 1-8 
High School Incomplete (9-11) 
High School Graduate (12 or GED) 
Technical/Trade/Vocational AFTER High School 
Some College, no 4-year degree (includes AA/AS) 
College Graduate (BS, BA, or other 4-year degree) 
Post-graduate or professional schooling 
(Master's, PhD, JD, or MD) 
n % 
67 
26 
32 
9 
67 
17 
50 
67 
34 
33 
67 
22 
10 
2 
30 
3 
67 
7 
15 
17 
8 
11 
5 
38.8 
47.8 
13.4 
25.4 
74.6 
50.7 
49.3 
32.8 
14.9 
3.0 
44.8 
4.5 
10.4 
22.4 
25.4 
11.9 
16.4 
7.5 
6.0 
Table 25 (continued) 
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Income - Gross Monthly (Mean = $2,084, SD = $1,506) 
$0-$1,250 
$1,251 -$2,580 
$2,581 -$4,080 
$4,081 - $7,250 
Income - Family 
$10,000 or less 
$10,001 - $15,000 
$15,001 -$20,000 
$20,001 - $30,000 
$30,001 - $50,000 
$50,001 - $75,000 
$75,001 - $100,000 
n 
57 
26 
13 
13 
5 
57 
12 
14 
7 
5 
11 
5 
3 
% 
45.6 
22.8 
22.8 
8.8 
21.0 
24.6 
12.3 
8.8 
19.2 
8.8 
5.3 
Modifying Factors 
Table 30 summarizes the responses for (a) time since first diagnosed, (b) time 
started taking blood pressure drugs, (c) number of different antihypertensives prescribed, 
and (d) knowledge of blood pressure effects. 
Time since first diagnosed. The Medicare elders who responded had first been 
diagnosed from one to 51 years ago. Slightly more than one-third (34.3%) have been 
diagnosed with hypertension for 10 years or less. Those Medicare elders who have been 
diagnosed with hypertension between 11 years to 25 years are slightly more than 
approximately two-fifths (41.8%) and those 26 years to 51 years are less than one-quarter 
(23.9%). 
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Table 26 
Individual Perceptions 
Health Status: In general, would you say your health is? 
Excellent 
Very Good 
Good 
Only Fair 
Poor 
n 
2 
11 
27 
23 
4 
% 
3.0 
16.4 
40.3 
34.3 
6.0 
11 
43 
13 
16.4 
64.2 
19.4 
Self-Efficacy: How confident are you that you can get 
blood pressure Rx as prescribed by doctor? 
Very Confident 50 74.6 
Somewhat Confident 17 25.4 
Perceived Susceptibility: To your knowledge, 
can you avoid getting high blood pressure? 
Yes 
No 
Don't Know 
Perceived Threat: How dangerous do you perceive 
that high blood pressure is to your health? 
(0 = Not Dangerous to 10 = Extremely Dangerous) 
(Mean = 8.164, SD = 2.247) 
1-8 29 43.3 
9-10 38 56.7 
Perceived Seriousness: On a scale from zero to 100, 
how likely is it that your blood pressure would be high 
if you didn't take your blood pressure drugs? 
(0 = No Chance to 100 = Extremely Likely) 
(Mean = 89, SD = 15.798) 
1-60 
61-89 
90-100 
6 
14 
47 
9.0 
20.9 
70.1 
I l l 
Table 27 
Perceived Barriers (i.e., Cost) to the Acquisition of a Primary Blood Pressure Drug 
Never Rarely Sometimes Often Always 
Acquire Primary HBP Rx? (N = 67) % % % % % 
Take fewer pills or a smaller dose? 68.7 17.9 10.4 3.0 0 
Not fill a prescription at all? 82.1 9.0 7.5 1.5 0 
Put off or postpone getting 
a prescription drug filled? 85.1 7.5 7.5 0 0 
Use herbal medicines or vitamins 
when you felt sick rather than 
take your prescription drug? 95.5 1.5 3 0 0 
Take the drug less frequently 
than recommended; 
stretch out the time before a refill? 83.6 9.0 6.0 1.5 0 
Split pills to help them last? 88.1 3.0 6.0 1.5 1.5 
Shared pills with anyone else? 98.5 1.5 0 0 0 
Someone shared pills with you? 97.0 3.0 0 0 0 
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Table 28 
Perceived Barriers to Acquiring Blood Pressure Drugs 
Perceived Barriers - Out-of-Pocket Costs 
Not counting the costs paid by your insurance, how much do your blood pressure drugs 
cost you and your family each month? In other words, how much do you pay out-of-
pocket per month? (in dollars) 
n % 
1-10 
11-25 
26-50 
51-100 
101-300 
Perceived Barriers - Transportation 
In the past 12 months, have you ever not filled your blood pressure drugs because you did 
not have transportation to get to the pharmacy? 
n % 
Yes 
No 
67 
35 
10 
10 
8 
4 
52.2 
14.9 
14.9 
12.0 
6.0 
67 
3 
64 
4.5 
95.5 
Time started taking blood pressure drugs. Medicare elders were asked, How soon 
after your doctor prescribed a blood pressure drug didyou start taking it? The majority 
of respondents started taking their medication either immediately (43.3%) or right away 
(29.9%). Approximately 10% (10.5%) started taking it the same day or no later than the 
next day ([6.4%). 
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Table 29 
Perceived Benefit, Need, and Safety of the Acquisition of a Primary Blood Pressure Drug 
Perceived Benefit 
On a scale from zero to 100, how likely is it that your 
BP drugs lower your blood pressure? 
(0 = No Chance to 100 = Complete Cure) 
(Mean = 84.970, SD = 22.336) 
n % 
0 to 85 "24 35^8 
86 to 100 43 64.2 
Perceived Need 
How much do you believe that the BP drugs are 
needed to control your HBP? n % 
A little necessary 
Somewhat necessary 
Very necessary 
Extremely necessary 
Don't know 
Are you currently taking any prescribed HBP Rx, or not? 
Yes 
Perceived Safety 
How much do you believe that the BP drugs 
are needed to control your HBP? 
A little necessary 
Somewhat necessary 
Very necessary 
Extremely necessary 
Don't know 
Note. N = 61. 
1 
12 
23 
30 
1 
n 
67 
1.5 
17.9 
34.3 
44.8 
1.5 
% 
100 
n 
1 
12 
23 
30 
1 
% 
1.5 
17.9 
34.3 
44.8 
1.5 
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Number of different antihypertensives prescribed. The number of different 
antihypertensives prescribed for this sample population ranged from one to four different 
antihypertensives. Slightly more than one-third (35.8%) have been prescribed at least one 
antihypertensive. Those Medicare elders who have been prescribed two different 
antihypertensives account for more than approximately one-quarter (28.4%) of the 
respondents, with slightly more than one-fifth (22.4%) prescribed three different 
antihypertensives. More than 10% (13.4%) of the Medicare elders were prescribed four 
antihypertensives. 
Knowledge of blood pressure effects. The majority of Medicare elders interviewed 
had high levels of knowledge regarding blood pressure effects. Approximately 12% were 
extremely knowledgeable about blood pressure and its effects on the body, and 43.3% had 
very much knowledge about the effects of blood pressure. Approximately one-fifth had 
some (19.4%) or very little (20.9%) knowledge about high blood pressure. Less than 5% 
(4.5%) were not at all knowledgeable about the effects of high blood pressure. 
Social Support 
When asked, How much support do you get in making blood pressure drug 
decisions? respondents indicated a reasonably high level of support from doctors and 
pharmacists. Considerable variation exists among responses to the other answer categories 
to the question (see Table 31). 
Spouse. More than three-quarters (80.6%) of Medicare elders interviewed 
indicated that they received no support (none) from a spouse. Respondents said that they 
received support from a spouse less than 10% for each of the following response 
categories: a lot (9.0%), some (7.5%) and very little (3.0%). 
Table 30 
Modifying Factors 
15 
Factors % 
Time Since First Diagnosed 
(Mean = 19 years; SD - 12.9 years, Range: 1-51 years) 
Less than 10 years 
11 years to 25 years 
26 years or more 
23 
28 
16 
34.3 
41.8 
23.9 
Number of Different Antihypertensives Prescribed 
(Mean = 2 prescribed; SD = 1 prescribed, Range: 1-4 prescribed) 
One Antihypertensive 24 
Two Antihypertensives 19 
Three Antihypertensives 15 
Four Antihypertensives 9 
35.8 
28.4 
22.4 
13.4 
Time Stated Taking Blood Pressure Drugs 
How soon after your doctor prescribed 
a BP Rx did you start taking it? 
Immediately 
Right Away 
Same Day 
Next Day 
Knowledge of Blood Pressure Effects 
Are you knowledgeable of the effect high blood pressure 
has on your health? 
Not At All 
Very Little 
Some 
Very Much 
Extremely Much 
29 
20 
7 
16.4 
3 
14 
13 
29 
8 
43.3 
29.9 
10.5 
16.4 
4.5 
20.9 
19.4 
43.3 
11.9 
Note. N= 67. 
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Children. More than one-half (56.7%) of Medicare elders indicated that they 
received no support (none) from their children in making blood pressure drug decisions. 
Medicare elders who received very little support accounted for 10.4% of respondents. 
Approximately 14.9% of Medicare elders received some support, while those who 
received a lot of support accounted for 17.9%. 
Siblings. The majority of Medicare elders (83.6%) received no (none) support 
from their siblings in making blood pressure drug decisions. According to the respondents, 
their siblings provided very little support (9.0%), some support (1.5%), and a few received 
a lot (6%) of support in making blood pressure drug decisions. 
Friend. Less than three-quarters (71.6%) of the Medicare respondents relied upon 
a friend or friends for support when making blood pressure drug decisions. Slightly more 
than 10% (11.9%) received some support from their friend(s) and other respondents 
received either a lot (9.0%) or very little (7.5%) support when making blood pressure 
drug decisions. 
Neighbor. The majority (85.1%) of respondents indicated that they received no 
support (none) from a neighbor when making blood pressure drug decisions. Less than 5% 
received either very little (4.5%) or a lot (4.5%) of support from their neighbor. 
Approximately 6% received some support when making blood pressure drug decisions. 
Visiting Nurse. Almost no respondents (92.5%) received support (none) from a 
visiting nurse when making blood pressure drug decisions. Medicare elders received less 
than 5% of either very little (3%) or a lot (4.5%) of support from a visiting nurse. 
117 
Social Worker. Almost no respondents (94.0%) received support from a social 
worker when making blood pressure drug decisions. Medicare elders received less than 
5% of very little (1.5%), some (1.5%), or a lot (3.0%) of support from a social worker. 
Table 31 
Social Support Experienced by Medicare Elders 
How much support do you get in making blood pressure drug decisions from each? 
None Very Little Some A Lot 
Spouse 
Children 
Siblings 
Friend 
Neighbor 
Visiting Nurse 
Social Worker 
Doctor 
Pharmacist 
Other 
n(%) 
54 (80.6) 
38 (56.7) 
56 (83.6) 
48(71.6) 
57(85.1) 
62 (92.5) 
63 (94.0) 
9(11.9) 
29 (43.3) 
64 (95.5) 
n(%) 
2 (3.0) 
7 (10.4) 
6 (9.0) 
5 (7.5) 
3 (4.5) 
2 (3.0) 
1 (1.5) 
5 (7.5) 
11 (16.4) 
— 
n(%) 
5 (7.5) 
10(14.9) 
1 (1-5) 
8(11.9) 
4 (6.0) 
— 
1 (1-5) 
20 (29.9) 
10 (14.9) 
3 (4.5) 
n(%) 
6 (9.0) 
12(17.9) 
4 (6.0) 
6 (9.0) 
3 (4.5) 
3 (4.5) 
2 (3.0) 
34 (50.7) 
17 (25.4) 
— 
Note. N= 61. 
Doctor. A slight majority (50.7%) of Medicare elders received a lot of support 
from doctors when making blood pressure drug decisions; approximately one-third 
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(29.9%) indicated some support. Medicare elders received approximately 10% of either no 
support {none, 10.4%) or very little (7.5%) support from a doctor. 
Pharmacist. Less than one-quarter (25.4%) of Medicare elders received a lot of 
support from a pharmacist while more than two-fifths (43.3%) indicated that they received 
no support {none) when making blood pressure drug decisions. More than 10% received 
either very little (16.4%) or some (14.9%) support from a pharmacist in making blood 
pressure drug decisions. 
Other. Almost all respondents (95.5%) did not receive support from any other 
individual not previously mentioned {none); however, approximately 5% (4.5%) relied 
upon grandchildren, godchildren, daughters-in-law or church members for support when 
making blood pressure drug decisions. 
Cues to Action 
Side Effects 
The following responses from consenting Medicare elders are shown in Table 32. 
The majority of respondents suffered no side effects {never) when taking high blood 
pressure drugs; however, some of the respondents had side effects ranging from 
headaches, dry mouth, and insomnia, among others. 
Headache. Approximately 79.1% of Medicare elders never experienced a 
headache from taking blood pressure drugs. Approximately 6% rarely or sometimes 
experienced headaches. One respondent always suffered from headaches while 7.5% do 
not know if their antihypertensive was the reason for their headache. 
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Nausea. Approximately 83.6% never experienced nausea when taking their 
antihypertensives. Approximately 6% rarely or sometimes experienced nausea, and 4.5% 
responded do not know when asked about nausea after taking their blood pressure drugs. 
Dizziness. Less than three-quarters (70.1%) of respondents never experience 
dizziness when they take blood pressure drugs. Approximately 10% experience dizziness 
rarely (10.4%) or sometimes (9%). Approximately 3% always experience dizziness while 
6% do not know if dizziness occurs when they take blood pressure drugs. 
Loss of Appetite. More than three-quarters (85.1%) of Medicare elders never 
experience loss of appetite when they take blood pressure drugs. Approximately 3% 
experience loss of appetite rarely or sometimes (6%). Approximately 6% do not know if 
loss of appetite occurs when they take their blood pressure drugs. 
Insomnia. More than two-thirds (67.2%) of respondents never experience 
insomnia after taking their blood pressure drugs. Approximately 10% experience insomnia 
rarely (10.4%) or sometimes (9%). Approximately 4.5% often experience insomnia with 
approximately 1.5% always experiencing insomnia Approximately 6% do not know if 
insomnia occurs when they take their blood pressure drugs. 
Dry Mouth. Approximately one-half (50.7%) of respondents never experience dry 
mouth after taking their blood pressure drugs. Less than 10% (7.5%) experience it rarely. 
Less than one-fifth (19.4%) of the elders surveyed sometimes experience dry mouth. 
Approximately 9% often experience it. Approximately 6% always experience dry mouth 
while 7.5% do not know if dry mouth occurs when they take their blood pressure drugs. 
Incontinence. Less than three-quarters (74.6%) of respondents never experience 
incontinence after taking their blood pressure drugs. Approximately 3% experience 
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Table 32 
Side Effects 
Have you ever experienced any of the following side effects after taking your HBP Rx? 
Never Rarely Sometimes Often Always Don't 
Know 
n (%) n (%) n (%) 
Headache 
Nausea 
Dizziness 
Loss of Appetite 
Insomnia 
Dry Mouth 
Incontinence 
Allergic Reaction 
Other (Specify) 
53(79.1) 4(6.0) 4(6.0) 
56 (83.6) 4 (6.0) 4 (6.0) 
47(70.1) 7(10.4) 6(9.0) 
57(85.1) 2(3.0) 4(6.0) 
45(67.2) 6(9.0) 8(11.9) 
34(50.7) 50(74.6) 13(19.4) 
5 (7.5) 2 (3.0) 7 (10.4) 
55 (82.1) 5 (7.5) 3 (4.5) 
56 (83.6) 5 (7.5) — 
n(%) 
— 
— 
1 (1.5) 
— 
3 (4.5) 
3 (4.5) 
3 (4.5) 
— 
— 
n(%) 
1 (1-5) 
— 
2 (3.0) 
— 
1 (1-5) 
6 (9.0) 
1 (1-5) 
1 (1-5) 
1 (1-5) 
n(%) 
5 (7.5) 
3 (4.5) 
4 (6.0) 
4 (6.0) 
4 (6.0) 
5 (7.5) 
4 (6.0) 
3 (4.5) 
5 (7.5) 
Note. N = 67. 
incontinence rarely or sometimes (10.4%). Approximately 4.5% often experience 
incontinence while approximately 1.5% always experience incontinence. Approximately 
6% do not know if incontinence occurs when they take their blood pressure drugs. 
Allergic Reaction. Less than three-quarters (82.1%) of respondents never 
experienced an allergic reaction after take their blood pressure drugs. Approximately 7.5% 
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experience an allergic reaction rarely or sometimes (4.5%). Approximately 1.5% always 
experience allergic reaction while 4.5% do not know if an allergic reaction occurs when 
they take their blood pressure drugs. 
Other (specified). More than three-quarters (83.6%) of respondents never 
experience other side effects after taking their blood pressure drugs. Approximately 7.5% 
rarely experience other side effects. Approximately 1.5% always experienced other side 
effects, while 7.5% do not know if other side effects occur when they take their blood 
pressure drugs. Other side effects indicated by respondents included swelling tongue, dry 
cough, ringing in ears, heart issues, and cut down too much so that blood pressure shot 
up very high. 
Information 
Medicare elders when asked, Where do you get your information about high blood 
pressure treatment? the majority of respondents relied upon their healthcare provider. 
Very few utilized the internet or other when seeking information about high blood pressure 
treatment. The responses are summarized in Table 33. 
Healthcare Provider. More than one-half (52.2%) always get their information 
about high blood pressure treatment from their healthcare provider. More than 10% 
obtained their information about blood pressure treatment often (14.9%), sometimes 
(13.4%) or rarely (10.4%). Less than 10% never (9%) got information about high blood 
pressure treatment from their healthcare provider. 
Health Publications. Less than one-half (47.7%) never utilized health publications 
when seeking information about high blood pressure treatment. Approximately one-fifth 
(19.4%) of Medicare elders sometimes used health publications for information about high 
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blood pressure. More than 10% often (14.9%) or rarely (11.9%) relied upon health 
publications. More than 5% (6.0%) of respondents always referred to health publications 
to provide information about high blood pressure treatment. 
Internet. The majority (92.5%) of respondents never browse the internet for 
information about high blood pressure treatment. Approximately 6% sometimes use the 
internet while approximately 1.5% always consults the internet for information about high 
blood pressure treatment. 
Table 33 
Information Seeking for High Blood Pressure Treatment of Survey Respondents 
Where do you get your information about HBP treatment? 
Never Rarely Sometimes Often Always 
Healthcare Provider 
Health Publications 
Internet 
Friends 
Other 
n(%) 
6 (9.0) 
32 (47.8) 
62 (92.5) 
46 (68.7) 
56 (83.6) 
n(%) 
7 (10.4) 
8 (11.9) 
— 
7 (10.4) 
2 (3.0) 
n(%) 
9(13.4) 
13 (19.4) 
4 (6.0) 
10 (14.9) 
3 (4.5) 
n(%) 
10(14.9) 
10 (14.9) 
1 (1.5) 
4 (6.0) 
3 (4.5) 
n(%) 
35 (52.2) 
4 (6.0) 
— 
— 
3 (4.5) 
Friends. More than two-thirds (68.7%) never ask friends for information about 
high blood pressure treatment. More than 10% (14.9%) of respondents sometimes or 
rarely (10.4%) get information about high blood pressure treatment from friends. 
Approximately 6% often ask friends about high blood pressure treatment. 
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Other. More than three-quarters (83.6%) never got information about high blood 
pressure from anyone other than those previously mentioned. However, approximately 3% 
of Medicare elders rarely received information about high blood pressure, while 
approximately 4.5% sometimes, often, or always did. The sources of information ranged 
from 1.5% each for daughter-m-/aw, daughter, grandson, nurse, newspaper/no computer, 
with approximately 6% asking the pharmacist. 
Media Events 
Table 34 summarizes the percentages of responses to the following question: What 
media events have influenced you to learn more about how to get your high blood 
pressure drugs ? The majority of Medicare elders never were influenced by Medicare 
Mailings, Newspaper Articles, Public Service Announcements, Health Presentations, or 
Health Fair Brochures, but sometimes were influenced by a television program. 
Bivariate Relationships 
Demographics and Acquisition 
No significant relationships were found between gender, marital status, family 
income, and acquisition (refilled) of prescribed antihypertensives. There was no significant 
relationship between acquisition (refill) and out-of-pocket expense. However, while none 
of the low-income (less than $20,000) had difficulty acquiring their prescription drugs, 
approximately 6% of those in the higher income (20,001 or more) did not legally acquire 
(refill) their prescription drugs. 
Self-efficacy. There was no significant relationship between self-efficacy and legal 
acquisition (refill). Despite the high levels of confidence (very confident and somewhat 
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Table 34 
Media Events that Influenced Survey Respondents 
What influenced you ? 
Never Rarely Sometimes Often Always 
% 
59.7 
53.7 
62.7 
65.7 
59.7 
38.8 
% 
13.4 
16.4 
16.4 
14.9 
13.4 
6.0 
% 
13.4 
17.9 
7.5 
14.9 
23.9 
40.3 
% 
4.5 
6.0 
10.4 
3.0 
3.0 
13.4 
% 
9.0 
6.0 
3.0 
1.5 
0.0 
1.5 
Medicare Mailings 
Newspaper Article 
Public Service Announcement 
Health Presentation 
Health Fair Brochure 
Television Program 
Note. N= 67. 
confident) that Medicare elders had about their ability to get their blood pressure drugs, 
approximately 6% did not legally acquire (refill) their antihypertensives as prescribed. 
Multivariate Relationships 
Multivariate relationships include the analyses for principal components factor 
analysis. Initial extraction produced 33 factors from the 52 items (including sub-responses) 
on the survey instrument. The exclusion criterion was any factor not loading above .675 
with eigenvalues lower than 1.0. After elimination of those items not sufficiently loading on 
a factor, the final extraction produced 22 factors that were interpretable. 
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Principal Component Factor Analyses 
The following section summarizes the results of the principal component factor 
analyses for the 52 items and their sub-items loading +/- .675 or better on the factors 
having an eigenvalue of at least 1.0, the reliability of the factor scores, and the correlations 
between each factor and the six demographic items. The sample size of 67 corresponds 
with significant factor loadings of .675 (Hair, Jr., Anderson, Tatham, & Black, 1995) which 
will be utilized as the cut-off when eliminating variables. The 22-factor matrix accounted 
for 82.901 % of the total variance of the data. The factors are interpreted (see Table 35) as 
follows: 
Factor I: Health Beliefs. This factor comprises the belief about health status 
variable. This variable is concerned with beliefs about perceived level of health. The factor 
accounted for 9.222% of the total variance. 
Factor II: Perceptions about Antihypertensives. The variables that loaded on this 
factor are those related to the perceived need for antihypertensives to lower or control 
hypertension. Another variable included was the perception of risk that antihypertensives 
pose to health. This factor accounted for 8.461% of the total variance. 
Factor III: Perceptions about Acquisition of Antihypertensives. The variable that 
loaded on this factor was the monthly cost of antihypertensives. This factor accounted for 
7.272% of the total variance. 
Factor IV: Perceived Influence of Hypertension on Health. The variables in this 
factor include avoid getting hypertension or the dangers of hypertension. This factor 
accounts for 6.688% of the total variance. 
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Factor V: Self-efficacy. This factor includes the confidence in ability to acquire 
legally antihypertensives as prescribed. This factor accounts for 4.847% of the total 
variance. 
Factor VI: Knowledge of Antihypertensives. The variables in this factor include 
confidence in the ability to get antihypertensives and accounts for 4.455% of the total 
variance. 
Factor VII: Perceived Cost Barriers. The variables in this factor include 
perceptions of ways to reduce the out-of-pocket costs as well as reducing antihypertensive 
monthly costs. Methods of stretching time between refills or not acquiring at all or using 
alternatives are variables are included in this factor. This factor accounts for 4.284% of the 
total variance. 
Factor VIII: Willingness to Pay. Variables loaded in this factor are the out-of-
pocket monthly expenses for primary antihypertensive and the willingness to pay monthly 
for a Medicare Part D plan. This factor accounts for 3.774% of the total variance. 
Factor IX: Affordability. This factor was concerned with whether a healthcare or 
social worker provided ways to pay for antihypertensives or whether the healthcare 
provider asked if the respondent could afford the antihypertensive before it was prescribed. 
This factor accounts for 3.621% of the total variance. 
Factor X: Social Support. The variables that loaded on social support for 
antihypertensive decision making are siblings, friend, or neighbor for this factor. This 
factor accounts for 3.341% of the total variance. 
Factor XI: Adherence. Variables that loaded on this factor include whether 
respondents forgot to take their antihypertensives. This factor also included variables for 
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whether respondents stopped taking their antihypertensives when they felt better or worse 
after taking them. This factor accounts for 3.230% of the total variance. 
Factor XII: Side Effects. This factor includes variables for side effects experienced 
by respondents after taking their antihypertensives. The variables included headache, 
nausea, dizziness, loss of appetite, insomnia, dry mouth, incontinence, and allergic 
reaction. This factor accounts for 2.836% of the total variance. 
Factor XIII: Information. Health publications, friends, and other are variables 
loaded on this factor for where respondents sought information about hypertension 
treatment. This factor accounts for 2.595% of the total variance. 
Factor XIV: Media Events. The variables that loaded upon this factor include 
Medicare mailings, newspaper articles, public service announcement, health presentations, 
health fair brochures and television programs for this factor. This factor accounts for 
2.511 % of the total variance. 
Factor XV: Medication Taking. The variables that comprise this factor include the 
number of different antihypertensives prescribed, when started taking antihypertensives 
and number of antihypertensives taken. This factor accounts for 2.375% of the total 
variance. 
Factor XVI: Access Methods. The variables that loaded on this factor include local 
pharmacy, sharing with someone, and mail order to access their antihypertensives. This 
factor accounts for 2.167% of the total variance. 
Factor XVII: Insurance. The variables that loaded on this factor include plan type 
and whether Extra Help was received. This factor accounts for 2.153% of the total 
variance. 
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Factor XVIII: Acquisition with Medicare Part D. The variables that loaded on this 
factor include enrollment card experiences, antihypertensives not covered by plan, unable 
to afford, billing mistakes, or having to pay unanticipated costs. This factor accounts for 
2.041% of the total variance. 
Factor XIX: Perception about Choosing a Medicare Part D Plan. The variables that 
loaded on this factor included difficulty with choosing a Part D plan and if respondents 
made a good choice. This factor accounts for 1.869% of the total variance. 
Factor XX: Most Important Variables for Choosing a Medicare Part D Plan. This 
factor explores the variables that were most important to the selection of a Medicare Part 
D Plan. The variables that loaded on this factor are the amount for each prescription, the 
amount of monthly premiums and the specific drugs that were covered by the plan. This 
factor accounts for 1.807% of the total variance. 
Factor XXI: Decision-making Influence. The variables that loaded on this factor 
include whether there was a monthly premium, which prescription drugs were included in 
the formulary, and the monthly charge for each antihypertensive. This factor accounts for 
1.746% of the total variance. 
Factor XXII: Perceptions for Part D Experiences Compared with Pre-Part D. This 
factor had loadings of variables for how much respondents paid for antihypertensives 
before compared with current out-of-pocket expenditures. The comparison of monthly 
premiums as well as whether the respondents were able to obtain antihypertensives as 
needed and getting answers to questions. This factor accounts for 1.605% of the total 
variance. 
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Table 35 
Items and Factor Loadings for the Antihypertensive Acquisition Beliefs and Behaviors 
Instrument 
Factor Items Factor 
Loadings 
Factor I: Health Beliefs 
16a. Health Status .858 
Factor II: Perceptions about Antihypertensives 
8a. Hypertension would be high if not take antihypertensives 
12a. Perception that antihypertensives lower hypertension to healthy levels 
13a. Need antihypertensives to control hypertension 
15a. Perceptions of risk for antihypertensives 
.793 
.773 
.812 
.778 
Factor III: Perceptions about acquisition of antihypertensives 
10a. Monthly cost of antihypertensives .845 
Factor IV: Perceived influence of hypertension on health 
6a. Avoid getting hypertension 
7a. Danger of hypertension 
.770 
.796 
Factor V: Self-Efficacy 
5 a. Confident can acquire antihypertensives as prescribed .819 
Factor VI: Knowledge about antihypertensives 
23a. Knowledge of hypertension on health .839 
Factor VII: Perceived Cost Barriers 
9b. Not fill antihypertensive at all 
9c. Postpone getting antihypertensive filled 
9e. Take less frequently - stretch out time before refill 
.885 
.818 
.784 
Table 35 (continued) 
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Factor Items Factor 
Loadings 
Factor VIII: Willingness to Pay 
18a. Pay for Medicare Part D .840 
19a. Pay out-of-pocket for primary antihypertensive .832 
Factor IX: Affordability 
20a. Professional or social worker provide ways to pay for antihypertensives .840 
20b. Talk about which antihypertensives definitely not skip .825 
20d. Information where to get less expensive antihypertensives .714 
20e. Information about programs that help pay for antihypertensives .842 
Factor X: Social Support 
24c. Siblings .814 
24d. Friend .818 
24e. Neighbor .881 
Factor XI: Adherence 
26a. Forget to take .866 
26c. Stop taking - feel better .829 
26d. Stop taking - feel worse .865 
Factor XII: Side Effects 
21 a. Headache .840 
27b. Nausea .861 
27c. Dizziness .888 
27d. Loss of Appetite .888 
27e. Insomnia .847 
27f. Dry mouth .823 
27g. Incontinence .900 
27h. Allergic reaction .816 
Table 35 (continued) 
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Factor Items Factor 
Loadings 
Factor XIII: Information 
28b. Health publications .815 
28d. Friends .781 
28e. Other .856 
Factor XIV: Media Events 
29a. Medicare mailings .898 
29b. Newspaper article .870 
29c. Public service announcement .832 
29d. Health presentation .858 
29e. Health fair brochure .817 
29f. Television program .767 
Factor XV: Medication Taking 
22a. Number of different antihypertensives prescribed .835 
30a. Began taking antihypertensives .808 
31a. Number of antihypertensives taken . 8 84 
Factor XVI: Access Methods 
32a. Local Pharmacy .931 
32c. Share with someone .857 
32d. Mail Order .925 
Factor XVII: Insurance 
36a. Type of Plan .808 
37a. Extra Help status .757 
Factor XVIII: Acquisition with Medicare Part D 
38a. Difficulty getting enrollment card .794 
38b. Left pharmacy without antihypertensive - plan not cover .752 
Table 35 (continued) 
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Factor Items Factor 
Loadings 
38c. Left pharmacy without antihypertensive - can't afford .850 
38d. Switched antihypertensive - not covered by plan .739 
38f. Billing mistake for a premium or antihypertensive .845 
38g. Pay costs had not anticipated .877 
Factor XIX: Perceptions for choosing a Medicare Part D plan 
42a. Difficulty in choosing .813 
43a. Made a good choice .855 
Factor XX: Most important to choosing a Medicare Part D plan 
44a. Amount for each antihypertensive .828 
44d. The amount of monthly premiums .773 
44e. The specific antihypertensive covered .748 
Factor XXI: Decision-making Influence 
45b. Monthly Part D premiums .873 
45c. Antihypertensives covered by plan .899 
45d. Amount of monthly premiums .853 
45e. Specific antihypertensives covered .790 
Factor XXII: Perceptions for Part D Experiences compared with pre-Part D 
48a. How much pay for antihypertensives . 845 
48b. Cost of monthly premiums .767 
48c. Getting antihypertensives needed .849 
48d. Getting answers to questions .757 
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Summary Statistics 
Means and standard deviations are presented for the 22 interpretable items in Table 36. 
The highest mean was found in Factor II: Perceptions about Antihypertensives. Factor XX: 
Most Important Variables for Choosing a Medicare Part D Plan had the lowest overall 
mean. 
Internal Consistency of the 22 Interpretable Factors 
Coefficient alphas were computed for each of the 22 factors to assess the internal 
consistency of items represented by each factor. The factor scores were calculated by 
adding respondents' coded responses for each item. Items were selected as a factor if 
loadings were +/- .675 or greater. The results are presented in Table 37 and shows that the 
internal consistency indices ranged from -.132 to .860. Additional review of Factor IV, V, 
XVII, and XIX are necessary to determine if additional variables should be utilized in 
further analyses. 
Correlations 
The six demographic and the mental health-age variables were compared with each 
of the 22 factor scores. The factor scores were computed (by adding each item responses 
to the other variables within the factor). None of the 22 correlations reached significance 
at the .05 level for either the demographic or mental health-age variables. 
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Table 36 
Means and Standard Deviations for the Antihypertensive Acquisition Beliefs and 
Behaviors Variables 
Perception Statement M SD Overall 
M 
Factor I: Health Beliefs 
16a Health status - belief about health 
Factor II: Perceptions about Antihypertensives 
8a. Perception that your blood pressure would 
be high if not take antihypertensive 
12a. Perception that antihypertensives lower 
hypertension to healthy levels 
13a. Antihypertensives needed to control hypertension 
15a. Perception of risk for antihypertensives 
Factor HI: Perceptions about Acquisition of Antihypertensives 
10a. Monthly cost of antihypertensives 
Factor IV: Perceived influence of Hypertension on Health 
6a. Avoid getting hypertension 
7a. Danger of hypertension 
Factor V: Self-efficacy 
5a. Confident can acquire antihypertensives as prescribed 
Factor VI: Knowledge about Effect of Hypertension 
23a. Knowledge about hypertension related to health 
Factor VII: Perceived Cost Barriers 
9b. Not fill antihypertensive at all 
9c. Put off or postpone having a antihypertensive filled 
9e. Take antihypertensive less frequently 
Factor VIII: Willingness to Pay 
18a. Pay for Medicare Part D 
19a. Pay out-of-pocket for primary antihypertensive 
3.24 
89.00 
1.43 
3.37 
.906 
15.798 
84.97 
4.27 
16.27 
33.58 
.55 
8.16 
22.336 
.827 
3.417 
33.58 
58.090 
.803 
2.247 
.891 
1.085 
.28 
.22 
.25 
43.74 
24.93 
.670 
.573 
.636 
62.115 
38.579 
3.24 
48.63 
4.35 
1.43 
3.37 
.25 
34.33 
Table 36 (continued) 
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Perception Statement M SD Overall 
M 
Factor IX: Affordability 
20a. Professional or social worker provide 
ways to pay for antihypertensives 
20b. Talk about which antihypertensives definitely not skip 
20d. Information where to get less expensive 
antihypertensives 
20e. Information about programs that help pay 
for antihypertensives 
Factor X: Social Support 
24c. Siblings 
24d. Friend 
24e. Neighbor 
Factor XI: Adherence 
26a. Ever forget to take antihypertensives 
26b. Stop taking - feel worse 
26d. Stop taking - feel better 
Factor XII: Side Effects 
21a Headache 
27b. Nausea 
27c. Dizziness 
27d. Loss of Appetite 
27e. Insomnia 
27f. Dry Mouth 
27g. Incontinence 
27h. Allergic Reaction 
Factor XIII: Information 
28b. Health Publications 
28d. Friends 
28e. Other 
Factor XIV: Media Events 
29a. Medicare Mailings 
29b. Newspaper Article 
29c. Public Service Announcement 
.28 
.16 
.27 
.34 
.36 
.30 
.58 
.30 
.76 
.51 
.18 
.61 
.40 
.75 
.45 
.82 
1.34 
.73 
.45 
1.19 
.58 
.43 
.90 
.94 
.75 
.386 
.447 
.478 
.483 
.779 
1.017 
.779 
.775 
.786 
.458 
1.435 
1.129 
1.429 
1.259 
1.435 
1.647 
1.442 
1.197 
1.340 
.956 
1.076 
1.316 
1.229 
1.159 
.39 
.48 
.69 
.73 
1.04 
Table 36 (continued) 
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Perception Statement 
29d. Health Presentation 
29e. Health Fair Brochure 
29f. Television Program 
Factor XV: Medication Taking 
22a. Number of different antihypertensives prescribed 
30a. Began taking antihypertensives 
31a. Number of antihypertensives taken 
Factor XVI: Access Methods 
32a. Local pharmacy 
32c. Share with someone 
32d. Mail order 
Factor XVII: Insurance 
36a. Type of Plan 
37a. Extra Help Status 
Factor XVIII: Acquisition with Medicare Part D 
38a. Difficulty getting enrollment card 
38b. Left pharmacy without antihypertensive-plan not cover 
38c. Left pharmacy without antihypertensive-cannot afford 
38d. Switched antihypertensive-not covered by plan 
38f. Billing mistake for a premium or antihypertensive 
38g. Pay costs had not anticipated 
Factor XIX: Perception about choosing a Medicare Part D plan 
42a. Difficulty in choosing 
43a. Made a good choice 
Factor XX: Most important to choosing a Medicare Part D plan 
44a. Amount for each antihypertensive 
44d. The amount of monthly premiums 
44e. The specific antihypertensive covered 
Factor XXI: Decision-making influence 
45b. Monthly premiums 
45c. Prescription drugs covered by the plan 
M 
.60 
.70 
1.33 
2.09 
2.15 
2.06 
3.57 
.03 
.54 
1.70 
.24 
.03 
.21 
.21 
.28 
.07 
2.79 
1.72 
.13 
.09 
.10 
2.04 
2.10 
SD 
.954 
.938 
1.175 
1.063 
1.158 
1.071 
1.1118 
.244 
1.295 
.798 
.430 
.171 
.410 
.538 
.454 
.265 
.33 
2.40 
.930 
.901 
.11 
.344 
.288 
.308 
.976 
1.116 
Overall 
M 
2.10 
1.38 
.97 
.22 
.561 
2.51 
Table 36 (continued) 
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Perception Statement M 
2.09 
2.81 
1.93 
2.25 
2.34 
2.34 
SD 
.933 
1.145 
1.049 
1.106 
1.081 
1.162 
Overall 
M 
3.385 
45d. Amount the plan charges for each prescription drug 
45e. Specific antihypertensives covered 
Factor XXII: Perceptions for Part D 
experiences compared with pre-Part D 
48a. How much pay for antihypertensive 
48b. Cost of monthly premiums 
48c. Getting antihypertensives needed 
48d. Getting answers to questions 
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Table 37 
Coefficient Reliability Measures for the Antihypertensive Acquisition Beliefs and 
Behaviors Scales 
Perceptions Alpha 
Factor I Health Beliefs .490 
Factor II Health Status .491 
Factor III Perceptions about Acquisition of Antihypertensives .466 
Factor IV Perceived Influence of Antihypertensives .270 
Factor V Self-Efficacy .132 
Factor VI Knowledge about Antihypertensives .313 
Factor VII Perceived Cost Barriers .634 
Factor VIII Willingness to Pay .732 
Factor IX Affordability .688 
Factor X Social Support .693 
Factor XI Adherence .550 
Factor XII Side Effects .853 
Factor XIII Information .604 
Factor XIV Media Events .789 
Factor XV Medication Taking .833 
Factor XVI Access Methods .515 
Factor XVII Insurance . 186 
Factor XVIII Acquisition with Medicare Part D .522 
Factor XIX Perception about Choosing a Medicare Part D Plan .686 
Factor XX Most Important to Choosing a Medicare Part D Plan .305 
Factor XXI Decision-making Influence .838 
Factor XXII Perceptions for Part D Experiences Compared with Pre-Part D .860 
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Hypotheses Testing Results 
The results of the hypotheses testing are summarized in Table 38. Tables 39 
through 45 present data about specific hypotheses. The following hypotheses were tested: 
Table 38 
Hypotheses Results Summarized 
Hypotheses Number Type of Test Results 
HI 
H2 
H2a 
H2b 
H2c 
H2d 
H2e 
H3 
H3a 
H3b 
H4 
Logistic Regression 
Multiple Regression 
Multiple Regression 
Multiple Regression 
Chi-Square 
Chi-Square 
Chi-Square 
Model Comparison 
Model Comparison 
Model Comparison 
Model Comparison 
Accepted 
Accepted 
Rejected 
Accepted 
Rejected 
Rejected 
Rejected 
Rejected 
Rejected 
Rejected 
Rejected 
Ho 1: Medicare elders do not legally acquire 100% of prescribed antihypertensive. 
Ha 1: Medicare elders legally acquire at least 70% of their prescribed antihypertensives. 
This hypothesis is accepted. Medicare elders participating in this study legally acquired 
95.5% of prescribed antihypertensives. 
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Table 39 
Legal Acquisition of Prescribed Antihypertensives 
Dependent Independent Reference 
Variable Variables 
a SE OR 95% for OR 
of a Lower Upper 
Legal 
Acquisition Gender 
Education 
0 = Male 
1 = Female 
0 = Not HS 
Graduate 
-1.877 
.095 
1 = HS Graduate 
or Higher 
0 = Low 
1 = High 
-1.72 
1.26 
1.254 
.735 
.153 
1.100 
5.130 
.013 
.094 
.042 
1.808 
12.849 
.748 Access* 
Perception 0 = Not good -1.510 .972 .527 .033 1.486 
Choose Part D Choice 
1 = Good Choice 
*p < .05 
Ho2: The enhanced Health Belief Model overall does not explain Medicare elders' 
antihypertensive behaviors. 
Ha2: The enhanced Health Belief Model overall explains less than 60% of 
antihypertensive behaviors for Medicare elders. 
This hypothesis is accepted. The enhanced Health Belief Model overall explains less than 
60% (53.8%) of antihypertensive behaviors for Medicare elders. 
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Table 40 
The Enhanced Health Belief Model for Legal Acquisition of Antihypertensives 
Unstandardized Standardized 95% Confidence 
Variable 
Education 
Self-efficacy 
Perceived Health Status 
Perceived Need 
Perceived Susceptibility 
Perceived Seriousness 
Perceived Need 
Perceived Barriers: Cost 
Perceived Benefits 
Coefficients 
B 
.052 
-.019 
.007 
-.060 
.008 
-.048 
-.060 
.026 
.003 
SE 
.36 
.029 
.033 
.038 
.084 
.119 
.038 
.042 
.001 
Coefficients 
a 
.216 
-.081 
.031 
-.237 
.014 
-.055 
-.237 
.085 
.280 
level for B 
Lower 
-.021 
-.050 
-.060 
-.135 
-.161 
-.287 
-.135 
-.059 
.000 
Upper 
.126 
.070 
.074 
-.211 
.176 
.191 
.016 
.111 
.005 
P 
.159 
.738 
.834 
.118 
.928 
.687 
.118 
.536 
.056 
Ho2a: Individual perceptions for the dangerousness of high blood pressure have 
no influence on Medicare elders' decision to acquire antihypertensives. 
Ha2a: Medicare elders who perceive their hypertension as dangerous may be more 
likely to acquire legally their antihypertensives as prescribed. 
This hypothesis is rejected. Hypertension was not perceived as dangerous enough to be a 
statistically significant influence on Medicare elders' decision to acquire antihypertensives. 
Perceived safety of antihypertensives was statistically significant atp < .05. 
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Table 41 
Legal Acquisition of Antihypertensives Related to Perceived Dangerousness 
Zero-Order r 
Variable Perceived Perceived Perceived Legally 
Safety Seriousness Threat Acquire a sr2 b 
Perceived Threat -.146 -.120 .011 -.033 
Perceived Seriousness .451 -.152 -.177 .002 -.004 
Perceived Safety -.098 .253 -.274 -.281* .001* -.005 
Intercept = 1.288 
Mean 1.63 8.90 8.16 .96 
SD 2.800 1.580 2.247 .208 R2 = .12* 
*p < .05 
Ho2b: Perceived benefit of taking antihypertensives has no influence on Medicare 
elders' decision to acquire antihypertensives. 
Ha2b: Medicare elders who perceive the benefits of taking antihypertensives will 
be more likely to acquire legally their antihypertensives. 
This hypothesis is accepted. Perceived benefit does have a statistically significant (p < .5) 
influence on Medicare elders' decision to acquire legally their antihypertensives. 
Ho2c: Perceived barriers have no influence on Medicare elders' acquisition of 
antihypertensives. 
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Table 42 
Legal Acquisition of Antihypertensives Related to Perceived Benefits 
Zero-Order r 
Variable 
Perceived Perceived Legally 
Benefit Need Acquire sr2 
Perceived Need 
Perceived Benefit .342 
Mean 
SD 
4.27 
.827 
.105 
.254 
8.50 
2.23 
.199 
.002 
.96 
.208 
.034 
.003 
.021 -.134 
.001 .353 
Intercept = 5.410 
R2 = .13* 
*p < .05 
Ha2c: Medicare elders' monthly out-of-pocket expenditures will have a 
statistically significant influence on their decision to acquire antihypertensives. 
This hypothesis is rejected. Out-of-pocket expenditures were not a statistically significant 
(p > .05 for both) influence on deciding whether to acquire antihypertensives. 
Ho2d: Perceived seriousness of hypertension will have no influence on Medicare 
elders' decision to acquire antihypertensives. 
Ha2d: Medicare elders who perceive hypertension as serious will be more likely to 
acquire antihypertensives than those who do not perceive hypertension as serious. 
This hypothesis is rejected. Perceived seriousness does not have (p >.05) a statistically 
significant influence on Medicare elders' decisions to acquire antihypertensives. 
144 
Table 43 
Out-of-Pocket Expenditures and Antihypertensive Acquisition 
Not 
Acquire Legally 
Legally Acquire 
Out-of-Pocket Monthly HBP Rx 2.1 (1) 97.3 (36) 
($10 or Less) 
Out-of-Pocket Monthly HBP Rx 6.7 (2) 93.3 (28) 
($11 or More) 
Out-of-Pocket Monthly Medicare 
Part D Premium 
($30 or Less) 0.0(0) 100.0(37) 
Out-of-Pocket Monthly Medicare 
Part D Premium 
($31 or More) 10.0 (3) 90.0 (27) 
Ho2e: Cues to action has no influence on Medicare elders' decision to acquire 
antihypertensives. 
Ha2e: Medicare elder's decision to acquire their antihypertensives is influenced by 
information and side effects. 
This hypothesis is rejected. Side effects does not have a statistically significant (p >.05) 
influence on Medicare elder's decisions to acquire their antihypertensives. 
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Table 44 
Perceived Seriousness Influence on Antihypertensive Acquisitions 
Not 
Acquire Legally 
Legally Acquire 
Perceived Seriousness 0.00 (0) 100 (8) 
(Low, 70 or less) 
Perceived Seriousness 
(High, 71 or more) 51.0 (3) 94.9 (56) 
Ho3: Constructs from the both the Medication Adherence Model and Consumer Choice 
do not significantly explain Medicare elders' antihypertensive acquisition behaviors. 
Ha3: Constructs from both the Medication Adherence Model and Consumer Choice 
significantly explains Medicare elders' antihypertensive acquisition behaviors. 
This hypothesis is rejected. Neither Medication Adherence nor Consumer Choice 
significantly explains Medicare elders' antihypertensive acquisition behaviors. Each 
construct adds to the model but not at a statistically significant level. Comparing the 
enhanced Health Belief Model with the addition of Medication Adherence and Consumer 
Choice increased the overall percentage from 94.9 to 95.8. 
Ho3a: Constructs from the Medication Adherence Model added to the enhanced 
Health Belief Model does not help to explain antihypertensive acquisition behavior 
for Medicare elders significantly greater than the enhanced Health Belief Model. 
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Table 45 
Influence of Information and Side Effects on Acquisition Behaviors 
Not 
Acquire Legally 
Legally Acquire 
Side Effects (No = 0) 8.7 (2) 91.3 (21) 
Side Effects (Yes =1) 2.3 (1) 97.7 (43) 
Ha3a: Constructs from the Medication Adherence Model helps to explain 
Medicare elders' antihypertensive acquisitions significantly greater than the 
enhanced Health Belief Model. 
This hypothesis is rejected. The model constructs from Medication Adherence do not 
significantly help to explain acquisition behaviors better than the enhanced Health Belief 
Model. The enhanced Health Belief Model alone explains 94.9% and the addition of the 
Medication Adherence constructs increased the overall percentage to 95.5. 
Ho3b: Constructs from Consumer Choice added to the enhanced Health Belief 
Model do not help to explain Medicare elders' antihypertensive acquisition 
behaviors significantly greater than the enhanced Health Belief Model. 
Ha3b: Constructs from Consumer Choice added to the enhanced Health Belief 
Model does help to explain Medicare elders' antihypertensive acquisition behavior 
significantly greater than the enhanced Health Belief Model. 
This hypothesis is rejected. The enhanced Health Belief Model helps to explain Medicare 
elders better, though not significantly better than the Consumer Choice constructs. The 
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enhanced Health Belief Model overall explains 94.9% and adding Consumer Choice 
increased the percentage to 95.2. 
Ho4: The proposed Pharmaceutical Acquisition Model for Medicare Elder (enhanced 
Health Belief Model with constructs from Consumer Choice Theory and 
Medication Adherence) does not explain antihypertensive acquisition behavior for 
Medicare elders significantly better than the enhanced Health Belief Model. 
Ha 4: The proposed Pharmaceutical Acquisition Model for Medicare Elderly (enhanced 
Health Belief Model with constructs from Consumer Choice Theory and 
Medication Adherence) explains antihypertensive acquisition behavior for Medicare 
elders significantly better than the enhanced Health Belief Model. 
This hypothesis is rejected. The Pharmaceutical Acquisition Model for Medicare Elderly 
explains antihypertensive acquisition slightly better than the enhanced Health Belief Model 
but not at a statistically significant level. The enhanced Health Belief Model overall 
explains 94.9% and the Pharmaceutical Acquisition Model for Medicare Elderly overall 
explains 96.6%. 
148 
Chapter 5 
DISCUSSION 
The purpose of this study was to test the usefulness of the proposed 
Pharmaceutical Acquisition Model for Medicare Elders (PAMME); an expansion of the 
enhanced Health Belief Model (HBM) (Janz & Becker, 1984), using constructs from 
Consumer Choice Theory (Friedman, 1990) and the Medication Adherence Model 
(Johnson, 2002) with respect to decision making for antihypertensive acquisitions. The 
various components of the PAMME were tested to determine which factors exerted 
influence with respect to decision making for antihypertensive acquisitions. The 
performance of the proposed PAMME was compared to that of the enhanced HBM to 
determine which model is better at predicting antihypertensive acquisition behaviors of 
Medicare elders. 
Limitations 
Data Collection 
Invitation sample size. The target population was selected from Senior Services of 
Southeastern Virginia's Medicare Medication Management database. Initially, database and 
file review identified 1,179 individuals with hypertension. From the initial review 320 were 
excluded for not meeting the selection criterion of 65 years of age or older. A total of 868 
invitations were mailed in three phases from April 2009 to June 2009. During Phase 1, 679 
invitations were mailed; 147 and 43, respectively, were mailed during Phase 2 and Phase 3. 
Invitees were selected from those eligible Medicare elders identified as meeting the initial 
selection criterion (aged 65 years of age or older, hypertensive, and prescribed at least one 
antihypertensive). When postage costs increased, an additional screening identified those 
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lost to follow-up or unable to contact us (deceased, undeliverable mail, mental illness, 
including dementia and Alzheimer's) as well as those with disconnected administered 
numbers or who moved from the coverage area. 
True population eligible to be surveyed. When those deceased, not capable, 
undeliverable, or otherwise lost to follow-up were excluded from the 869 potentially 
eligible, the true population eligible to participate was 269. Of those truly eligible, 67 
surveys were completed, which is the minimum required for statistical significance given 
power calculations for alpha = .05 (National Statistical Service, 2009). The other 599 
were excluded for the following reasons: deceased (17.6%), not capable (14.7%), not 
eligible (14.4%), undeliverable (16.9%), and lost to follow-up (25.9%). 
Response to invitations sent. Medicare elders who responded to the invitation/ 
consent letter consented either to be included in the study or declined to participate. 
Responders were those Medicare elders who either wrote or called to confirm their 
interest or to decline the invitation. Overall, 117 of those Medicare eligible to participate 
replied to the invitation (43.5% response rate). Of the 117, 81 Medicare elders responded 
favorably (consented) to the invitation to participate (favorable response rate of 69.2% of 
respondents). Of those who consented, 67 were able to complete successfully the survey 
(82.7%). Approximately 6% did not complete the survey after they had consented due to 
death, developing Alzheimer's, moving from the area, or declining upon being contacted. 
Thirty-six (36) Medicare elders declined to participate in the study (30.8% of respondents) 
when invited. Overall, 152 Medicare elders who were sent invitations did not reply (non-
responders). However, 14 (9.2%) were excluded from the list of non-responders for 
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identifiable reasons. Of those, 14.3% from the population of eligible participants were 
identified as undeliverable through address or telephone number not being current. 
Survey Administration 
Mailing costs. When the surveys were initially mailed, the cost of a first-class 
stamp was $.42. That cost later increased to $.44, raising the cost of mailing invitations. 
Further screening was done on those awaiting invitations to determine if there were 
foreseeable reasons for non-response to minimize those undeliverable or not capable of 
being interviewed. Mailing the "thank you" gift of the pillbox increased from $.61 to $.78 
per gift. This increase in postage also affected the cost of mailing the results of the survey. 
Timing of mailing. The survey was originally scheduled to be conducted at the 
beginning of the year while FY 2008 was still fresh in Medicare elders' minds. However, 
delays in both survey approval and the mailing of the invitation/consent letters resulted in 
the first batch of surveys not being administered until the end of April 2009, with the last 
batch of survey responses collected through the end of August 2009. 
Informed consent. Initially, invitation letters were sent to potential participants to 
provide them with the study details and to request their written consent for follow-up 
contact for the purposes of completing the administered survey. While the informed 
consent letters were mailed with postage-paid return envelopes, many of the invitation/ 
consent letters were not returned (67.9%). While the invitation response rate was in line 
with other research using mailed methods (approximately 32.1 %), further file review was 
necessary to determine if non-responders would be able to be reached via another method. 
However, after several unsuccessful attempts were made to contact Medicare elders by 
mail and by telephone they were declared lost to follow-up. 
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Volunteers. The dedication level of the volunteers assisting the primary researcher 
was lower since the volunteers did not have a stake in the outcome. The volunteers had 
other priorities and were not as vigilant about data collection as the primary researcher 
was. While any assistance was greatly appreciated, the number of surveys completed may 
possibly have been reduced by the time constraints of the primary researcher. It may be 
necessary to hire paid employees in future research to have some control over the 
productivity of those involved with survey administration and other data collection efforts. 
Target population demographics: The target population comprised individuals 65 
years of age and older who were not taking prescription drugs for mental health (i.e., 
dementia, Alzheimer's among others). In this population, there is the possibility of losing 
Medicare elders to follow-up based upon death, relocation (out-of-state, assisted living, 
nursing home or with family), or declining health. Increases in the time between encounters 
reduces the ability to follow-up as other researchers have found that more than six months 
following an encounter, it may become difficult to locate those with chronic illness 
(Brinkhof, Pujades-Rodriguez, & Egger, 2009). The target population of hypertensive 
Medicare elders in southeastern Virginia contains approximately 39,197 individuals 
(Virginia Department of Health, Center for Health Statistics, 2008) of whom 1,178 had 
been assisted by SSSEVA with Medicare Part D enrollment. 
Administered interviews. Survey administration could not always be conducted via 
telephone due to the mental illness or trust issues of the consenting Medicare elders, or the 
researcher's inability to contact them after three attempts. 
Mental illness. Administered surveys were unable to be successfully completed by 
those individuals who consented and were contacted, but had mental health issues. Those 
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attempts were not included in the assessment, but were identified as not capable. It was 
later determined that those individuals with mental health issues were already being treated 
so no referrals to their respective doctors were necessary. 
Trust. While the consenting respondents had indicated that they were comfortable 
with talking on the telephone, trust issues entered into the equation with frequent 
screening of calls and/or not answering calls from telephone numbers they did not readily 
recognize. The Medicare elders explained that they prefer to see the interviewer's face to 
decide whether to complete the survey. Several participants explained that they screen 
their calls and do not answer any surveys by telephone because they do not know if they 
can trust the person calling them. Those surveys would not have been completed if the 
interviewer had not been able to meet with them at their nutrition sites. 
Inability to reach. In addition to the trust issues, Medicare elders at rural locations 
were not easily contacted via telephone due to regular attendance at congregate meal sites. 
Three site visits were conducted (Isle of Wight, Suffolk, and Franklin) to reach those 
consenting Medicare elders. The site directors and staff set up appointment times for the 
consenting Medicare elders to meet with a trained interviewer. Inability to contact 
Medicare elders by mail or telephone (mail came back as undeliverable, telephone numbers 
were no longer in service, or calls left on answering machines were not returned after three 
attempts) as well as death notices proved to be an obstacle to gaining approval for further 
contact. 
Survey length. Medicare elders who consented also were concerned about the 
survey length (52 questions). A few respondents took advantage of the option to take a 
break and reschedule the completion of their Part D and Extra Help experiences for 
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another day (taking either one or two days more to complete). For those who were able to 
continue with the survey, the interviewer was able to inform them that the remainder of the 
survey (Medicare Part D and Extra Help questions) would not take more than 10 minutes 
to complete. 
Incentive for survey completion. The seven-day pillbox given to help manage pill 
taking was not always seen as an incentive. Many other activities (nutrition, exercise, and 
health presentations) through Senior Services of Southeastern Virginia used the pillboxes 
as incentives as well. Consenting Medicare elders did complete the survey, but declined the 
pillbox, stating that they had too many already. The interviewer explained that an extra 
pillbox was nice for traveling, but not all accepted the incentive, even with that assertion. 
Survey Instrument Development 
The administered survey instrument was developed by combining previously tested 
survey instruments for assessment of mental health, medication adherence, perception of 
affordability, and experiences with the Medicare Part D drug benefit. The combined 
instruments were then sent to expert reviewers who reviewed the survey instrument for 
appropriateness for use with Medicare elders. The expert panel was comprised of 
gerontologists, elder care managers, elder caregivers, and Medicare elders. The expert 
panel was asked to assess the survey instrument for question appropriateness, whether any 
questions were harmful, and if they appeared to measure the intended concepts. After the 
expert panel provided input, the survey instrument was revised to reflect the expert panel's 
suggestions. The improved survey instrument was then administered to 35 Medicare elders 
(taking at least one antihypertensive) who would not be included in the final survey 
administration. After the survey instrument was pilot-tested, revisions were made to 
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exclude questions that did not load well (alpha coefficient of less than .675) during factor 
analyses or were confusing to the pilot respondents. 
Survey Instrument Analyses 
The principal component and factor analyses of the Antihypertensive Belief and 
Behaviors survey instrument revealed that Medicare elders who responded to this survey 
were influenced by cost of both the monthly premium and out-of-pocket expenses when 
making acquisition decisions. Surprisingly, Medicare elders were candid in their practice of 
sharing with someone who could be another family member, friend, or neighbor or having 
someone share with them. In addition, the doctor or healthcare professional who 
prescribed the antihypertensives was not a variable that loaded on any of the factors. 
Pharmacists were seen as more helpful, which could be a possible reason that Medicare 
elders are still using the local pharmacy despite Medicare claims that mail order could save 
them more money (Centers for Medicare and Medicaid Services, 2009). Affordability 
remains an issue for those Medicare elders who left the pharmacy without their 
antihypertensives because they could not afford them. Surprisingly, spouse and children 
did not load on the social support factor; many respondents were widowed (without 
children or children were not close) or single (widowed, divorced, or never married). 
Lessons Learned 
The most important lesson learned was that Medicare elders are very busy with 
social activities, doctor visits, and other daily living activities, so trying to reach them to 
complete a telephone survey is not an easy task. Additionally, with the increasingly popular 
use of cellular telephones, it becomes very important when requesting a telephone number 
for conducting a telephone survey that the researcher specifies, At which number can you 
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best be reached1} Without obtaining Medicare elders' home and/or mobile administered 
telephone numbers, it may be difficult to reach them. As increasingly more Medicare elders 
are mastering the computer, it may be possible within the next couple of years to survey 
them via their e-mail address versus their home or mobile administered telephone number. 
Future Research Proposed 
One method that could be used to research this topic further would be contacting 
non-responders to determine a statistically significant difference between the response of 
those who participated and those who did not. 
Another method would be to widen the scope to additional chronic disease states. 
Medicare elders usually have more than one chronic illness and while this study utilized 
hypertension and antihypertensives, additional research could expand this focus to other 
disease classes. A similar study could be conducted with the inclusion of questions to 
identify other chronic illnesses for which Medicare elders were taking prescription drugs. 
Funding for the study could be sought from either the National Institutes of Health or the 
Centers for Disease Control and Prevention with trained assistants being paid to collect 
data. Additionally, by widening the focus to more than just hypertension, it may be possible 
to attract a larger number of participants. 
Conclusion 
Overall, this study was helpful in exploring the possible linkages between health 
beliefs, consumer choice, and medication adherence. While the hypotheses were not all 
statistically significant in their results, the information gained allows other researchers to 
build upon this beginning. The inclusion of both consumer choice and medication 
adherence into this study may yet prove to be tools necessary to understand better the 
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complexity of the decision-making challenge of Medicare elders with respect to 
antihypertensive and other prescription drug acquisitions. 
157 
REFERENCES 
Abraham, J. M., Feldman, R., Carlin, C, & Christianson, J. (2006). The effect of quality 
information on consumer health plan switching: Evidence from the Buyers Health 
Care Action Group. Journal of Health Economics, 25, 762-781. 
Agency for Healthcare Research and Quality. (2002). Preventing disability in the elderly 
with chronic disease. Research in Action, Issue 3. Available from www.ahrq.gov 
Agnew, J., Halpin, H., & Lipton, H. (2003). Cost and utilization of outpatient prescription 
drugs among the elderly: Implications for a Medicare benefit. [Abstract] Academy 
Health Meeting 2003, Abstract No. 492. 
Al-Ali, N., & Haddad, L. G. (2004). The effect of the Health Belief Model in explaining 
exercise participation among Jordanian myocardial infarction patients. Journal of 
Transcultural Nursing, 15(2), 114-121. 
Al Khaja, K., Sequeira, R., & Mather, V. (2001). Rational pharmacotherapy of 
hypertension in the elderly: Analysis of the choice and dosage of drugs. Journal of 
Clinical Pharmacy & Therapeutics, 26(1), 33-42. Retrieved March 1, 2008, from 
http://search.ebscohost.com.proxy.lib.odu.edu/login.aspx?direct=true 
&db=rzh&AN=2003069759&site=ehost-live 
American Heart Association. (2007a). Hypertension in seniors & isolated systolic 
hypertension (ISH). Hypertension. Retrieved January 15, 2008, from 
www.aha.org. 
American Heart Association. (2007b). What is high blood pressure? Retrieved January 10, 
2008, from http://www.americanheart.org 
print_presenter.jhtml ;j sessionid=URZPNDXHUD 
158 
American Journal of Nursing. (2004). AJN Reports: Pick a card - Any card? AJN Reports, 
104(7), 24-26. 
American Medical Association. (2002). Featured CSA Report: Improving the quality of 
geriatric pharmacotherapy (A-02). Retrieved February 12, 2005, from http:// 
www.ama-assn.org/ama/pub/category/print/13592.html 
Andrawes, W., Bussy, C, & Belmin, J. (2006). Prevention of cardiovascular events in 
elderly people. Drugs & Aging, 22(10), 859-876. 
Antonacci, X. X. (2002). The effect of health beliefs on health-promoting behavior in the 
elderly. Unpublished manuscript, New York. 
Appel, L. J., Brands, M. W., Daniels, S. R., Karanja, N., Elmer, P. J., & Sacks, F. M. 
(2006). Dietary approaches to prevent and treat hypertension: A scientific 
statement from the American Heart Association. Hypertension (vol. 47, pp. 296-
308). Baltimore: American Heart Association. 
Aquino, M., Fyfe, M., MacDougall, L., & Remple, V. (2004). West Nile virus in British 
Columbia. Emerging Infectious Diseases, 70(8), 1499-1501. 
Atta, H. Y. (1994). Psychosocial determinants of age-appropriate immunizations of 
infants in Norfolk, Virginia. Unpublished dissertation, Old Dominion University, 
Norfolk, VA. 
Balkrishnan, R. (1998). Predictors of medication adherence in the elderly. Clinical 
Therapeutics, 20(4), 764-771. 
Balon, R. (2002). Managing compliance. Psychiatric Times, 19(5), 1-10. Retrieved 
October 29,2005, from http://www.psychiatrictimes.come/p20543.html 
Bandura, A. (1986). Social foundations of thought and action. Englewood, NJ: Prentice 
Hall. 
Bandura, A. (1997). Self-efficacy: The exercise of control. New York: W. H. Freeman. 
Bardel, A., Wallander, M. A., & Svardsudd, K. (2007). Factors associated with adherence 
to drug therapy: A population-based study. European Journal of Clinical 
Pharmacology, 63(3), 307-314. 
Barlas, S. (2004). Medicare discount drug program begins. Geriatric Times, 35. 
Barnes, S., & Thomas, A. (1990). A modified cancer education program. Cancer Nursing, 
13(1), 48-55. 
Bearden, W. O., & Mason, J. B. (1978). Consumer-perceived risk and attitudes toward 
genetically prescribed drugs. Journal of Applied Psychology, 63(6), 741-746. 
Benson, J., & Britten, N. (2002). Patients' decisions about whether or not to take 
antihypertensive drugs: Qualitative study. Primary Care, 325,1-5. 
Blum, J., Bowman, J., & White, C. (2005, October). The impact of enrollment in 
Medicare prescription drug benefit on premiums. Prepared by Alavere Health 
LLC for the Henry J. Kaiser Family Foundation. Retrieved November 23,2005, 
from www.kff.org 
Blustein, J. (2000). Drug coverage and drug purchases by Medicare Elders with 
hypertension: High out-of-pocket costs mean that some elderly Americans go 
without essential medications. Health Affairs, 19(2), 219-230. 
Bowman, B. (2007). New study shows elderly struggling with medication costs. Retrieved 
January 10,2007, fromwww.wral.com/news/local/story/163208/ 
160 
Brewer, N. T., Chapman, G B., Brownlee, S., & Leventhal E. A. (2002). Cholesterol 
control, medication adherence and illness cognition. British Journal of Health 
Psychology, 7, 433-447. 
Brinkhof, M. W., Pujades-Rodriquez, M., & Egger, M. (2009). Mortality of patients lost 
to follow-up in antiretroviral treatment programmes in resource-limited settings: 
Systematic review and meta-analysis. PLoS One, 4(6), e5790. 
Brown, L. W., & Williams, R. D. (1994, March). Culturally sensitive breast cancer 
screening programs for older black women. Nurse Practitioner, XX (March), 21-
32. 
Budnitz, D. S., Shehab, N., Kegler, S. R., & Richards, C. L. (2007). Medication use 
leading to emergency department visits for adverse drug events in older adults. 
Annuals of Internal Medicine, 147(11), 755-765. 
California Healthcare Foundation. (2005). Rxfor affordability: Helping patients cope with 
medication costs. Retrieved October 18, 2007, from http://www.chcf.org/topics/ 
chronicdisease/index.cfm?itemID= 115515 
California Healthcare Foundation. (2006). The Medicare drug benefit: How good are the 
options? Retrieved October 18, 2007, from www.chcf.org 
Carroll, L. L. H. (2003). Predictors of oral health behaviors: Examining the effect of 
patient perceived humanistic attitude in the context of the Health Belief Model. 
Unpublished dissertation, Old Dominion University, Norfolk, VA. 
Catz, S. L., Kelly, J. A., Bogart, L. M., Benotsch, E. G, & McAuliffe, T. L. (2000). 
Patterns, correlates, and barriers to medication adherence among persons 
prescribed new treatments for HIV disease. Health Psychology, 19, 124-133. 
161 
Centers for Disease Control and Prevention. (2005a). Health-related quality of life. 
Retrieved May 27, 2006, from http://www.cdc.gov/hrqol/ 
Centers for Disease Control and Prevention. (2005b). Healthy aging for older adults. 
Retrieved October 13,2006, from http://www.cdc.gov/aging/ 
Centers for Disease Control and Prevention. (2007a). State heart disease and stroke 
prevention program addresses high blood pressure: High blood pressure facts. 
Centers for Disease Control and Prevention. (2007b). Summary Health Statistics for U. S. 
Adults: National Health Interview Survey, 2006. (Vol. Series 10). Hyattsville, MD: 
U. S. Department of Health and Human Services. 
Centers for Medicare & Medicaid Services. (2005a). FAQ results. Retrieved May 12, 
2005, from www.cms.hhs.gov/faqsearch/faqprint.asp?site=SMC&topl=77 
Centers for Medicare & Medicaid Services. (2005b). Overall health care cost growth 
projections slow from 2003 Medicare drug coverage expected to lower prices. 
Medicare News. (Press release.) Retrieved May 27,2005, from www.cms.hhs.gov/ 
mmu/ 
Centers for Medicare & Medicaid Services. (2005c). Medicare modernization update. 
Medicare News (Press release.) Retrieved April 17,2005, from www.cms.hhs.gov/ 
media/press/release.asp?Counter=1356 
Centers for Medicare & Medicaid Services. (2005d). Medicare Modernization Act: 
Prescription drug benefit/Medicare Advantage programs. Retrieved December 13, 
2005, from www.cms.hhs.gov/ 
Centers for Medicare & Medicaid Services. (2005e). National health care expenditures: 
Projections 2003-2013. Retrieved December 13, 2005, from www.cms.hhs.gov/ 
162 
Centers for Medicare & Medicaid Services. (2006). Gap coverage. Retrieved December 
14,2006, from www.cms.hhs.gov 
Centers for Medicare & Medicaid Services. (2008). Bridging the coverage gap. (CMS 
Publication No. 11213). Retrieved February 13,2008, from www.medicare.gov 
Centers for Medicare & Medicaid Services. (2009). Things to think about when you 
compare Medicare drug coverage. (CMS Pub. No. 11163.) Retrieved October 3, 
2009, from http://www.medicare.gove/Publications/Pubs/pdf/! 1163.pdf 
Centers for Studying Health System Change. (2003). Unequal access: African-American 
Medicare elders and the prescription drug gap. 64(July), 1-4. 
Chobanian, A. V. (2007, August 23) Isolated systolic hypertension in the elderly. Thomson 
Gale, New England Journal of Medicine Audio, retrieved from http://content nejm 
org/content/vol357/issue8/images/ 
data/DCl?NEJM_Summary_8_23_2003.mp3. 
Conway-Welch, C. (2000). Medicare: Lessons learned by a former Medicare 
commissioner. Policy, Politics & Nursing Practice, 7(1), 26-30. 
Cooper, J. K., Love, D. W., & Raffoul, P. R. (1982). Intentional prescription nonadherence 
(noncompliance) in the elderly. Journal of the American Geriatrics Society, 30(5), 
329-333. 
Corrigan, P.W. (2002). Adherence to anti-psychotic medications and health behavior 
theories. Journal of Mental Health, 11(3), 243-254. 
Creative Research Systems. (2003). Sample size calculator. Retrieved September 13, 
2007, from www.surveysystem.com/sscalc.htm 
163 
Crystal, X. X., Johnson, R. W., Harman, J,, et al. (2000). Medicare reforms that will raise 
out-of-pocket costs for some elderly people need careful consideration. Journal of 
Gerontology, Social Sciences, 55B, S51-S62. 
Cutler, D. M, Long, G., Berndt, E. R., Royer, J., Founder, A., Sasser, A., & Cremieux, P. 
(2007). The value of antihypertensive drugs: A perspective on medical innovation. 
Health Affairs, 26(1), 97-110. 
Datti, B., & Carter, M. W. (2006). The effect of direct-to-consumer advertising on 
prescription drug use by older adults. Drugs Aging, 23(1), 71-81. 
Davis, M. P., & Srivastava, M. (2003). Demographics, assessment, and management of 
pain in the elderly. Drugs Aging, 20(1), 23-57. 
DeSalvo, J. S., & Huq, M. (2002, Spring). Introducing non-linear pricing into consumer 
choice theory. Journal of economic education, 166-179. 
Donaldson, C, Thomas, R., & Torgerson, D. J. (1997). Validity of open-ended and 
payment scale approaches to eliciting willingness to pay. Applied Economics, 
29(1), 79-85. 
Ead, H. A. (1998). Medicine in old Egypt. Transcribed from the History of Science, by 
George Sarton, Heidelberg, Germany. 
Eissa, A., Andrew, M. J., & Baker, R. A. (2003). Postoperative confusion assessed with 
the Short Portable Mental Health Status Questionnaire. ANZ Journal of Surgery, 
73(9), 697-700. 
Elam, L. (2006, March). Dual eligibles: Dual eligibles and the Medicare drug benefit. 
Kaiser EDU.org Tutorial. Retrieved October 13, 2006, from www.kaiserEDU.org 
164 
Esposito, L. (1992). Medication knowledge and compliance. Home care vs. senior housing 
clients. Caring: National Association for Home Care Magazine, 11(11), 42-45. 
Families USA. (2003). Out-of-bounds: Rising prescription drug prices for seniors. 
Retrieved December 15,2006, from www.familiesusa.org 
Families USA. (2004). Sticker shock: Rising prescription drug prices for seniors. 
Retrieved December 15,2006, from www.familiesusa.org 
Families USA. (2006) Special report: Coverage in the "donut hole " grows scarcer in 
2007. Retrieved December 15,2006, from www.familiesusa.org 
Federman, A. D., Halm, E. A., Zhu, C, Hochman, T., & Siu, A. L. (2006). Association of 
income and prescription drug coverage with generic medication use among older 
adults with hypertension. American Journal of Managed Care, 12, 611-618. 
Field, T. S., Gilman, B. H., Subramanian, S., Fuller, J. C, Bates, D. W., & Gurwitz, J. H. 
(2005, December). The costs associated with adverse drug events among Older 
Adults in the Ambulatory Setting. Medical Care, 43(12), 1171-1176. 
Fischer, M. A., & Avorn, J. (2003). Economic consequences of underuse of generic drugs: 
Evidence from Medicaid and implications for Prescription Drug Benefit Plans. 
HSR: Health Service Research, 3(4), 1051 -1064. 
Foley, K. A., Vasey, J., Berra, K., Alexander, C. M., & Markson, L. E. (2005). The 
hyperlipidemia: Attitudes and beliefs in treatment (HABIT) survey or patients: 
Results of a validation study. Journal of Cardiovascular Nursing, 20(1), 35-42. 
Folland, S., Goodman, A. C, & Stano, M. (2004). The economics of health and health 
care (4th ed.). Upper Saddle River, NJ: Prentice Hall. 
165 
Fonseca, M. G, & Zeidan, R. M. (2004). Epistemological considerations on agent-based 
models in evolutionary consumer choice theory. E.Co, 6(3), 4-8. 
Friedman, B., & Basu, J. (2004). The rate and cost of hospital readmission for preventable 
conditions. Medical Care Research and Review, 61(2), 225-240. 
Friedman, D. D. (1990). Price theory: An intermediate text. South-Western Publishing. 
Ganguli, G (2003). Consumers devise cost-cutting measures: Medical and legal issues to 
consider. Health Care Manager, 22(3), 275-281. 
Gaskin, D. J., Briesacher, B. A., Limeangeo, R., & Brigantti, B. L. (2006). Exploring 
racial and ethnic disparities in prescription drug spending and use among Medicare 
elders. The American Journal of Geriatric Pharmacotherapy, 4(2), 96- 111.. 
Gavin, K. (2007). Study: Senior Medicare drug costs vary widely among states. University 
Record Online. Retrieved September 13, 2007 from urecord@ umich.edu 
Gazmararian, J. A., Baker, D. W., Williams, M. V., Parker, R. M., Scott, T. J., Green, D. 
C, et al. (2008). Health literacy among Medicare enrollees in a managed care 
organization. The Journal of the American Medical Association, 281(6), 545-
551. 
George, J., Munro, K., McCaig, D. J., & Stewart, D. C. (2006). Prescription medications: 
beliefs, experiences, behavior and adherence of sheltered housing residents. The 
Annuals of Pharmacotherapy, 40(12), 2123-2129. 
Glanz, K., Lewis, F. M., & Rimer, B. K. (1990). Health Behavior and Health Education: 
Theory, Research and Practice. San Francisco: Jossey-Bass. 
Glanz, K., Rimer, B. K., & Lewis, F. M. (2002). Health behavior and health education. 
Theory, research and practice. San Francisco: Wiley & Sons. 
166 
Gohar, R, Greenfield, S. M., Beevers, D. G.., Lip, G Y. H., & Jolly, K. (2008). Self-care 
and adherence to medication: A survey in the hypertension outpatient clinic. BMC 
Complementary and Alternative Medicine, 8(4). 
Gottlieb, H. (2000). Medication nonadherence: Finding solutions to a costly medical 
problem. Drug Benefit Trends, 72(6), 57-62. 
Gregory, V. (2004, September 4). Rising Medicare costs wallop elderly. North Gate News 
Online, Retrieved January 12,2005, from http://journalism.berkeley.edu/ngno/ 
stories/003076_print.html 
Grymonpre, R. E., Didur, C. D., Montgomery, P. R., & Sitar, D. S. (1998). Pill counts, 
self-report, and pharmacy claims data to measure medication adherence in the 
elderly. The Annals of Pharmacology, J2(7-8), 749-754. 
Hair, J. R, Jr., Anderson, R. E., Tatham, R. L., & Black, W. C. (1995). Multivariate data 
analysis (4th ed.). Upper Saddle River, NJ: Prentice Hall. 
Haug, M. R., Musil, C. M., Warner, C. D., & Morris, D. L. (1998). Interpreting bodily 
changes as illness: A longitudinal study of older adults. Social Science & Medicine, 
46(12), 553-567. 
Haynes, R. B., McDonald, H. P., & Garg, A. X. (2002). Helping patients follow prescribed 
treatment. Journal of the American Medical Association, 288(11), 2880-2883. 
Henry J. Kaiser Family Foundation. (2005). National Medicare pharmacy data. Retrieved 
January 27, 2006, from www.kff.org 
Henry J. Kaiser Family Foundation. (2006a). Prescription drug trends. Retrieved October 
13, 2007, from www.kff.org 
167 
Henry J. Kaiser Family Foundation. (2006b). Seniors and the Medicare prescription drug 
benefit. December. Chartpack. Retrieved September 18, 2006,. from www.kff.org 
Henry J. Kaiser Family Foundation. (2006c). Voices of elders: Early experiences with the 
Medicare Drug Benefit. Retrieved May 27, 2006, from www.kff.org 
Henry J. Kaiser Family Foundation. (2006d). Seniors' early experiences with their new 
Medicare Drug Plans-June 2006, (Pub. No. 7547). Retrieved August 28, 2006, 
from www.kff.org 
Henry J. Kaiser Family Foundation. (2007a). Medicare Advantage Overview. Retrieved 
January 10,2007, from www.kaisernetwork.org 
Henry J. Kaiser Family Foundation. (2007b). Medicare: Medicare at a Glance. February, 
Fact Sheet. Retrieved October 13, 2007, from www.kff.org 
Henry J. Kaiser Family Foundation. (2007c). Prescription drugs: Avandia, Actos labels to 
include black box warnings. Retrieved September 13, 2007, from 
www.kaisernetwork.org 
Henry J. Kaiser Family Foundation. (2008). Medicare: Medicare at a Glance. Fact Sheet. 
Retrieved December 22, 2008, from www.kff.org 
Hoadley, J., Hargrave, E., Merrell, K., Cubanski, J., & Neuman, T. (2006, November). 
Benefit design and formularies of Medicare Drug Plans: A comparison of 2006 
and 2007 offerings (A First Look). Retrieved December 14, 2006, from 
www.kff.org 
Hoadley, J., Thompson, J., Hargrave, E., Merrell, K., Cubanski, J., & Neuman, T. (2007). 
Medicare Part D 2008 data spotlight: Premiums. Retrieved January 12, 2008, 
from www.kff.org 
168 
Hodgetts, D., Chamberlain, K., & Bassett, G (2003). Between television and the audience: 
Negotiating representations of ageing. Health: An Interdisciplinary Journal for the 
Social Study of Health, Illness and Medicine, 7, 417-438. Retrieved July 9, 2008, 
from http://hea.sagepub.eom/cgi/content/abstract/7/4/417 
Home, R., Graupner, K., Frost, S., Weinman, J., Wright, S.M., Hankins, M. (2004). 
Medicine in a multicultural society: The effect of cultural background on beliefs 
about medications. Social Science & Medicine, 59(6), 1307-1313. 
Home, R., & Weinman, J. (1999). Patients' beliefs about prescribed medicines and their 
role in adherence to treatment in chronic physical illness. Journal of Psychosomatic 
Research, 47(6), 555-567. 
Hsu, J., Fung, V., Price, M, Huang, J., Brand, R., Hui, R., et al. (2008). Medicare elders' 
knowledge of Part D Prescription Drug Program benefits and responses to drug 
costs. The journal of the American Medical Association, 22(16), 1929-1936. 
Hughes, C. M. (2004). Medication non-adherence in the elderly: How big is the problem? 
Drugs & Aging, 27(12), 793-811. 
Israel, G D. (2003, June). Determining sample size. (PEOD6, 1-5). Gainesville, FL: 
University of Florida, IFAS Extension. Retrieved August 28,2007, from http:// 
edis.ifas.ufl.edu/pdffiles/PD/PD00600.pdf 
Jackson, J. E., Doescher, M. P., Saver, B. G, & Fishman, P. (2004). Prescription drug 
coverage, health, and medication acquisition among seniors with one or more 
chronic conditions. Medical Care, 42(11), 1056-1065. 
James, C, Thomas, M., Lillie-Blanton, M., & Garfield, R. (2007, January). Key facts: 
Race, ethnicity & medical care. Available at www.kff.org 
169 
Janz, N. K., & Becker, M. H. (1984). The health belief model: A decade later. Health 
Education Quarterly, 11, 11-47. 
Johnson, M. J. (2002). The medication adherence model: A guide for assessing medication 
taking. Resident Theory Nurse Practitioner, 16(3), 179-192. 
Kaisernetwork.org. (2007, August 21). Share of seniors with drug coverage significantly 
increased under Medicare Part D, some seniors still vulnerable to high costs, study 
finds. Kaiser Daily Health Policy Report. Retrieved September 10, 2007, from 
http://www.kaisernetwork.org/daily_reports/ 
Kanavos, P., & Gemmill, M. (2004). Senior citizens and the burden of prescription drug 
outlays: What lessons for the Medicare prescription drug benefit? Applied Health 
Economics and Health Policy, 3(4), 217-227. 
Kim, K. K., Horan, M. L., Gendler, P., & Patel, M. K. (1991). Development and 
evaluation of the Osteoporosis Health Belief Scale. Research in Nursing & Health, 
14(2), 155-163. 
Kirking, D. M., Lee, J. A., Ellis, J. J., Briesacher, B., & McKercher, P. L. (2006). Patient-
reported underuse of prescription medications; A comparison of nine surveys. 
Medical Care Research and Review, 63(A), 427-446. 
Klein, D., Turvey, C, & Wallace, R. (2004). Elders who delay medication because of cost: 
Health insurance, demographic, health, and financial correlates. The Gerontologist, 
44(6), 779-787. 
Klein, D.E., Wustrack, G, & Schwartz, A. (2006). Medication adherence: Many 
conditions, a common problem. Proceedings of the Human Factors and 
Ergonomics Society, 50th Annual Meeting, 1088-1092. 
170 
Klein, P. (2003). Medicare reform draws praise and criticism. Fairfield Business Journal, 
42(50), 15-16. 
Klinedinst, N. J. (2005). Effects of a nutrition education program for urban, low-income, 
older adults: A collaborative program among nurses and nursing students. Journal 
of Community Health Nursing, 22(2), 93-104. 
LeBuono, C. (2004, October 11). Medication underuse due to cost called a serious issue. 
Drug Topics. Retrieved December 18, 2005, from www.drugtopics.com/ 
drugtopics 
Lacey, A. L. (1988). Health beliefs and health behavior in elderly chronically ill males. 
Unpublished manuscript, Chicago. 
Lasbley, M. E. (1987). Predictors of breast self-examination practice among elderly 
women. Advanced Nursing Science, 9(4), 25-34. 
Leeser, I. R. (1989). The relationship between perceived severity of the disease, perceived 
susceptibility to the disease, nurse-client relationship and compliance with a 
therapeutic regimen among asymptomatic elderly hypertensive clients. 
Unpublished manuscript, New York. 
Lehan, E., & McCarthy, G. (2006). An examination of the intentional and unintentional 
aspects of medication non-adherence in patients diagnosed with hypertension. 
Journal of Clinical Nursing, 698-706. 
Lillard, L. A., Rogowski, J., & Kington, R. (1999). Insurance coverage for prescription 
drugs: Effects on the use and expenditures in the Medicare Population. Medical 
Care, 37(9), 926-936. 
171 
Loeb, S. J., Penrod, J., Falkenstern, S., Gueldner, & Poon, L. W. (2003). Supporting older 
adults living with multiple chronic conditions. Western Journal of Nursing 
Research, 25(1), 8-29. 
Lu, T. C, Tsai, C. L., Lee, C. C, Ko, P. C. I., Yen, Z. S., Yuan, A., Chen, S. C, et al. 
(2006). Preventable deaths in patients admitted from emergency department. 
Emergency Medicine Journal, 23, 452-455. 
Lynch, J. G, Jr., & Zauberman, G (2007). Construing consumer decision making. Journal 
of Consumer Psychology, 17(2), 107-112. 
Lynch, T. (2006). Medication costs as a primary cause of nonadherence in the elderly. The 
Consultant Pharmacist: The Journal of the American Society of Consultant 
Pharmacists, 21(2), 143-146. 
Ma, J., Lee, K., & Stafford, R. S. (2006). Changes in antihypertensive prescribing during 
US outpatient visits for uncomplicated hypertension between 1993 and 2004. 
Hypertension, 48, 846-852. Retrieved January 3, 2008, from http:// 
hyper.ahajournals.org/cgi/content/full/48/5/846. 
MacLaughlin, E. H., Raehl, C. L., Treadway, A. K., Sterling, T. L., Zoller, D. P., & Bond, 
C. A. (2005). Assessing medication adherence in the elderly: Which tools to use in 
clinical practice? Drugs & Aging, 22(3), 231 -255. 
Madden, J. M., Graves, A. J., Zhang, R, Adams, A. S., Briesacher, B. A., Ross-Degnan, 
D., et al. (2008). Cost-related medication nonadherence and spending on basic 
needs following implementation of Medicare Part D. The Journal of the American 
Medical Association, 299(16), 1922-1928. 
Malhotra, S., Karan, R. S., Pahdhi, P., & Jain, S. (2001). Drug related medical 
emergencies in the elderly: Role of adverse drug reactions and non-compliance. 
Postgraduate Medical Journal, 77, 703-707. 
Maloney, S. K., Finn, J., Bloom, D. L., & Andresen, J. (1996). Personal decision-making 
styles and long-term care choices. Health Care Financing Review, 18(1), 141-155. 
Matthews, T. (2004). The Medicare Modernization Act. State Government News, 47(4), 
32-34. 
Mattson, M. (1999). Toward a reconceptualization of communication cues to action in the 
Health Belief Model. Communication Monographs, 66. 
McCloskey, A. (2002). Failing America's seniors: Private health plans provide inadequate 
Rx drug coverage. Medical Benefits, 79(14), 9-10. 
McDonald-Miszczak, L., Maris, P., Fitzgibbon, T., & Ritchie, G. (2004). A pilot study 
examining older adults' beliefs related to medication adherence. Journal of Aging 
and Health, 16(5), 591-614. 
McGuinnes, B., Todd, S., Passmore, P., & Bullock, R. (2006). The effects of blood 
pressure lowering on development of cognitive impairment and dementia in 
patients without apparent prior cerebrovascular disease. Cochrane Database 
System Review, 19(2), CD 004034. 
Meyer, J. (2002). Group offers health solutions: Ensuring access to prescription drugs for 
seniors remains group's priority. State Government News, 45(6), 17-19. 
Middleton, K., Hing, E., & Xu, J. (2007, June 29). Advance data: From vital and health 
statistics. (U. S. Department of Health and Human Services Pub. No. 389). 
Atlanta, GA: Centers for Disease Control and Prevention. 
173 
Minino, A. M., Heron, M. P., & Smith, B. L. (2006, June 28). Deaths: Preliminary data 
for 2004. (Vol. 54.). Atlanta, GA: Centers for Disease Control and Prevention, 
Division of Vital Statistics. 
Mojatabai, R. (2005). Brief reports: Compliance with Mental Health and Other Specialty 
Care Referrals among Medicare/Medicaid Dual Enrollees. Community Mental 
Health Journal, 41(3), 339-344. 
Mojatabai, R., & Olfson, M. (2003). Medication costs, adherence and health outcomes 
among Medicare elders. Health Affairs, 22(4), 220-229. 
Montemayer, K. (2002, November/December). How to help your low-income patients get 
prescription drugs. Family Practice Management, 51-56. 
Moran, J. R., & Simon, K. H. (2005). Income and the use of prescription drugs by the 
elderly: Evidence from the notch cohorts. (NBER Working Paper Series # 11068). 
Available at http://www.nber.org/papers/wl 1068 
Morrow, D., Leirer, V, & Sheikh, J. (1988). Adherence and medication instruction. 
Review and recommendations. Journal of the American Geriatrics Society, 56(12), 
1147-1160. 
National Heart Lung and Blood Institute. (2006). High blood pressure. Available from 
http://www.nhlbi.nih.gov/health/dci/Diseases/Hbp/HBP_WhatIs.html 
National Institutes of Health. (2003a). Your guide to lowering blood pressure. (NIH 
Publication No. 03-5232). pp. 1-20. 
National Institutes of Health. (2003b). Testing interventions to improve adherence to 
pharmacological treatment regimens. Retrieved April 18, 2005, fromhttp:// 
obssr.od.nih.gov/ 
174 
National Statistical Service. (2009). Sample size calculator. Retrieved July 28,2009, from 
http://www.nss.gov.au/nss/home.NSF/pages/Sample+Size+ 
Calculator+Description? Open... 
Neff, M. (2004). Summary of new Medicare legislation. American Family Physician, 
69(3), 469. 
Nex0e, J., Kragstrup, J., & S0gaard, J. (1999). Decision on influenza vaccination among 
elderly: A questionnaire study based on the Health Belief Model and the 
multidimensional locus of control theory. Scandinavian Journal of Primary Health 
Care, 17, 105-110. 
Nickolaus, T, S. N., & Becker, C. (2000, December). Treatment of arterial hypertension 
with diuretics, beta- and calcium channel blockers in old patients. Gerontological 
Geriatrics, 33,427-432. 
Nilsson, P. M. (2005). Reducing the risk of stroke in elderly patients with hypertension: A 
critical review of the efficacy of antihypertensive drugs. Drugs & Aging, 22(5), 
517-524. 
O'Brien, E. (2003, May). Will prescription drug coverage for the low-income elderly pay 
for itself? A review of the literature. Georgetown University Health Policy Institute 
Working Paper prepared for the Henry J. Kaiser Foundation Commission on 
Medicaid and the Uninsured. Retrieved April 14,2005, from www.kff.org 
Okonofua, E., Cutler, N. E., Lackland, D. T., & Egan, B. M. (2005). Ethnic differences in 
older Americans awareness, knowledge and beliefs about hypertension. American 
Journal of Hypertension, 18(1), 972-979. 
175 
Osterberg, L & Blaschke, T. (2005). Adherence to medication. New England Journal of 
Medicine, 353, 487-497. 
Ostrosky, J. D. (2003). Enhancing Medication Adherence in Seniors. Virginia 
Commonwealth University (VCU) School of Pharmacy Power Point presentation, 
1-39. 
Patterns and costs for hypertension treatment. (2000). Clinical Drug Investigation, 20(3), 
181-195. 
Piette, J. D. (2005). Rx affordability: Helping patients cope with medication costs. 
California Healthcare Foundation, i-29. 
Piette, J. D., Heisler, M, & Wagner, T. H. (2004a). Cost-related medication underuse 
among chronically ill adults: The Treatment people forgo, how often, and who is at 
risk. American Journal of Public Health, 94(10), 1782-1787. 
Piette, J. D., Heisler, M., & Wagner, T. H. (2004b). Problems paying out-of-pocket 
medication costs among older adults with diabetes. Diabetes Care, 27(2), 384-391. 
Piette, J. D., Wagner, T. H., Potter, M. V., & Schillinger, D. (2004). Health insurance 
status, cost-related medication underuse, and outcomes among diabetes patients in 
three systems of care. Medical Care, 42(May), 102-109. 
Pinto, E. (2007). Blood pressure and aging. Postgraduate Medical Journal, 83(916), 109-
114. 
Poisal, J. A., & Chulis, G S. (2000). Medicare elders and drug coverage. Health Affairs, 
19,2. 
176 
Prendergast, H. M., Marquez, Jr., A., Schilichting, A., & Figuroa-Pal, E. (2007). 
Emergency department utilization: Characterization and comparison of an urban 
elderly minority and non-minority population. [Electronic version]. Internet 
Journal of Emergency Medicine, 3,2. 
Raehl, C. L., Bond, C. A., Woods, T. J., Petty, R. A., & Sleeper, R. B. (2006, May). 
Screening tests for intended medication adherence among the elderly. The Annals 
of Pharmacotherapy, 40(5), 888-893. 
RAND. (1999). Prescription drugs and the elderly: Policy implications of Medicare 
coverage. Research Brief: Center for the Study of Aging. Retrieved July 10,2006, 
from http://www.rand.org/publications/RB/RB5028/rb5028 .html 
Reed, M. (2005, May). An update on American's access to prescription drugs. Center for 
Studying Health System Change. (Issue brief #95.) pp. 1-4. 
Reed, M., Hargraves, J. L., & Cassil, A. (2003). Unequal access: African-American 
Medicare elders and the prescription drug gap. Center for Studying Health System 
Change, (Pub. No. 64.) pp. 1-4. 
Reinberg, S. (2008). Hypertension: A health challenge for women. Retrieved March 2, 
2008, from http://www.medicinenet.com/script/main/ 
art.asp?articlekey=87260&pf=3&page= 
Renz, A., Ide, M., Newton, T., Robinson, P., & Smith, D. (2008). Psychological 
interventions to improve adherence to oral hygiene instructions in adults with 
periodontal diseases. Wiley. 
177 
Resnick, B., Wehren, L., & Orwig, D. (2003). Reliability and validity of the self-efficacy 
and outcome expectations for Osteoporosis Medication Adherence Scales. 
Orthopaedic Nursing, 22(2), 139-147. 
Robeznicks, A. (2004). Cost keeps many from taking their meds: Underuse of 
prescriptions is seen as an obstacle to quality healthcare. Retrieved February 13, 
2005, from amednews.com 
Rosenblatt, R. A., Wright, G. E., Baldwin, L. M., Chan, L., Clitherow, P., Chen, F. M., et 
al. (2000, January). The effect of the doctor-patient relationship on emergency 
department use among the elderly. American Journal of Public Health, 90(1), 97-
102 
Rosendorff, C, Black, H. R., Cannon, C. P., Gersch, B. J., Gore, J., Izzo, J. L., Jr., et al. 
(2007, May 14). Treatment of hypertension in the prevention and management of 
ischemic heart disease: A scientific statements from the American Heart Association 
Council for High Blood Pressure Research and the Councils on Clinical Cardiology 
and Epidemiology and Prevention. Circulation, 115,2761-2788. Retrieved March 
2,2008, from http://circ.ahajournals.Org/cgi/content/full/l 15/21/2761 
Rosenstock, I. M., Strecher, V. J., & Becker, M. H. (1988). Social learning theory and 
Health Belief Model. Health Education Quarterly, 75(2), 175-183. 
Ryan, C. (1991). Hypertension in the elderly patient. American Heart Journal, 
722(October), 1225-1227. 
Ryan, C. J., & Zerwic, J. J. (2003). Perceptions of symptoms of myocardial infarction 
related to health care seeking behaviors in the elderly. Journal of Cardiovascular 
Nursing, 75(3), 184-196. 
178 
Sarver, J. H., Sudano, J., & Baker, D. W. (2000). Financial barriers to prescription 
medication use among the elderly. [Abstract]. Academy Health Services Research 
Health Policy Meeting 2000. p. 17. 
Senior Services of Southeastern Virginia. (2006). SSSEVA 's Access & Acquisition of 
Prescription Drugs Survey. 
Schedlbauer, A., Schroeder, K., Peters, T., & Fishey, T. (2008). Interventions to improve 
adherence to lipid lowering medication. Wiley 
Schlomann, P., & Schmitke, J. (2007). Lay beliefs about hypertension: An interpretation 
synthesis of the qualitative research. Journal of the American Academy of Nurse 
Practitioners, 19(1), 358-367. 
Schroeder, K., Fishey, T., & Ebrahim, S. (2008). Interventions for improving adherence to 
treatment in patients with high blood pressure in ambulatory settings. Wiley. 
Schwartz, G L., & Sheps, S. G. (2006). Hypertension treatment. ACP Medicine Online. 
Retrieved December 23,2007, from http://www.medscape.com/ 
viewarticle/535324?rss 
Sherer, R. (2003). The debate over medications: What's best for your patients? Geriatric 
Times, p. 4. 
Sigma Six. (2007). Sample size calculations. Retrieved September 10, 2007, from 
www.iSixSigma.com 
Sloane, T. (2004). Consumer-driven to nowhere; Study throws cold water on recent efforts 
to beat health cost inflation. Modern Healthcare, 34(49), 21. 
Soumerai, S. B., Pierre-Jacques, M., Zhang, F., Ross-Degnan, D., Adams, A. S., Gurwitz, 
J., et al. (2006). Cost-related medication nonadherence among elderly and disabled 
179 
Medicare elders: A national survey 1 year before the Medicare drug benefit. 
Archives of Internal Medicine, 766(17), 1829-1835. 
Small, R. E., Freeman-Arnold, S. B., Goode, J. V., & Pyles, M. A. (1997). Evaluation of 
the total cost of treating elderly hypertensive patients with ACE inhibitors: A 
comparison of older and newer agents. Pharmacotherapy, 77(5), 1011-1016. 
Spence, M., Hui, R., & Chan, J. (2006). Cost reduction strategies used by elderly patients 
with chronic obstructive pulmonary disease to cope with a generic-only pharmacy 
benefit. Journal of Managed Care Pharmacy, 72(5), 377-382. 
Spiers, M. V., & Kutzik, D. M. (1995). Self-reported memory of medication use by the 
elderly. American Journal of Health-System Pharmacy, 52(9), 985-990. 
Stewart, R. B., & Caranasos, G. J. (1989, November). Medication compliance in elderly. 
The Medical Clinics of North America, 73(6), 1551-1563. 
Stuart, B. (2004). Navigating the new Medicare drug benefit. The American Journal of 
Geriatric Pharmacotherapy, 2(1), 75-80. 
Stuart, B., & Briesacher, B. (2002). Medication decisions - Right and wrong. Medical 
Care Research and Review, 99(2), 123-145. 
Stuart, B., Simoni-Wastila, L., & Chauncey, D. (2005). Assessing the impact of the 
coverage gaps in the Medicare Part D drug benefit. Health Affairs, 24(Jan.-June), 
167-179. 
Swartz, K. (2003). Medicare modernization and distributional implications. Inquiry, 40(4), 
315-317. 
Terrera, G. M., Matthews, F., & Brayne, C. (2008). A comparison of parametric models 
for the shape of cognitive change in the older populations. BMC Neurology, 8, 16. 
Retrieved July 27,2008, from http://www.biomedcentral.eom/147-2377/8/16 
Thull, J. (2007). The decision to buy. Agency Sales, 37(4), 52-54. 
University of Maryland. (2003). Attitudes, beliefs, and behaviors: An examination of 
health disparities in hypertension and diabetes among racial and ethnic 
minorities in Baltimore, Maryland, pp. 1-27. 
U. S. Census Bureau. (2005). 65+ in the United States: 2005. Retrieved July 10,2006, 
from www.uscensus.gov 
U. S. Census Bureau. (2008, July 25). State and County QuickFacts. USA QuickFacts 
from the U. S. Census Bureau Retrieved September 14, 2008, from http:// 
quickfacts .census. gov/ 
U. S. Department of Health and Human Services. (2000). Healthy People 2010: 
Understanding and Improving Health and Objectives for Improving Health 
(Volume 2). Washington, DC: U.S. Government Printing Office. 
U. S. Department of Health and Human Services. (2003, May). Your Guide to Lowering 
Blood Pressure. NIH publication 03-5232. Washington, DC: U.S. Government 
Printing Office. 
U. S. Department of Health and Human Services. (2004). Older Americans: Objectives 
for Improving Health. Washington, DC: U.S. Government Printing Office. 
U. S. Government Accounting Office. (2005). Prescription drugs: Price trends for 
frequently used brand and generic drugs from 2000 to 2004. Report to 
Congressional Requesters, GAO-05-779, i-25. 
181 
U. S. Government Accounting Office. (2006) Medicare: Communications to elders on the 
prescription drug benefit could be improved. Report to Congressional Requesters, 
GAO-06-654, 1-88. 
U. S. Government Accounting Office. (2007). Medicare Part D Low-Income Subsidy. 
Report to the Committee on Finance, U.S. Senate, GAO-07-555, 1-50 
Val, J. A., Amoros, B. G, Martinez, V. P., Ferre, M. L., & Leon, S. M. (1992). Descriptive 
study of patient compliance in pharmacologic antihypertensive treatment and 
validation of the Morisky and Green test. Aten Priaeria, 72(8), 491. 
van Uffelen, J. G., Chin, A., Paw, M. J., Klein, M., vanMechelen, W., & Hopman-Rock, M. 
(2007). Detection of memory impairment in the general population: Screening by 
questionnaire and telephone compared to subsequent face-to-face assessment. 
International Journal of Geriatric Psychiatry, 22(3), 203-210. 
Vermeire, E., Wens, J., Royen, P. V., Biot, Y., Hearnshaw, H., & Lindenmeyer, A. (2008). 
Interventions for improving adherence to treatment recommendations for people 
with type 2 diabetes mellitus. Wiley. 
Vernon, S. W. (1999). Risk perception and risk communication for cancer screening 
behaviors: A review. Journal of the National Cancer Institute Monographs, 25, 
101-119. 
Vik, S. A., Hogan, D. B., Patten, S. B., Johnson, J. A., Romonko-Slack, L., & Maxwell, 
C. J. (2006). Medication nonadherence and subsequent risk of hospitalization and 
mortality among older adults. Drugs Aging, 23(4), 345-356. 
182 
Vik, S. A., Maxwell, C. J., Hogan, D. B., Patten, S. B., Johnson, J. A., & Romonko-Slack, 
L. (2005). Assessing medication adherence among older persons in community 
settings. Canadian Journal of Clinical Pharmacology, 12(1), el52-el64. 
Virginia Department for the Aging. (2005). Medicare-Approved drug discount cards: 
Frequently asked questions and answers for Virginians. Retrieved December 12, 
2005, from http://www.vda.virginia.gov/HAPFAQspercent20_VA_.pdf 
Virginia Department for the Aging. (2006). Demographic Trends. (2006). Retrieved 
January 15,2007, from http://www.vda.virginia.gov/demographic.asp 
Virgini Department of Health. (2008). Health statistics. Retrieved November 20,2009, 
from http://www.vdh.state.ua.us/HealthStats/ 
Voelker, R. (2004). When cost is an adverse drug effect, patients cut corners and risk 
health. Journal of the American Medical Association, 292(18), 2201-2202. 
Wang, Y. R., Alexander, G C, & Stafford, R. S. (2007). Outpatient hypertension 
treatment, treatment intensification, and control in Western Europe and the United 
States, Archives of internal medicine, 167,141-147. Retrieved April 23, 2008, 
from www.archintemmed.com. 
Weeks, W. (2004). Preparing for MMA. Home Care Magazine, 27(11). 
Weschler, J. (2004a). Demand grows for more 'real world' drug-cost analysis: Dr. 
McClellan asks for more real world evidence to determine best therapies. Managed 
Healthcare Executive, 14(5), 13-14. 
Weschler, J. (2004b). Drug reimportation still focus of debate: McClellan takes over at 
CMS; tackles Medicare reforms, drug benefits. Dermatology Times, 25(5), 115. 
183 
Weschler, J. (2004c). New leader to tackle Medicare reforms, drug benefit: McClellan 
takes over at CMS amidst escalating battle over drug imports. Managed 
Healthcare Executive, 14(4), 14-16. 
White, J. (2002). Hypertension: Nutrition management for older adults. 
Wilensky, G R. (2004). Medicare bill sets precedent for future funding: almost all seniors 
are better off under the Medicare Prescription Drug, Improvement, and 
Modernization Act of 2003, signed into law by President Bush on December 8, 
2003. Healthcare Financial Management, 58(2), 30-31. 
Williams, C. M. (2002). Using medications appropriately in older adults. American Family 
Physician, 66(10), 1917-1924. 
Wilson, B., Schoen, C, & Neuman, P. (2007). Physician-patient communication about 
prescription medication nonadherence: A50-state study of American seniors. 
Journal of General Internal Medicine, 22(1), 6-12. 
Winter, J., Balza, R., Caro, R, Heiss, R, Jun, B., Matzkin, R., et al. (2006, May 16). 
Medicare prescription drug coverage: consumer information and preferences. 
Proceedings of the National Academy of Sciences of the United States, 103(20), 
7929-7934. 
Wofford, J. L., Schwartz, E., Timerding, B. L., Folmar, S., Ellis, S. D., & Messick, C. H. 
(1996). Emergency department utilization by the elderly: Analysis of the National 
Hospital Ambulatory Medical Care Survey. Academic Emergency Medicine, 3, 
694-699. 
World Health Organization. (2002). USA: problems of access to drugs. Essential Drugs 
Monitor, 31, p. 27. 
184 
Wuensch, K. L. (2009, June 8). SPSS Lessons - Factor Analysis. Retrieved August 28, 
2009, from http://core.ecu.edu/psych7wenschuhk/SPSS/ SPSS-Lessons-htm. 
Xu, K. T., Smith, S. R., & Borders, T. F. (2003). Access to prescription drugs among 
noninstitutionalized elderly people in west Texas. American Journal of Health 
System Pharmacists, 60{April), 675-682. 
Yaari, R., Fischer, A. S., Garnat, A. C , Bagwell, V. P., & Thai, L. J. (2006). Utility of the 
telephone interview for cognitive status for enrollment in clinical trials. Alzheimer's 
& Dementia, 2(2), A3. 
Yagoda, L. (2004). Medication adherence and older adults. National Association of Social 
Workers Practice Update, 1-4 
SUMMARY OF APPENDICES 
APPENDIX I. 
APPENDIX II. 
APPENDIX III. 
APPENDIX IV 
APPENDIX V 
Definition of Terms 
Sample Size Calculations 
Survey Instruments 
A. Seniors' Early Experiences with Their New Drug Plan -
June 2006 
B. The Short Portable Mental Status Questionnaire (SPMSQ) 
C. Questions to Identify Patients Experiencing Medication 
Cost Problems 
D. Medication Adherence - Morisky Scale 
E. Senior Services of Southeastern Virginia (SSSEVA): 
Access & Acquisition of Prescription Drugs Survey 
F. Integrated Administered Survey 
Senior Services of Southeastern Virginia Consent Letter 
Sample Consent Letter 
186 
APPENDIX I: Definition of Terms 
Several key terms are defined as follows: 
1. Medicare Elders: An individual over 65 years of age eligible for the Medicare 
program (Centers for Medicare & Medicaid Services, 2005). 
2. The Medicare Modernization Act of 2003 (MMA): A long awaited benefit 
added to Original Medicare to extend benefits for prescription drug coverage. 
The intention of MMA is to reduce overall annual prescription drug costs for 
Medicare elders (Centers for Medicare & Medicaid Services, 2005). Along 
with the prescription drug discount plan there are provisions for Health 
Savings Accounts (HSAs) and other health care cost saving initiatives 
(Centers for Medicare & Medicaid Services, 2005). 
3. Medicare Part D: As a result of the enactment of the Medicare Modernization 
Act of 2003, the prescription drug discount program designed to provide 
coverage to Medicare elders previously lacking any other prescription 
coverage (Centers for Medicare & Medicaid Services, 2005). 
4. Extra Help: Included in the Medicare Modernization Act of 2003, the 
provision for a Low-Income Subsidy (LIS) which is the Extra Help that low-
income, low-asset Medicare elders require to help with premiums for Part D 
plans and to minimize co-pays for prescription drug acquisitions (Centers for 
Medicare & Medicaid Services, 2005). 
5. Formularies: Prescription Drugs that are included in each plans negotiated 
discounted pricing schedule which includes name brand and generic offerings 
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(Hoadley, Hargrave, Merrell, Cubanski & Neuman, 2006; Centers for 
Medicare & Medicaid Services, 2005). 
6. Coverage Gap ("Donut Hole"): Period of time where Medicare beneficiary is 
responsible for 100 percent of out-of-pocket prescription drug costs until 
catastrophic coverage begins (Centers for Medicare & Medicaid Services, 
2006). 
7. Hypertension: Blood pressure levels above 140/90 are required to be 
clinically diagnosed with hypertension (aka high blood pressure) (American 
Heart Association, 2007). The chronic illness is called the "silent killer" as 
often times there are no symptoms to alert individuals to potentially life 
threatening conditions (American Heart Association, 2007a). 
8. Hypertension Treatment: 
a. ACE Inhibitors: Angiotensin converting enzyme (ACE) inhibitors are used 
to help protect the kidneys from hypertension and diabetes by improving 
blood flow through dilation of blood vessels (American Heart Association, 
2007a; Small, Freeman-Arnold et al., 1997). 
b. Angiostein II Receptor Blockers (ARBs) are often prescribed when ACE 
inhibitors are not tolerated and function in lowering chemicals that narrow the 
blood vessels to allow blood to flow more freely (Small, Freeman-Arnold et 
al., 1997). 
c. Diuretics are often prescribed to help eliminate unnecessary sodium and 
water through urination. Reducing excess fluid and salt allow the heart to 
pump more easily (American Heart Association, 2007a). 
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d. Beta-Blockers are used to help the heart work more efficiently by blocking 
the effects of the sympathetic nervous system (American Heart Association, 
2007a). 
e. Calcium Channel Blockers are utilized to slow calcium movement into 
heart cells and blood vessel walls to improve heart functioning through 
widening of blood vessels (American Heart Association, 2007a). 
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APPENDIX II: Sample Size Calculations 
Source: Six Sigma, 2007 
Determining sample size is a very important issue because samples that are too large may 
waste time, resources and money, while samples that are too small may lead to inaccurate 
results. In many cases, we can easily determine the minimum sample size needed to 
estimate a process parameter, such as the population mean J2. 
When sample data is collected and the sample mean x is calculated, that sample mean is 
typically different from the population mean/*. This difference between the sample and 
population means can be thought of as an error. The margin of error E is the maximum 
difference between the observed sample mean * and the true value of the population 
mean/*: 
"™ 4n 
where: 
A is known as the critical value, the positive z value that is at the vertical boundary for 
the area of / 2 in the right tail of the standard normal distribution, 
o" is the population standard deviation. 
«is the sample size. 
2=° H 
Rearranging this formula, we can solve for the sample size necessary to produce results 
accurate to a specified confidence and margin of error. 
V7 
This formula can be used when you know o" and want to determine the sample size 
necessary to establish, with a confidence of 1 - a , the mean value / ' to within ± E . You 
can still use this formula if you don't know your population standard deviation o"and you 
have a small sample size. Although it's unlikely that you know o" when the population 
mean is not known, you may be able to determine °" from a similar process or from a 
pilot test/simulation. 
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Appendix III: Survey Instruments (A - E) 
A. Seniors' Early Experiences with Their New Drug Plan - June 2006 
Source: The Henry J. Kaiser Family Foundation 
Methodology 
Seniors' Early Experiences with Their Medicare Drug Plans - the 13th in a series 
that comprises three large surveys and ten smaller tracking polls - is based on 
interviews with 1,585 adults ages 65 and older. The survey was designed and 
analyzed by researchers at the Kaiser Family Foundation. 
A nationally representative random sample of 1,217 adults ages 18 and 
older, including 285 participants ages 65 and older, was interviewed about a few 
topics in the news as part of the ongoing Kaiser Health Poll Report survey 
(referred to as the "main survey"), and asked the Medicare questions that follow. 
In addition, a nationally representative random sample of 1,300 adults ages 65 and 
older was asked the Medicare questions only, for a total of 1,585 seniors. 
Individuals were contacted by administered by Princeton Survey Research 
Associates International between June 8 and June 18,2006. Interviews were 
conducted in English and Spanish. 
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Throughout these findings, we report on several different groups of seniors: 
• All seniors (unweighted n=l,585) 
• Seniors enrolled in Medicare drug plans, including those who reported being 
in stand-alone prescription drug plans, Medicare and Medicaid enrollees 
(i.e. dual eligibles), and Medicare HMO enrollees (40 percent of all 
seniors, unweighted n=623). 
• Seniors enrolled in stand-alone Medicare drug plans - same as above, but 
excluding those in Medicare HMOs (32 percent of all seniors, unweighted 
n=509) 
• Seniors enrolled in stand-alone Medicare drug plans that they chose on their 
own (as opposed to being assigned to a plan) (25 percent of all seniors, 
unweighted n=392) 
• Seniors who have used their Medicare drug plans (28 percent of all seniors, 
unweighted n=443) 
This survey is representative of seniors in the U.S. living outside institutions, 
but not of all Medicare elders because the survey did not include seniors living in 
institutional settings, such as nursing homes, nor younger, pre-65 Medicare elders 
with permanent disabilities. 
The margin of sampling error for the survey is plus or minus 3 percentage points 
for all seniors, and plus or minus 4 points for seniors enrolled in Medicare drug 
plans. For results based on smaller subsets of respondents the margin of sampling 
error is higher. Note that sampling error is only one of many potential sources of 
error in this or any other public opinion poll. 
Values less than 0.5percent are indicated by an asterisk (*). "VOL" indicates that 
a response was volunteered by respondent, not an explicitly offered choice. 
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1. For each item I name, please tell me how important it will be in your vote for 
Congress this year (2006). Will it be one of the single most important issues, very 
important, somewhat important or less important than that? (First/Next,) 
(READ AND RANDOMIZE)? 
a. Situation in Iraq 
b. The US (United 
States) campaign 
against Terrorism 
c. Prescription 
drug benefit for 
the elderly 
d. The economy 
e. Healthcare 
overall 
f. Immigration 
Issues 
g. Local issues 
where you live 
h. Corruption in 
Washington 
i. Gas Prices 
j . The overall 
performance of the 
President 
k. The overall 
performance of 
Congress 
1. The overall 
performance of 
your 
Congressional 
Representative 
Single 
Most 
Important 
Very 
Important 
Somewhat 
Important 
Less 
Important 
DK/ 
Refused 
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As you may know, a new prescription drug benefit is now available for people on 
Medicare. Given what you know about it, in general, do you have a favorable or 
unfavorable view of the new Medicare drug benefit? 
Favorable Unfavorable Neither/Neutral DK/Refused 
Is your impression of the new Medicare drug benefit based mainly on... (READ 
AND RANDOMIZE 1-3)? 
Based on those with a favorable or unfavorable impression of Medicare 
drug benefit 
Your own experience 
What you've seen and heard on television, radio, and in 
newspapers 
What you've learned from friends and family 
Some other source 
(DO NOT READ) Don't know/Refused 
Do you have ANY health insurance plan or program that helps you pay for 
prescription drugs, or not? 
Yes No Don't Know Refused 
I'm going to read you some statements about your health insurance and how your 
health care bills are paid. For each one, please tell me whether you think it 
describes your situation or not. (First/Next,)... (READ IN ORDER) (Does this 
describe your situation, or not?) 
Based on seniors with any health insurance plan or unsure (n= 1,203) 
a. You have Medicare and have also signed up or been 
enrolled in a separate Medicare drug plan, sometimes 
called "Part D" 
b. You have Medicare and Medicaid or 
the program that provides health insurance and long 
term care to certain low-income seniors 
c. You are a member of a Medicare HMO 
d. You have Medicare and health care from the 
Veteran's Administration or VA 
e. You have Medicare and a plan from a current or 
former employer 
Item f based on those who said no/don't know to all 
other items (n=166) 
f. You have something else I haven't mentioned 
Yes No 
DK/ 
Refused 
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6. You said yes to more than one of the above. Please tell me which one of the 
following BEST describes your health coverage? 
a. Medicare and a plan from an employer or union 
b. Medicare plus a separate Medicare drug plan, 
sometimes called "Part D" 
c. A Medicare HMO 
d. Medicare and Medicaid or (State Medicaid 
program name) 
e. Medicare and VA 
f. Something else 
Yes No 
DK/ 
Refused 
7. Have you also signed up or been enrolled in a separate Medicare prescription drug 
plan, sometimes called "Part D", or not? 
Yes No Don't Know Refused 
8. To the best of your knowledge, if seniors wait until next year or later to enroll in a 
Medicare drug plan will they have to pay higher premiums, sometimes called a 
"premium penalty", or not? 
Yes No Don't Know Refused 
9. To the best of your knowledge, if seniors wait until next year or later to enroll in a 
Medicare drug plan will they have to pay higher premiums, sometimes called a 
"premium penalty", or not? 
Yes No Don't Know Refused 
10. Did you apply to Social Security for the program that gives low-income seniors 
extra help with prescription drug costs, or not? 
Yes No Don't Know Refused 
a. Was your application approved, or not? 
Approved Disapproved Don't Know Refused 
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11. Would you say it was very easy, somewhat easy, somewhat difficult, or very 
difficult to choose a Medicare drug plan, OR were you just put in a plan and 
didn't make a choice for yourself? 
Very 
Easy 
Somewhat 
Easy 
Somewhat 
Difficult 
Very 
Difficult 
Put in a Plan 
Didn't Make a 
Choice 
Refused 
12. In choosing your Medicare drug plan, please tell me how important each of the 
following was to your decision. (First,) how about... ? (READ AND 
RANDOMIZE). READ FOR FIRST ITEM, REPEAT AS NECESSARY: Was 
this very important, somewhat important, not too important or not at all important 
(in choosing your Medicare drug plan)? 
a. The reputation 
of the company 
offering the plan 
b. The amount 
the plan charges in 
monthly premiums 
c. The specific 
drugs covered by 
the plan 
d. The amount 
the plan charges 
for each 
prescription 
e. A 
recommendation 
from someone you 
trust 
Single 
Most 
Important 
Very 
Important 
Not too 
Important 
Not at all 
Important 
DK/ 
Refused 
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13. Which one was the MOST important to your decision to choose your Medicare 
drug plan? (IF NECESSARY, READ ITEMS RATED "VERY IMPORTANT" 
INQ12) 
a. The amount for each prescription 
b. A recommendation from someone you 
trust 
c. The reputation of the company 
d. The amount of monthly premiums 
e. The specific drugs covered 
f. All are important 
g. None are important 
h. Don't Know/Refused 
14. How satisfied are you with the (IF Q6=4: drug coverage under your plan/IF 
(Q6=l,3 OR Q7=l): Medicare drug plan you are enrolled in)? Would you say you 
are very satisfied, somewhat satisfied, not too satisfied, not at all satisfied? 
Very 
Satisfied 
Somewhat 
Satisfied 
Not too 
Satisfied 
Not at all 
Satisfied 
Don't 
Know 
Refused 
15. All in all, have your experiences using your (IF Q6=4: plan/IF (Q6=l, 3 OR 
Q7=l): new Medicare drug plan) been very positive, somewhat positive, 
somewhat negative, or very negative? 
Very 
Positive 
Somewhat 
Positive 
Somewhat 
Negative 
Very 
Negative 
Don't 
Know 
Refused 
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16. Compared with how you got your prescriptions before, please tell me whether 
your new Medicare drug plan is better, worse, or about the same in terms of each 
of the following. (READ AND RANDOMIZE). (READ FOR EACH ITEM) 
Compared with how you got your prescriptions before, is your new drug plan 
better, worse, or about the same in terms of (INSERT)... 
a. How much you pay for 
prescriptions 
b. The cost of your monthly 
premiums 
c. Getting the medicines you 
need 
d. Getting answers to your 
questions 
Better Worse Same Don't 
Know 
Refused 
17. Overall, do you feel you made a good choice in selecting your Medicare drug 
plan, or do you think you would have been better off with a different plan? 
Based on seniors enrolled in stand-alone Medicare drug plans that 
they chose on their own 
Made a Good 
Choice 
Better off with a different 
plan 
Don't Know Refused 
18. If you had to choose today, would you pick the same plan or would you choose a 
different drug plan? 
Based on seniors enrolled in stand-alone Medicare drug plan 
Would pick the 
same plan 
Would choose a different 
plan 
Don't 
Know 
Refused 
19. (IF Q6=4: Since January of this year,) Have you tried to fill any prescriptions 
under your (IF Q6=4: plan/IF (Q6=l, 3 OR Q7=l): new Medicare drug plan yet), 
or not? 
Based on seniors enrolled in Medicare drug plans 
a. 
Yes No Don't Know Refused 
20. Compared to what you paid for prescriptions last year, are you now saving 
money, paying more or paying about the same overall for your prescriptions? 
Saving money Paying more Paying about the same Refused 
21. Would you say that you are saving a lot of money, or just a little? 
Saving a lot of 
money 
Saving Just a 
little 
Don't Know Refused 
22. Would you say that you are paying a lot more money, or just a little more? 
Paying a lot more 
money 
Paying just a 
little more 
Don't Know Refused 
23. Have these additional costs been a major problem, a minor problem or not a 
problem for you? Based on seniors who are paying more 
Major 
Problem 
Minor 
Problem 
Not a Problem Don't Know Refused 
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24. Please tell me whether or not you've had any of the following experiences related 
to getting your prescription medicines since (IF Q6=4: January 2006/IF (Q6=l,3 
OR Q7=l): joining your new Medicare drug plan). Have you... or not? (READ 
AND RANDOMIZE) 
a. Had difficulties getting enrollment card 
b. Left the pharmacy without your 
prescription because one of your drugs 
wasn't covered by y\our plan 
c. Left the pharmacy without your 
prescription because you could not afford 
it 
d. Had to switch drugs because one of 
your drugs that you were taking wasn't 
covered by your plan 
e. Had to switch from a brand-name to a 
generic drug 
f. Had to deal with a billing mistake for a 
prescription or a premium 
g. Had to pay costs you hadn't expected -
either for a prescription or a premium 
Have Have 
Not 
Don't 
Know 
Refused 
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25. Was this a major problem, minor problem or not a problem for you? Based on 
seniors who have used their Medicare drug plans (YES - Had an experience) 
a. Had 
difficulties 
getting 
enrollment card 
b. Left the 
pharmacy 
without your 
prescription 
because one of 
your drugs 
wasn't covered 
by y\our plan 
c. Left the 
pharmacy 
without your 
prescription 
because you 
could not afford 
it 
d. Had to switch 
drugs because 
one of your drugs 
that you were 
taking wasn't 
covered by your 
plan 
e. Had to switch 
from a brand-
name to a generic 
drug 
f. Had to deal 
with a billing 
mistake for a 
prescription or a 
premium 
g. Had to pay 
costs you hadn't 
expected - either 
for a prescription 
or a premium 
Major 
Problem 
Minor 
Problem 
Not a 
Problem 
No - Did Not 
Have An 
Experience 
Don't 
Know/ 
Refused 
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26. Thinking about the (IF 2+ PROBLEMS IN Q25A-G: problems/IF ONE 
PROBLEM IN Q25A-G: problem) you had related to getting your prescriptions, 
would you say (IF 2+ PROBLEMS IN Q25A-G: they have/IF ONE PROBLEM 
IN Q25A-G: it has) been resolved to your satisfaction, or not? 
Based on seniors who have used their Medicare drug plans 
Experienced one or more problems related to filling 
prescriptions 
Problems resolved to satisfaction 
Problems NOT resolved 
Had one or more experiences, but not a problem 
Didn't have any of the listed experiences 
Don't know/Refused 
27. Earlier you said you changed a medication since (IF Q6=4: January 2006/IF 
(Q6=l, 3 OR Q7=l): joining your new Medicare drug plan). Do you think the 
new drug works better, just as well or not as well as the old one? 
Works better 
Just as well 
Not as well as the old one 
Don't know/Refused 
28. Since (IF Q6=4: January 2006/IF (Q6=l,3 OR Q7=l): joining your new drug 
plan), have you NOT filled a prescription, skipped doses, or taken less than the 
prescribed dose of a medication because of the cost, or not? 
Based on seniors enrolled in Medicare drug plans 
Yes 
No 
Don't know/Refused 
29. To the best of your knowledge, if you are dissatisfied with your (IF Q6=4: plan/IF 
(Q6=l,3 OR Q7=l): new Medicare drug plan) can you change to a different plan 
whenever you want, or do you have to wait for a specific period? 
Based on seniors enrolled in Medicare drug plans 
Can change to different plan 
Have to wait 
Don't know/Refused 
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30. Some plans have what's called a "coverage gap" or "donut hole" - a point where 
the plan stops paying for prescriptions and seniors are required to pay the full cost 
of their medicines for a while. Does your (IF Q6=4: plan/IF (Q6=l,3 OR Q7=l): 
Medicare drug plan) have such a coverage gap, or not? 
Based on seniors enrolled in Medicare drug plans 
Yes, coverage gap 
No, no coverage gap 
Don't know/Refused 
31. Since (IF Q6=4: January 2006/IF (Q6=l,3 OR Q7=l): joining your new Medicare 
drug plan), have you asked your DOCTOR for help getting your plan to pay for 
the drugs you need, or not? 
Based on seniors enrolled in Medicare drug plans 
Yes 
No 
Don't know/Refused 
32. How much help have you received from your DOCTOR in getting your plan to 
pay for the drugs you need? Would you say you received (READ) 
Based on seniors enrolled in Medicare drug plans who asked their 
doctor for help 
A little help 
Some help 
Don't know/Refused 
33. Since (IF Q6=4: January 2006/IF (Q6=l,3 OR Q7=l): joining your new Medicare 
drug plan), have you asked your PHARMACIST for help getting your plan to pay 
for the drugs you need, or not? 
Based on seniors enrolled in Medicare drug plans 
Yes 
No 
Don't know/Refused 
34. How much help have you received from your PHARMACIST in getting your plan 
to pay for the drugs you need? Would you say you received (READ) 
Based on seniors enrolled in Medicare drug plans who asked their 
pharmacist for help 
Yes 
No 
Don't know/Refused 
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35. Overall, what message would you send to policymakers in Washington? Would 
you say the new Medicare drug benefit (READ) 
Based on seniors enrolled in Medicare drug plans 
A 
B 
C 
D 
Is working well and no real changes are needed 
Could be improved with some minor changes OR 
Is not working and needs major changes 
Don't know/Refused 
36. Thinking back to last year, in 2005, did you have any insurance plan or program 
that helped you pay for prescription drugs, or not? 
Yes 
No 
Don't know/Refused 
37. Do you currently take any prescription medicine on a daily basis, or not? 
Yes 
No 
Don't know/Refused 
38. How many different prescription drugs do you take? 
39. In general, would you say your health is excellent, very good, good, only fair, or 
poor? 
Excellent 
Very good 
Good 
Only fair 
Poor 
Don't know/Refused 
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DEMOGRAPHICS: 
(READ) Finally, I have just a few questions we will use to describe the people who 
took part in our survey... 
Dl. RECORD RESPONDENT'S SEX 
Male 
Female 
D2. What is your age? (RECORD EXACT AGE AS A TWO-DIGIT CODE) 
D3. In politics today, do you consider yourself a Republican, Democrat, or 
Independent? 
Republican 
Democrat 
Independent 
(VOL.) No preference/Not interested in politics 
(VOL.) Other party 
Don't know 
Refused 
D4. These days people are so busy they can't find time to register to vote, or move 
around so often they don't get a chance to re-register.. .Are you NOW registered 
to vote in your precinct or election district, or haven't your been able to register so 
far? 
Yes, registered 
No, not registered 
Don't know/Refused 
D5. What is the LAST grade or class that you COMPLETED in school? (DO NOT 
READ) 
None, or grade 1-8 
High school incomplete (grades 9-11) 
High school graduate (grade 12 or GED certificate) 
Technical, trade or vocational school AFTER high school 
Some college, no four-year degree (includes associate degree) 
College graduate (B.S., B.A., or other four-year degree) 
Post-graduate or professional schooling after college (e.g., 
toward a Master's degree or PhD; law or medical school) 
Refused 
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D6. Are you currently married, living with a partner, widowed, divorced, separated, or 
have you never been married? 
Married 
Living as married 
Divorced 
Separated 
Widowed 
Never been married 
Don't know/ Refused 
D7. Last year — that is, in 2005 ~ what was your total family income from all sources, 
before taxes? Just stop me when I get to the right category. (READ) 
$10,000 or less 
$10,001 to $15,000 
$15,001 to $20,000 
$20,001 to $30,000 
$30,001 to $50,000 
$50,001 to $75,000 
$75,001 to $100,000 
$100,001 to $200,000 
More than $200,000 
(DO NOT READ) Don't know 
(DO NOT READ) Refused 
D8. Are you, yourself, of Hispanic or Latino background, such as Mexican, Puerto 
Rican, Cuban, or some other Spanish background? 
D9. What is your race? Are you white, black, Asian or some other race? (IF 
RESPONDENT SAYS HISPANIC ASK: Do you consider yourself a white 
Hispanic or a black Hispanic? CODE AS WHITE (1) OR BLACK (2). IF 
RESPONDENTS REFUSED TO PICK WHITE OR BLACK HISPANIC, 
RECORD HISPANIC AS "OTHER," CODE 4) 
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B. The Short Portable Mental Status Questionnaire (SPMSQ) 
1. What are the date, month, and year? 
2. What is the day of the week? 
3. What is the name of this place? 
4. What is your phone number? 
5. How old are you? 
6. When were you born? 
7. Who is the current president? 
8. Who was the president before him? 
9. What was your mother's maiden name? 
10. Can you count backward from 20 by 3's? 
SCORING:* 
0-2 errors: normal mental functioning 
3-4 errors: mild cognitive impairment 
5-7 errors: moderate cognitive impairment 
8 or more errors: severe cognitive impairment 
*One more error is allowed in the scoring if a patient has had a grade school 
education or less. 
*One less error is allowed if the patient has had education beyond the high school 
level. 
Source: Pfeiffer, E. (1975). A short portable mental status questionnaire for the 
assessment of organic brain deficit in elderly patients. Journal of American Geriatrics 
Society. 23,433-41. 
Compiled by the Great Plains Area Chapter of the Alzheimer's Association, 1999. 
http://www.hospitalmedicine.org/geriresource/toolbox/pdfs/short_portable_mental_statu. 
pdf 
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C. Questions to Identify Patients Experiencing Medication Cost Problems 
1. Not counting the costs paid by your insurance, how much do your 
prescription drugs cost you and your family each month? In other words, 
how much do you typically pay "out-of-pocket" per month for 
prescription drugs? 
2. In the past 12 months, how often did you worry about being able to pay 
for your prescription medicines? 
3. During the past 12 months, you spent less on food, heat, or other basic 
needs so that you would have enough money for your medicines? 
4. In the past 12 months, did you ever have to borrow money from a friend 
or relative outside of your household to pay for your prescription 
medicines? 
5. In general, over the past 12 months did you have to increase the amount 
of credit card debt you carried month-to-month because of the cost of 
your prescription drugs? 
6. In the past 12 months, how often have you ever done any of the following 
because you were concerned about the cost of your prescription drugs? 
A. Take fewer pills or a smaller dose 
B. Not fill a prescription at all 
C. Put off or postpone getting a prescription filled 
D. Use herbal medicines or vitamins when you felt sick rather than 
take your prescription medication 
E. Take the medication less frequently than recommended to stretch 
out the time before a refill 
7. In the past 12 months, did someone at your health center ever... 
A. Arrange for you to meet with a social worker or other professional 
to help you find a way to pay for your drugs? 
B. Talk with you about which drugs you definitely should not skip? 
C. Ask you whether you could afford the medication when they gave 
you a prescription? 
D. Give you information about where to get less expensive drugs? 
E. Give you information about programs that help people pay for their 
drugs? 
Source: California Healthcare Foundation (November 2005), 
Rx for Affordability: Helping Patients Cope with Medication Costs 
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D. Medication Adherence - Morisky Scale 
Option 1: 
Thinking of the drugs PRESCRIBED to you by your doctor, please answer the following 
questions. No=0; Yes=l 
A 
B 
C 
D 
Do you ever forget to take your drugs 
Are you careless at times about taking 
your drugs? 
When you feel better, do you 
sometimes stop taking your drugs? 
Sometimes if you feel worse when you 
take your drugs, do you stop taking 
them? 
No Yes 
Option 2: 
May also be administered as a 5-point response option 
Thinking of the drugs PRESCRIBED to you by your doctor, please answer the following 
questions. Never=0; Rarely=l; Sometimes=2; Often=3; Always=4 
A 
B 
C 
D 
Do you ever forget to 
take your drugs 
Are you careless at 
times about taking your 
drugs? 
When you feel better, 
do you sometimes stop 
taking your drugs/ 
Sometimes if you feel 
worse when you take 
your drugs, do you stop 
taking them? 
Never Rarely Sometimes Often Always 
Source: Vik, Maxwell, Hogan, Patten, Johnson, Romonko-Slack, 2005, el54-el55. 
E. Senior Services of Southeastern Virginia (SSSEVA): Access & Acquisition of 
Prescription Drugs Survey 
Date/Time Contacted: 
Number of Contact Attempts: 
Demographic Information: (Verify Database Information) 
Name: From Database 
Address: From Database 
Administered: From Database 
Gender: M F 
Birth date: 
• What age were you on your last birthday? 
Ethnicity: African/American/Black Hispanic Asian 
Caucasian/White Other 
Medicare Status: 
• Do you have Medicare? YES NO 
Medicaid Status: 
• Do you have Medicaid? YES NO 
Employment Status: 
o Never Worked 
o Retired - Not Working 
o Retired - Working Part-time 
o Retired - Working Full-time 
o Not Retired Yet: Working - Part-time 
o Not Retired Yet: Working - Full-time 
o Other 
Annual Income 
o 0-$5000 
o $5001-$10,000 
o $10,001-$15,000 
o $15, 001-$20,000 
o $20,001 - $25,000 
o $25,001-above 
Insurance Status: 
• Do you have insurance that covers your prescriptions? YES NO 
If YES, Plan Name: 
If NO, How do you pay for your prescriptions? 
• Does your employer (or previous employer) help pay for your prescriptions 
(creditable coverage)? YES NO 
If NO, Continue with Part D Status 
If YES, Part D NOT REQUIRED, Continue with Extra Help Status 
Part D Status: 
• Have you enrolled in a Part D plan? YES NO 
If NO, Why not? 
If YES enrolled, Have you received your card? YES NO 
If NO, When did you enroll? 
If YES received card, have you used your card? YES NO 
If YES, have you noticed any savings? YES NO 
How much do you think you have saved? 
If NO, Why do you believe you have not saved money? 
• Have you had any problems using your card? YES NO 
If YES, What happened? 
• Have you switched plans? YES NO 
If YES, Why did you switch? 
• What is your current plan? 
Cognitive Processes Part D: 
• 
• 
Did anyone help you to enroll in a Part D plan? YES NO 
IF YES, Who helped? 
o Friend 
o Family member(s) 
o Media Broadcasts 
o Information Sessions 
o Senior Services 
o Auto-Enrolled/Facilitated Enrollment 
o Other 
What made you decide to enroll in a Part D plan? 
o Fear of late enrollment penalty 
o Anticipated Savings 
o No prescription coverage 
o Cost of plans 
o Plan coverage 
o Wanted to save money 
o Other 
How did you enroll in Part D? 
o Help from Senior Services 
o Applied on-line 
o Called Medicare's 800 number 
o Caregiver or family member enrolled 
o Enrollment event 
o Other 
• How important is price to you in selecting a Part D plan? 
o Very Important 
o Important 
o Somewhat Important 
o Not Very Important 
• How important is price to you in choosing to fill a prescription? 
o Very Important 
o Important 
o Somewhat important 
o Not Very Important 
• Do you have any suggestions for improving the Part D enrollment process? 
YES NO 
If YES, please give a FEW examples 
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Extra Help Status: 
• Did you receive a letter from Social Security telling you about Extra Help? 
YES NO 
If YES, what did it tell you? 
YES 
YES 
YES 
NO 
NO 
NO 
• Have you been screened eligible for Extra Help? 
• Did you apply for Extra Help? 
• Were you approved for Extra Help? 
If YES, What percentage of help were you approved for? 
100% 75% 50% 25% Don't Know 
If NO, Why not? 
Cognitive Processes Extra Help: 
• Did anyone help you to apply for Extra Help? YES NO 
• What helped you decide to apply for Extra Help? 
o Friends 
o Family 
o Media Broadcasts 
o Information Received in Mail 
o Couldn't afford Part D premiums 
o Other 
Social Supports: 
• Does anyone help you with health care decisions? YES NO 
If YES, who helps? 
• Has anyone discussed Part D enrollment with you? YES NO 
If YES, Who? 
(If Applicable) 
• Has anyone helped you enroll in Part D? YES NO 
If YES, who helped? 
• Has anyone talked to you about applying for Extra Help? 
If YES, who talked to you? 
YES NO 
(If Applicable) 
• Did anyone help you apply for Extra Help? YES NO 
If YES, who was involved? 
Other Programs Status (i.e. T P C . ) 
• Have you received free drugs through any program(s)? 
YES NO 
If YES, Which program(s)? 
Which drugs were you able to get? 
• Axe you still getting free drugs? YES NO 
If NO, Why not? 
Disability Status: 
• Are you currently receiving disability benefits? YES NO 
If YES, How long have you been receiving them? 
What age did you start receiving benefits? 
Accessibility: 
• Are you currently taking any prescriptions? YES NO 
If YES, How many have been prescribed? 
How many do you regularly fill? 
Which ones? 
• Have you been able to fill all prescriptions prescribed by your doctor? 
YES NO 
If NO, Why not? 
• What prescriptions have you been able to fill? 
• What methods have you tried to get your prescriptions? 
• Have you had been able to take all prescriptions as prescribed? 
YES NO 
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If NO, What has prevented you from doing so? 
• Have you used any techniques to extend your drugs? 
If YES, What have you tried? 
o Skipped dosages? 
o Split pills? 
o Shared pills with anyone else? 
o Someone shared pills with you? 
o Other 
Health Status: 
• How would you assess your health? 
o Poor 
o Fair 
o Good 
o Excellent 
• In the past year, have you had to go to emergency room? 
YES NO 
If YES, Why? 
How many times have you gone? 
• Within the past six months, have you gone to see your doctor? 
YES NO 
• What conditions or illnesses has your doctor told you that you have? 
• For which conditions or illnesses are you currently taking prescription 
drugs? 
• Does your doctor provide you with free prescription samples? 
YES NO 
• If YES, which ones? 
• What other methods are you using to control or prevent illness (all that apply)? 
o OTC (over-the-counter) remedies 
o Home remedies 
o Vitamins/Natural Supplements 
o Other 
Transportation: 
• How do you get to doctor visits? 
o Friend/Neighbor drives 
o Relative drives 
o Take bus 
o Drive my own car 
o Walk 
YES NO 
YES NO 
YES NO 
YES NO 
YES NO 
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o Senior Services Transportation 
o Other 
How do you get drugs from the pharmacy? 
o Friend/Neighbor takes 
o Relative brings me 
o Take bus 
o Drive my own car 
o Walk 
o Senior Services Transportation 
o Home Delivered 
o Other 
Follow-up: 
• Would you be willing to share your ideas in a focus group? 
YES NO 
If YES, please request best times to contact. Let respondent know they will be 
contacted about meeting time and location. 
Please note any special needs (transportation, disability, etc.) 
• Anything else you would like to add? YES NO 
If YES, allow for a few comments and proceed to THANK YOU. 
Thank you for your time and for helping to provide information that may help in 
improving the Part D and Extra Help programs. 
F. Modified Administered Survey Instrument 
Name: 
Administered Number: 
Attempt #1: 
Date: Time: Completed Yes/No 
Attempt #2: 
Date: Time: Completed Yes/No 
Attempt #3: 
Date: Time: Completed Yes/No 
Hello! My name is and I am calling to get 
your ideas and opinions about Medicare Part D and to determine whether you are able 
to get your blood pressure medicine or not. We are conducting this administered 
survey to find out if Part D is working for you and if you are able to get your blood 
pressure medicines as prescribed by your doctor. 
Thank you for agreeing to participate in this research. When you complete the 
survey you will receive a seven day pill box. Your answers are voluntary and you 
may choose not to answer any questions you feel uncomfortable answering. You may 
decide to stop the interview at any time. 
Let's get started. 
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(READ) First, I have just a few questions we will use to describe the people who 
took part in our survey... 
DEMOGRAPHICS; 
D1. RECORD RESPONDENT'S GENDER (Do not Ask) 
A 
B 
Male 
Female 
D2. What is your ethnicity? Are you white, black, Hispanic, Asian or some other 
ethnicity? 
A 
B 
C 
D 
E 
Caucasian/White 
African/American/Black 
Hispanic 
Asian 
Other 
D3. Are you currently married, living with a partner, widowed, divorced, separated, 
or have you never been married? 
A 
B 
C 
D 
E 
F 
G 
Married 
Living as married 
Divorced 
Separated 
Widowed 
Never been married 
Don't know/ Refused 
D4. Last year - that is, in 2007 — what was your gross monthly income? 
(ROUND TO WHOLE DOLLAR AMOUNT) 
D5. Last year — that is, in 2007 - what was your total family income from all 
sources, before taxes? Just stop me when I get to the right category. (READ) 
A 
B 
C 
D 
E 
F 
G 
H 
I 
J 
K 
$10,000 or less 
$10,001 to $15,000 
$15,001 to $20,000 
$20,001 to $30,000 
$30,001 to $50,000 
$50,001 to $75,000 
$75,001 to $100,000 
$100,001 to $200,000 
More than $200,000 
(DO NOT READ) Don't know 
(DO NOT READ) Refused 
D6. What is the LAST grade or class that you COMPLETED in school? 
(DO NOT READ) 
A 
B 
C 
D 
E 
F 
G 
H 
None, or grade 1-8 
High school incomplete (grades 9-11) 
High school graduate (grade 12 or GED 
certificate) 
Technical, trade or vocational school AFTER high 
school 
Some college, no four-year degree (includes 
associate degree) 
College graduate (B.S., B.A., or other four-year 
degree) 
Post-graduate or professional schooling after 
college (e.g., toward a Master's degree or PhD; 
law or medical school) 
Refused 
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Next, I am going to start by asking you a few questions to verify the date, 
(month, day, year) and day of the week. Then I will ask how old you are and 
when were you born. 
1. What are the month, day and year? 
2. What is the day of the week? 
3. How old are you? 
4. When were you bom? 
Next, I am going to ask you some questions about your high blood pressure 
experiences and the drugs prescribed. 
Individual Perceptions 
SELF-EFFICACY 
5. How confident are you that you can get your blood pressure medicine as 
prescribed? 
A 
Very 
Confident 
Somewhat 
Confident 
Somewhat 
Negative 
Very 
Negative 
Don't 
Know Refused 
PERCEIVED SUSCEPTIBILITY 
6. To your knowledge, can you avoid getting high blood pressure? 
A 
Very 
Confident 
Somewhat 
Confident 
Somewhat 
Negative 
Very 
Negative 
Don't 
Know Refused 
PERCEIVED THREAT 
7. How dangerous do you perceive that high blood pressure is to your health? (on a 
scale from 0 to 10 with 0 = Not Dangerous to 10 = Extremely Dangerous) 
0 10 
Not Extremely 
Dangerous Dangerous 
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PERCEIVED SERIOUSNESS 
8. On a scale from zero (0) to 100, how likely is it that your blood pressure would be 
high if you didn't take your blood pressure drugs? (on a scale from 0 to 100 with 
0 = No Chance to 100 Extremely Likely) 
0 100 
No Extremely 
Chance Likely 
PERCEIVED BARRIERS - COST 
9. In the past 12 months, how often have you ever done any of the following because 
you were concerned about the cost of your blood pressure drugs? 
A 
B 
C 
D 
E 
F 
G 
H 
Take fewer pills or a 
smaller dose 
Not fill a prescription 
at all 
Put off or postpone 
getting a prescription 
filled 
Use herbal medicines 
or vitamins when you 
felt sick rather than 
take your prescription 
medication 
Take the medication 
less frequently than 
recommended to 
stretch out the time 
before a refill 
Split pills to make them 
last 
Shared pills with 
anyone else 
Someone shared with 
you 
Never Rarely Sometimes Often Always 
10. Not counting the costs paid by your insurance, how much do your blood pressure 
drugs cost you and your family each month? In other words, how much do you 
typically pay "out-of-pocket" per month for your blood pressure 
drugs? 
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PERCEIVED BARRIERS - TRANSPORTATION 
11. In the past 12 months, have you ever not filled your blood pressure drugs because 
you did not have transportation to get to the pharmacy? 
A 
B 
C 
D 
Yes 
No 
Don't Know 
Refused 
PERCEIVED BENEFIT 
12. On a scale from zero (0) to 100, how likely is it that your blood pressure drugs 
lower your blood pressure? (on a scale from 0 to 100 with 0 = No Chance to 100 
Complete Cure) 
0 
No 
Chance 
— 100 
Complete 
Cure 
PERCEIVED NEED 
13. Do you believe that the blood pressure drugs prescribed are needed to control 
your high blood pressure? 
A 
Not at all 
Necessary 
A Little 
Necessary 
Somewhat 
Necessary 
Very 
Necessary 
Extremely 
Necessary 
Don't 
Know 
14. Are you currently taking any prescribed blood pressure drugs, or not? 
A 
B 
C 
D 
Yes 
No 
Don't Know 
Refused 
PERCEIVED SAFETY 
15. To what extent do you believe that blood pressure drugs are risky to your health? 
(on a scale from 0 to 100 with 0 = Not Harmful to 100 Extremely Harmful) 
0 
Not 
Harmful 
— 100 
Extremely 
Harmful 
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Next, I am going to ask you a few questions about your health, willingness to pay 
and affordability. 
HEALTH STATUS 
16. In general, would you say your health is excellent, very good, good, only fair, or 
poor? 
A 
B 
C 
D 
E 
F 
Excellent 
Very good 
Good 
Only fair 
Poor 
Don't know/Refused 
WILLINGNESS TO PAY 
17. How much would you be willing to pay to have better health? 
A 
B 
C 
D 
E 
F 
Nothing 
Up to $100 
Between $101 and $500 
Between $501 and $1000 
Over $100lor more 
Don't Know/Refused 
18. How much are you willing to pay (per month) for a Medicare Part D plan? 
(RECORD) 
19. How much are you willing to pay (per month) for your primary blood pressure 
drug? (RECORD) 
AFFORDABILITY 
20. In the past 12 months, did someone ever... 
A 
B 
C 
D 
E 
Arrange for you to meet with 
a social worker or other 
professional to help you find a 
way to pay for your drugs? 
Talk with you about which 
drugs you definitely should 
not skip? 
Ask you whether you could 
afford the medicine when they 
gave you a prescription? 
Give you information about 
where to get less expensive 
drugs? 
Give you information about 
programs that help people pay 
for the drugs? 
Yes No 
Don't 
Know Refused 
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Modifying Factors 
Next, I am going to ask you when you were diagnosed with high blood pressure, 
the number of drugs prescribed and how much you know about the effects of high 
blood pressure. 
TIME SINCE DIAGNOSED 
21. How long ago did the doctor tell you had high blood pressure? (When First 
Diagnosed) (RECORD) 
MEDICATION TAKING BEHAVIORS 
22. How many different blood pressure drugs has your doctor prescribed? 
(RECORD NUMBER) 
KNOWLEDGE 
23. Are you knowledgeable of the effect high blood pressure has on your health? 
A 
Not at All Very 
Little 
Some Very 
Much 
Extremely 
Much 
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Now, I am going to read you a list of people and I would like you to tell me how 
much support you receive from each of them. 
SOCIAL SUPPORT 
24. How much support do you get in making blood pressure drug decisions 
from each of the following: (READ) 
A 
B 
C 
D 
E 
F 
G 
H 
I 
J 
Spouse 
Children 
Siblings 
Friend 
Neighbor 
Visiting 
Nurse 
Social 
Worker 
Doctor 
Pharmacist 
Other 
None Very 
Little 
Some A Lot Don't 
Know 
25. How much help have you received from your DOCTOR in getting free samples of 
your blood pressure drugs? (READ) 
A 
B 
C 
D 
A little help 
Some help 
(DON'T READ) Don't know 
(DON'T READ) Refused 
CUES TO ACTION - SYMPTOMS 
26. Thinking of the blood pressure drugs PRESCRIBED to you by your doctor, 
please answer the following questions. 
A 
B 
C 
D 
Do you ever 
forget to take 
your blood 
pressure 
drugs? 
Are you 
careless at 
times about 
taking your 
blood pressure 
drugs? 
When you feel 
better, do you 
sometimes stop 
taking your 
blood pressure 
drugs? 
Sometimes if 
you feel worse 
when you take 
your blood 
pressure drugs, 
do you stop 
taking them? 
Never Rarely Sometimes Often Always 
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CUES TO ACTION - SIDE EFFECTS 
27. Have you ever experienced any of the following side effects after taking your 
blood pressure drugs? (Read List in Random Order) 
A 
B 
C 
D 
E 
F 
G 
H 
I 
Headache 
Nausea 
Dizziness 
Loss of 
Appetite 
Insomnia 
Dry Mouth 
Incontinence 
Allergic 
Reaction 
Other 
(specify) 
Never Rarely Sometimes Often Always Don't 
Know 
CUES TO ACTION - INFORMATION 
28. Where do you get your information about high blood pressure treatment? 
A 
B 
C 
D 
E 
Healthcare 
Provider 
Health 
Publications 
Internet 
Friends 
Other 
Never Rarely Sometimes Often Always 
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CUES TO ACTION - MEDIA EVENTS 
29. What media events have influenced you to learn more about how to get your high 
blood pressure drugs? 
A 
B 
C 
D 
E 
F 
Medicare 
Mailings 
Newspaper 
Article 
Public Service 
Announcement 
Health 
Presentation 
Health Fair 
Brochure 
Television 
Program 
Never Rarely Sometimes Often Always 
MEDICATION TAKING BEHAVIORS 
30. How soon after your doctor prescribed a blood pressure drug did you start taking 
it? (RECORD) 
31. What are the names of the blood pressure drugs you actually take (per day)? 
Ask whether it is a Name Brand or Generic. (Record Names & Type) 
Name Brand Generic 
RxNamel: 
RxName2: 
Rx Name3: 
Rx Name4: 
RxName5: 
Rx Name6: 
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ACCESS BEHAVIORAL METHOD 
32. Where do you usually get (acquire) your primary blood pressure drug? 
A 
B 
C 
D 
E 
At the local 
Pharmacy 
Receive free 
samples 
Share with 
Someone 
From Mail 
Order 
Other 
Never Seldom Sometimes Often Always 
OUTCOME 
33. Which of the previously mentioned blood pressure drugs do you acquire as 
prescribed (either 30 day or 90 day supply)? (Record Names & 
Frequency of refill) 
Name Refill Frequency 
34. Have you gotten less than the prescribed supply of your blood pressure 
drug? 
A 
Never Seldom Sometimes Often Always 
35. Have you ever not gotten any of your blood pressure drugs? 
A 
Yes No Don't Know Refused 
If YES, Why? 
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Now, we have completed the blood pressure portion of the survey. At this point you 
can decide to take a break and I will call you back later to discuss the Medicare Part 
D and Extra Help, or we can continue. Which would you prefer? 
IF would like to take a break: Thank you for your time. What is a good day 
and time for me to call you back? (RECORD DAY & TIME). Schedule a call back. 
IF would like to continue: 
Next, I am going to ask you a few general questions about Medicare Part D and 
Extra Help. 
MEDICARE PART D & EXTRA HELP STATUS 
36. What type of Medicare Part D plan do you have? 
A 
Prescription 
Drug Discount 
Plan 
(Stand Alone) 
Medicare 
Advantage 
Plan with Rx 
Other Don't 
Know 
Refused 
37. Are you receiving Extra Help to help pay for prescription drug costs, or not? 
A 
Yes No 
Don't 
Know Refused 
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Now, I would like to ask you a few questions about your Medicare Part D 
experiences and your opinions about how you think the policy is working. 
MEDICARE PART D AND EXTRA HELP EXPERIENCES AND OPINIONS: 
38. Please tell me whether or not you've had any of the following experiences 
related to getting your blood pressure prescription medicines since joining 
your Medicare Part D drug plan. 
Have you... or not? (READ AND RANDOMIZE) 
A 
B 
C 
D 
E 
F 
G 
Had difficulties getting 
enrollment card 
Left the pharmacy without 
your prescription because one 
of your drugs wasn't covered 
by your plan 
Left the pharmacy without 
your prescription because you 
could not afford it 
Had to switch drugs because 
one of your drugs that you 
were taking wasn't covered 
by your plan 
Had to switch from a brand-
name to a generic drug 
Had to deal with a billing 
mistake for a prescription or a 
premium 
Had to pay costs you hadn't 
expected - either for a 
prescription or a premium 
Have Have 
Not 
Don't 
Know 
Refused 
39. Given what you know about Part D, in general, do you have a favorable or 
unfavorable view of the Medicare Part D drug benefit? 
A 
Favorable Unfavorable Neither/Neutral 
Don't 
Know Refused 
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40. Is your impression of the Medicare Part D drug benefit based mainly on... 
(READ AND RANDOMIZE 1-3)? 
Based on those with a favorable or unfavorable impression of Medicare Part 
D drug benefit 
A 
B 
C 
D 
E 
F 
Your own experience 
What you've seen and heard on television, 
radio, and in newspapers 
What you've learned from friends and family 
Some other source 
(DO NOT READ) Don't know 
(DO NOT READ) Refused 
Yes No 
41. Since many plans are now requiring generics to be substituted for name brand 
drugs, to cut costs, do you think the generic drug works better, just as well or 
not as well as the name brand? 
A 
B 
C 
D 
E 
Works better 
Just as well 
Not as well as the name brand 
Don't know 
Refused 
42. Would you say it was very easy, somewhat easy, somewhat difficult, or very 
difficult to choose a Medicare drug plan, OR were you just put in a plan and 
didn't make a choice for yourself? 
A 
Very 
Easy 
Somewhat 
Easy 
Somewh 
at 
Difficult 
Very 
Difficult 
Put in a 
Plan Didn't 
Make 
a Choice 
Refused 
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43. Overall, do you feel you made a good choice in selecting your Medicare 
prescription drug discount plan, or do you think you would have been better off 
with a different plan? 
A 
Made a Good 
Choice 
Better off with a 
different plan Don't Know Refused 
44. Which one was the MOST important to your decision to choose your Medicare 
drug plan? 
A 
B 
C 
D 
E 
F 
G 
H 
I 
The amount for each prescription 
A recommendation from someone you trust 
The reputation of the company 
The amount of monthly premiums 
The specific drugs covered 
All are important 
None are important 
Don't Know 
Refused 
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45. In choosing your Medicare drug plan, please tell me how important each of the 
following was to your decision. (First,) how about... ? (READ AND 
RANDOMIZE) 
READ FOR FIRST ITEM, REPEAT AS NECESSARY: Was this very important, 
somewhat important, not too important or not at all important (in choosing your 
Medicare drug plan)? 
A 
B 
C 
D 
E 
The reputation of 
the company 
offering the plan 
The amount the 
plan charges 
in monthly 
premiums 
The specific 
drugs covered 
by the plan 
The amount the 
plan charges for 
each prescription 
A 
recommendation 
from someone 
you trust 
Single 
Most 
Important 
Very 
Important 
Not 
too 
Important 
Not at 
all 
Important 
DK/ 
Refused 
46. To the best of your knowledge, if seniors waited to enroll in a Medicare drug plan 
would they have to pay a "late enrollment penalty", or not? 
A 
Yes No Don't Know Refused 
47. To the best of your knowledge, if you are dissatisfied with your Medicare drug 
plan can you change to a different plan whenever you want, or do you have to 
wait for a specific period? 
A 
B 
C 
D 
Can change to different plan 
Have to wait 
Don't know 
Refused 
48. Compared with how you got your prescriptions before, please tell me whether 
your Medicare drug plan is better, worse, or about the same in terms of each of 
the following. (READ AND RANDOMIZE). (READ FOR EACH ITEM) 
Compared with how you got your prescriptions without Medicare Part D, is your 
drug plan better, worse, or about the same in terms of (INSERT)... 
A 
B 
C 
D 
How much you 
pay for 
prescriptions 
The cost of your 
monthly 
premiums 
Getting the 
medicines you 
need 
Getting answers 
to your questions 
Better Worse Same Don't 
Know 
Refused 
49. Compared to what you paid for blood pressure drugs before Medicare Part D, 
are you now saving money, paying more or paying about the same overall for 
your prescriptions? 
A 
Saving money Paying more Paying about 
the same 
Refused 
50. Would you say that you are saving a lot of money, or just a little? 
A 
Saving a lot of 
money 
Saving Just a little 
Don't Know Refused 
51. Would you say that you are paying a lot more money, or just a little more? 
A 
Paying a lot more 
money 
Paying just a little 
more 
Don't 
Know Refused 
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52. Overall, what message would you send to policymakers in Washington? Would 
you say the Medicare Part D drug benefit (READ) 
A 
B 
C 
D 
E 
Is working well and no real changes are needed 
Could be improved with some minor changes 
Is not working and needs major changes 
Don't know 
Refused 
Thank you for completing this survey about blood pressure medication and for helping to 
improve the Medicare Part D policy. As mentioned before you will be receiving a seven 
day pill box as our thank you for participating. 
If you would like to receive a copy of the survey results we will be happy to send them to 
you when the study is complete. 
Wants report? Yes No 
Verify Address to send gift to: 
Name: 
Street Address: 
City: State: Zip code: 
APPENDIX IV: Senior Services of Southeastern Virginia Consent Letter 
% 
Senior Services of 
Southeastern Virginia 
T H E CENTER FOR AGING 
November 7.2008 
Ms. Arvi Marie Kopitzke, BBA, MPA, PhD(c) 
1168 Boiling Avenue 
NorfoBc,VA 23508 
Dear Ms. Kopitzke: 
We are approving your request to utilize the Medicare Management Access database to 
develop a contact list for the purpose of dissertation data collection. Additionally, permission 
to contact enroltees to assess prescription drug plan enrollment and acquisition experiences 
is granted. 
Letters of consent wH be sent to Medicare elders, enrolled through Senior Services of 
Southeastern Virginia, for whom complete contact data is available. Data collection must be 
safeguarded utflizing MIPPA and IRB guidelines. 
Results of data analyses must be shared with Senior Services of Southeastern Virginia 
(SSSEVA) to enhance medication education, assistance and enrollment efforts. Senior 
Services of Southeastern Virginia must be acknowledged in any publications or print media 
which arise from this research. 
Sincerely, 
9" 
John N. Skirven 
Chief Executive Officer 
Interstate Corporate Center, 6350 Center Drive, Bldg. 5, Suite 101, Norfolk, VA 23S02-4107 
Phone: 757-4*1-9481- Fax: 757-461-1068- E-Mail: services9ssseva.org- Web: wwvvjsseva.org 
APPENDIX V: Sample Consent Letter 
DATE 
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NAME 
ADDRESS 
CITY, STATE ZIP 
Dear NAME, 
As a follow-up to your Part D enrollment, we would like to invite you to be part of a 
research study that will help us to find out if Medicare's prescription drug discount 
benefit is working for you and if you are able to save any money. 
If you are called, we will be asking questions about how you chose your Part D plan and 
whether you had any problems using the plan. There will also be a few questions about 
Extra Help and your opinions and experiences. We will also ask about your health status 
and how you get your blood pressure medicines. If you are willing to finish the 
administered survey, we will send you a seven day pill box as a thank you. 
If you want to accept this invitation, please fill out and sign the reply card. If you want to 
call us to tell us you would like to be included in this study, please leave your name, 
administered number and the best days and times for you to be called at 757-461-9481 
x7230. 
If you have any questions about this study you may contact me at 757-683-6180. Thank 
you for your time. 
Sincerely, 
Ann Marie Kopitzke, BBA, MPA, PhD Candidate 
Medication Education Coordinator 
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Please include me in your study. I am interested in being contacted for my opinions and 
experiences with Medicare Part D. I would also like to tell you about how I get my blood 
pressure medicines. 
Printed Name 
Signature 
Date Administered 
Good days and times to call 
After you fill out and sign, please put this invitation reply card into the stamped, 
addressed return envelope and mail it back to us. 
Thank you for your time. 
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